Nothing Special   »   [go: up one dir, main page]

EP2831118A1 - Anti-lgr5 antibodies and immunoconjugates - Google Patents

Anti-lgr5 antibodies and immunoconjugates

Info

Publication number
EP2831118A1
EP2831118A1 EP13716131.1A EP13716131A EP2831118A1 EP 2831118 A1 EP2831118 A1 EP 2831118A1 EP 13716131 A EP13716131 A EP 13716131A EP 2831118 A1 EP2831118 A1 EP 2831118A1
Authority
EP
European Patent Office
Prior art keywords
seq
antibody
sequence
amino acid
lgr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13716131.1A
Other languages
German (de)
French (fr)
Inventor
Jo-Anne Hongo
Weiguang Mao
Paul Polakis
Andrew Polson
Rajesh Vij
Yan Wu
Wei-Ching Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48093115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2831118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP2831118A1 publication Critical patent/EP2831118A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to anti-LgR5 antibodies and immunoconjugates and methods of using the same.
  • LgR5 Leucine-rich repeat-containing G protein-coupled receptor 5
  • ISCs actively cycling intestinal stem cells
  • LgR5-expressing ISCs are sensitive to Wnt modulation and are primarily responsible for homeostatic regeneration of the intestinal epithelium. Elimination of LgR5-expressing cells in mice does not affect homeostasis of intestinal epithelium, however, suggesting that other cell types can compensate for loss of this cell population. Tian et al., Nature 478: 255-259 (2011).
  • R- spondins enhance WNT signaling by WNT3A, and all four R-spondins, RSPOl, RSP02, RSP03, and RSP04, are able to bind to LgR5. Lau et al., Nature 476: 293-297 (2011).
  • Human LgR5 is a 907 amino acid protein, of which -540 amino acids are predicted to be in the extracellular space following cleavage of the amino-terminal signal sequence.
  • LgR5 comprises 17 imperfect leucine-rich repeat motifs in the ectodomain, and a cysteine-rich region located between the leucine-rich repeats and the first transmembrane domain.
  • the invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
  • an isolated antibody that binds to LgR5 has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within amino acids 22-555 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 22-123 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 22-323 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 22-424 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 324-555 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 324-424 of SEQ ID NO: 67; (b) binds LgR5 with an affinity of ⁇ 5 nM, or ⁇ 4 nM, or ⁇ 3 nM, or ⁇ 2 nM, or ⁇ 1 nM, and optionally >
  • the isolated anti-LgR5 antibody binds to an epitope within amino acids 22-323 of SEQ ID NO: 67 with an affinity of ⁇ 5 nM, or ⁇ 4 nM, or ⁇ 3 nM, or ⁇ 2 nM, or ⁇ 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM. .
  • the isolated anti-LgR5 antibody binds to an epitope within amino acids 22-123 of SEQ ID NO: 67 with an affinity of ⁇ 5 nM, or ⁇ 4 nM, or ⁇ 3 nM, or ⁇ 2 nM, or ⁇ 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM.
  • the isolated anti-LgR5 antibody binds to an epitope within amino acids 324-424 of SEQ ID NO: 67 with an affinity of ⁇ 5 nM, or ⁇ 4 nM, or ⁇ 3 nM, or ⁇ 2 nM, or ⁇ 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM.
  • the anti-LgR5 antibody does not significantly disrupt the binding of R-spondin (RSPO) to LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not significantly disrupt wnt/beta-catenin signaling. In some embodiments of any of the isolated anti- LgR5 antibodies, the anti-LgR5 antibody does not significantly disrupt RSPO activation of LgR5 signaling. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody activates caspase 3 cleavage.
  • RSPO R-spondin
  • the anti-LgR5 antibody recognizes both human and rodent LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody recognizes human LgR5 but not rodent LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not significantly inhibit tumor growth in its unconjugated form. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not induce stem cell differentiation.
  • the anti-LgR5 antibody is a monoclonal antibody. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody is a human, humanized, or chimeric antibody. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody antibody is an IgGl, IgG2a or IgG2b antibody. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody is an antibody fragment that binds LgR5.
  • LgR5 is human LgR5 of SEQ ID NO: 67.
  • an antibodythat binds LgR5 binds an epitope within amino acids 22-323 of SEQ ID NO: 67.
  • the antibody binds to LgR5 with an affinity of ⁇ 5 nM.
  • the antibody is a monoclonal antibody.
  • the antibody is a human, humanized, or chimeric antibody.
  • the antibody is an IgGl, IgG2a or IgG2b antibody.
  • the antibody is an antibody fragment that binds LgR5.
  • LgR5 is human LgR5 of SEQ ID NO: 67.
  • the antibody comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31.
  • the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (c) HVR- H3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the antibody further comprises a heavy chain framework FR3 sequence of SEQ ID NO: 41.
  • the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27,
  • the antibody further comprises a light chain framework FR3 sequence of SEQ ID NO: 35.
  • an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7; or
  • the antibody comprises a VH sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 7. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7.
  • an antibody that binds LgR5 comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55.
  • the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
  • the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51,
  • HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52
  • HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:23; or
  • the antibody comprises a VH sequence of SEQ ID NO: 24. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 23. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 24 and a VL sequence of SEQ ID NO: 23.
  • an antibody that binds LgR5 comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO:495.
  • the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 48, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
  • the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45,
  • HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46
  • HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21; or
  • the antibody comprises a VH sequence of SEQ ID NO: 22. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 21. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 22 and a VL sequence of SEQ ID NO: 21.
  • an antibody that binds LgR5 comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61.
  • the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62.
  • the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57,
  • HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58
  • HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:25; or
  • the antibody comprises a VH sequence of SEQ ID NO: 26. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 25. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25.
  • an isolated nucleic acid that encodes an antibody described herein is provided.
  • a host cell comprising the nucleic acid is provided.
  • a method of producing an antibody described herein is provided.
  • the method comprises culturing the host cell comprising the nucleic acid that encodes an antibody.
  • an immunoconjugate comprises an anti-LgR5 antibody and a cytotoxic agent.
  • an immunoconjugate has the formula Ab-(L-D)p, wherein: (a) Ab is an antibody described herein; (b) L is a linker; (c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and (d) p ranges from 1-8.
  • D is an auristatin.
  • D has formula D E
  • R 2 and R 6 are each methyl, R 3 and R 4 are each isopropyl, R 5 is H, R 7 is sec-butyl, each R 8 is independently selected from CH 3 , 0-CH 3 , OH, and H; R 9 is H; and R 18 is -C(R 8 ) 2 -C(R 8 ) 2 - aryl.
  • D is MMAE having the structure:
  • n 0 or 1.
  • D is a nemorubicin derivative. In some embodiments, D has a structure selected from:
  • an immunoconjugate comprises a linker that is cleavable by a protease.
  • the linker comprises a val-cit dipeptide or a Phe-Lys dipeptide.
  • an immunoconjugate comprises a linker that is acid-labile. In some such embodiments, the linker comprises hydrazone.
  • S is a sulfur atom
  • p ranges from 2-5.
  • an immunoconjugate comprises an antibody that comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • an antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (
  • immunoconjugate comprises an antibody that comprises a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7.
  • a pharmaceutical formulation comprises an immunoconjugate comprising an antibody that binds LgR5, e.g., as described herein.
  • a pharmaceutical formulation further comprises an additional therapeutic agent.
  • the additional therapeutic agent is Avastin® (bevacizumab).
  • a method comprises administering a pharmaceutical formulation comprising an immunoconjugate comprising an antibody that binds LgR5, e.g., as described herein.
  • the LgR5-positive cancer is selected from colorectal cancer, pancreatic cancer, ovarian cancer, and endometrial cancer.
  • the LgR5 -positive cancer is a small intestine cancer.
  • a small intestine cancer is a cancer of the duodenum, jejunum, and/or ilium.
  • a small intestine cancer is a cancer of the jejunum and/or ilium.
  • an LgR5- positive cancer comprises a Kras mutation, an APC mutation, or both a Kras mutation and an APC mutation (e.g., in at least a portion of the cancer cells).
  • a method comprises administering an additional therapeutic agent to the individual.
  • the additional therapeutic agent is Avastin® (bevacizumab).
  • methods of inhibiting proliferation of an LgR5 -positive cell comprising exposing the cell to an immunoconjugate comprising an antibody that binds LgR5 under conditions permissive for binding of the immunoconjugate to LgR5 on the surface of the cell.
  • an antibody that binds LgR5 is an antibody described herein.
  • proliferation of the cell is thereby inhibited.
  • the cell is a colorectal, small intestine, pancreatic, ovarian, or endometrial cancer cell.
  • an antibody that binds LgR5 is conjugated to a label.
  • an antibody that binds LgR5 is an antibody described herein.
  • the label is a positron emitter.
  • the positron emitter is 89 Zr.
  • a method of detecting human LgR5 in a biological sample comprises contacting the biological sample with an anti-LgR5 antibody under conditions permissive for binding of the anti-LgR5 antibody to a naturally occurring human LgR5, and detecting whether a complex is formed between the anti- LgR5 antibody and a naturally occurring human LgR5 in the biological sample.
  • an anti-LgR5 antibody is an antibody described herein.
  • the biological sample is a colorectal cancer sample, small intestine cancer sample, pancreatic cancer sample, ovarian cancer sample, or endometrial cancer sample.
  • a method for detecting an LgR5-positive cancer comprises (i) administering a labeled anti-LgR5 antibody to a subject having or suspected of having an LgR5 -positive cancer, and (ii) detecting the labeled anti-LgR5 antibody in the subject, wherein detection of the labeled anti-LgR5 antibody indicates a LgR5-positive cancer in the subject.
  • an anti-LgR5 antibody is an antibody described herein.
  • Figure 1 shows a graphic representation of the levels of human LgR5 gene expression in various tissues, as described in Example A.
  • the inset in Figure 1 shows a graphic representation of the levels of human LgR5 gene expression in normal colon tissues and colon tumors, as described in Example A.
  • Figure 2 shows expression of LgR5 in colon tumors by in situ hybridization, as described in Example B.
  • Figure 3 shows (A) the prevalence of various levels of LgR5 expression in a colon tumor tissue microarray, and (B) the heterogeneity of LgR5 expression in three cores from each colorectal adenocarcinoma sample, both determined by in situ hybridization, as described in Example B.
  • Figure 4 shows the properties of certain anti-LgR5 monoclonal antibodies developed as described in Examples C through F.
  • Figure 5 shows an alignment of the light chain variable region sequences of murine antibody mu8El 1 and humanized variants thereof (hu8El 1.vl to hu8El 1.v8).
  • the three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
  • Figure 6 shows an alignment of the heavy chain variable region sequences of murine antibody mu8El 1 and humanized variants thereof (hu8El 1.vl to hu8El 1.v8).
  • the three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
  • FIG. 7 shows the light chain variable region sequences of murine antibodies 3G12 and 2H6.
  • the three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
  • FIG 8 shows the heavy chain variable region sequences of murine antibodies 3G12 and 2H6.
  • the three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
  • Figure 9 shows affinity measurements of chimeric antibody ch8El 1 and various humanized variants, as described in Example E.
  • FIG. 10 shows the light chain variable region sequence of human antibody YW353.
  • the three hypervariable regions HVRs: HVRl, HVR2, HVR3 are indicated by boxes in the sequences.
  • FIG 11 shows the heavy chain variable region sequence of human antibody YW353.
  • the three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
  • Figure 12A-C show an alignment of LgR5 from human, cynomolgus monkey, rat, and mouse.
  • Figure 13 shows that anti-LgR5 immunoconjugates demonstrate efficacy in LoVo colon cancer xenografts, as described in Example L.
  • Figure 14 shows that anti-LgR5 immunoconjugates demonstrate efficacy in D5124 pancreatic cancer xenografts, as described in Example M.
  • Figure 15 shows that huYW353-vcMMAE immunoconjugate demonstrates efficacy at 3, 6, and 12 mg/kg in D5124 pancreatic cancer xenografts, as described in Example M.
  • Figure 16 shows Lg 5 mR A expression in normal tissue and polyps from colons of AV and AKV mice, as described in Example N.
  • Figure 17 shows survival of AKV mice administered anti-LgR5 antibody and anti-LgR5 antibody-drug conjugate have longer survival times than control AKV mice, as described in Example N.
  • Figure 18 shows percentage of tumor area that is positive for cleaved caspase 3 in AKV mice administered a control ADC, an anti-LgR5 ADC, or an anti-LgR5 antibody, as described in Example N.
  • Figure 19 shows AKV mice administered anti-LgR5 antibody-drug conjugate have longer survival times than untreated AKV mice and AKV mice administered gpl20-ADC or anti-LgR5, as described in Example N.
  • Figure 20 shows LgR5+ area in small intestine polyps and colon polyps in AKV LgR5 OTRJ+ mice, as described in Example N.
  • Figure 21 shows (A) CC3+GFP+ area per cellular area in control ADC and anti- LgR5-ADC treated AKV LgR5 OTRJ+ mice, and (B) exemplary immunohistochemistry staining in the control ADC and anti-LgR5-ADC treated AKV LgR5 mR/+ mice, as described in Example N.
  • Figure 22 shows Ki67+ area per cellular area (either GFP+ cells or GFP- cells) in control ADC and anti-LgR5-ADC treated AKV LgR5 mBJ+ mice, as described in Example N.
  • Figure 23 shows the ratio of GFP intensity to GFP+ area in crypts and tumors of AKV LgR5 mw+ mice, as described in Example N.
  • Figure 24 shows that huYW353-vcMMAE, hu8El 1V2-VCMMAE, and ch8El 1- vcMMAE immunoconjugate demonstrates efficacy in D5124 pancreatic cancer xenografts, as described in Example O.
  • Figure 25 shows that hu8El 1V2-VCMMAE immunoconjugate demonstrates efficacy in D5124 pancreatic cancer xenografts, as described in Example O.
  • Figure 26 shows that huYW353-vcMMAE and hu8El 1V2-VCMMAE
  • immunoconjugates demonstrate efficacy in LoVoXl .l colon cancer xenografts, as described in Example P.
  • Figure 27 shows that hu8El 1V2-VCMMAE immunoconjugate demonstrates efficacy in LoVoXl .l colon cancer xenografts, as described in Example P.
  • Figure 28 shows that huYW353-vcMMAE, huYW353-acetal-PNU, and huYW353-vcPNU immunoconjugates demonstrate efficacy in D5124 pancreatic cancer xenografts, as described in Example Q.
  • Figure 29 shows that hu8El lv2-acetal-PNU, hu8El 1V2-VCPNU, and hu8El lv2- PNU immunoconjugates demonstrate in D5124 pancreatic cancer xenografts, as described in Example .
  • Figure 30 shows the results of administering certain hu8El lv2
  • Figure 32 shows that an anti-LgR5 huYW353 PBD immunoconjugate demonstrates efficacy in D5124 pancreatic cancer xenografts, as described in Example T.
  • Figure 33 shows that an anti-LgR5 hu8El lv2 PBD immunoconjugate demonstrate efficacy in D5124 pancreatic cancer xenografts, as described in Example T.
  • Figure 34 shows that an anti-LgR5 hu8El lv2 PBD immunoconjugate demonstrates efficacy in a LoVoXl . l colong cancer cancer xenograft, as described in Example U.
  • Figure 35 shows the structures of (A) an antibody-vcMMAE immunoconjugate, (B) an antibody-acetal-PNU immunoconjugate, (C) an antibody-acetal-PNU immunoconjugate, (D) an antibody-PNU immunoconjugate, and (E) an antibody-vcPBD immunoconjugate.
  • an "acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below.
  • An acceptor human framework "derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
  • the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
  • Bind refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen).
  • binding affinity refers to intrinsic binding affinity which reflects a 1 :1 interaction between members of a binding pair (e.g., antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
  • An "affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
  • HVRs hypervariable regions
  • anti-LgR5 antibody and “an antibody that binds to LgR5" refer to an antibody that is capable of binding LgR5 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting LgR5.
  • the extent of binding of an anti-LgR5 antibody to an unrelated, non-LgR5 protein is less than about 10% of the binding of the antibody to LgR5 as measured, e.g., by a radioimmunoassay (RIA).
  • RIA radioimmunoassay
  • an antibody that binds to LgR5 has a dissociation constant (Kd) of ⁇ 1 ⁇ , ⁇ 100 nM, ⁇ 10 nM, , ⁇ 5 Nm, , ⁇ 4 nM, , ⁇ 3 nM, , ⁇ 2 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g., 10 "8 M or less, e.g. from 10 "8 M to 10 "13 M, e.g., from 10 "9 M to 10 "13 M).
  • an anti-LgR5 antibody binds to an epitope of LgR5 that is conserved among LgR5 from different species.
  • antibody is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
  • an "antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody and that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab') 2 ; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.
  • an "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more.
  • An exemplary competition assay is provided herein.
  • cancer refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation.
  • Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia.
  • cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, small intestine cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.
  • chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
  • the "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • cytotoxic agent refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
  • Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , 1 131 , 1 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of
  • Antibody effector functions refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
  • CDC complement dependent cytotoxicity
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • phagocytosis e.g. B cell receptor
  • B cell receptor e.g. B cell receptor
  • an "effective amount” of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
  • an “epitope” refers to the particular site on an antigen molecule to which an antibody binds.
  • Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present.
  • numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
  • FR refers to variable domain residues other than hypervariable region (HVR) residues.
  • the FR of a variable domain generally consists of four FR domains: FRl, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
  • full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
  • glycosylated forms of LgR5 refers to naturally occurring forms of LgR5 that are post-translationally modified by the addition of carbohydrate residues.
  • host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
  • a "human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non- human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
  • a "human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
  • the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
  • the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3.
  • the subgroup is subgroup kappa I as in Kabat et al supra.
  • the subgroup is subgroup III as in Kabat et al supra.
  • a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs ⁇ e.g. , CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
  • a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
  • a "humanized form" of an antibody, e.g., a non- human antibody refers to an antibody that has undergone humanization.
  • hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops").
  • native four-chain antibodies comprise six HVRs; three in the VH (HI, H2, H3), and three in the VL (LI, L2, L3).
  • HVRs generally comprise amino acid residues from the hypervariable loops and/or from the
  • CDRs complementarity determining regions
  • Exemplary hypervariable loops occur at amino acid residues 26-32 (LI), 50-52 (L2), 91-96 (L3), 26-32 (HI), 53-55 (H2), and 96-101 (H3).
  • CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 occur at amino acid residues 24-34 of LI, 50-56 of L2, 89-97 of L3, 31-35B of HI, 50-65 of H2, and 95-102 of H3.
  • CDRs generally comprise the amino acid residues that form the hypervariable loops.
  • CDRs also comprise "specificity determining residues," or "SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs.
  • Exemplary a-CDRs (a-CDR-Ll, a-CDR-L2, a-CDR-L3, a-CDR-Hl, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of LI, 50-55 of L2, 89-96 of L3, 31-35B of HI, 50-58 of H2, and 95-102 of H3. ⁇ See Almagro and Fransson, Front. Biosci.
  • HVR residues and other residues in the variable domain ⁇ e.g., FR residues) are numbered herein according to Kabat et al supra.
  • An "immune-conjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
  • mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
  • domesticated animals e.g., cows, sheep, cats, dogs, and horses
  • primates e.g., humans and non-human primates such as monkeys
  • rabbits e.g., mice and rats
  • rodents e.g., mice and rats.
  • the individual or subject is a human.
  • an "isolated antibody” is one which has been separated from a component of its natural environment.
  • an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
  • electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatographic e.g., ion exchange or reverse phase HPLC
  • An "isolated nucleic acid” refers to a nucleic acid molecule that has been separated from a component of its natural environment.
  • An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
  • isolated nucleic acid encoding an anti-LgR5 antibody refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.
  • LgR5 refers to any native, mature LgR5 which results from processing of an LgR5 precursor protein in a cell.
  • the term includes LgR5 from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated.
  • the term also includes naturally occurring variants of LgR5, e.g., splice variants or allelic variants.
  • the amino acid sequence of an exemplary human LgR5 precursor protein, with signal sequence (amino acids 1-21) is shown in SEQ ID NO: 67.
  • the amino acid sequence of an exemplary mature human LgR5 is shown in SEQ ID NO: 68.
  • the predicted sequence for amino acids 33 to 907 of an exemplary cynomolgus monkey LgR5 is shown in SEQ ID NO: 69.
  • the amino acid sequences for exemplary rat LgR5 precursor (with signal sequence, amino acids 1-21) and mature sequences are shown in SEQ ID NOs: 70 and 71, respectively.
  • the amino acid sequences for exemplary mouse LgR5 precursor (with signal sequence, amino acids 1-21) and mature sequences are shown in SEQ ID NOs: 72 and 73, respectively.
  • Lg 5 -positive cancer refers to a cancer comprising cells that express LgR5 on their surface.
  • LgR5 mRNA expression is considered to correlate to LgR5 expression on the cell surface.
  • expression of LgR5 mRNA is determined by a method selected from in situ hybridization and RT-PCR (including quantitative RT-PCR).
  • expression of LgR5 on the cell surface can be determined, for example, using antibodies to LgR5 in a method such as immunohistochemistry, FACS, etc.
  • LgR5 -positive cell refers to a cell that expresses LgR5 on its surface.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
  • polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • monoclonal indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
  • naked antibody refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel.
  • the naked antibody may be present in a pharmaceutical formulation.
  • Native antibodies refer to naturally occurring immunoglobulin molecules with varying structures.
  • native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3).
  • VH variable region
  • VL variable region
  • the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
  • package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
  • Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTA ) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • composition refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
  • a “pharmaceutically acceptable carrier” refers to an ingredient in a
  • a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
  • treatment refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
  • antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
  • variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
  • the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (F s) and three hypervariable regions (HVRs).
  • F s conserved framework regions
  • HVRs hypervariable regions
  • antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880- 887 (1993); Clarkson et al., Nature 352:624-628 (1991).
  • vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
  • the term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
  • Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as
  • Alkyl is C1-C18 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1 -propyl (n-Pr, n-propyl, - CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1 -butyl (n-Bu, n-butyl, - CH2CH2CH2CH3), 2-methyl-l -propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, - CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, - CH2CH2CH2CH2
  • Ci-Cs alkyl refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 8 carbon atoms.
  • Representative “Ci-Cs alkyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, - n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl; while branched Ci-Cs alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, unsaturated Ci-Cs alkyls include, but are not limited to, -vinyl, -allyl, -1-buteny
  • Ci-Cs alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-C 8 alkyl, -0-(d-C 8 alkyl), -aryl, -C(0)R', -OC(0)R', - C(0)OR', -C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 -NHC(0)R', -SO 3 R', -S(0) 2 R', -S(0)R', -OH, - halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; where each R' is independently selected from H, -Ci-Cs alkyl and aryl.
  • C 1 -C 12 alkyl refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 12 carbon atoms.
  • a C 1 -C 12 alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-Cs alkyl, -0-(Ci-Cs alkyl), -aryl, -C(0)R', -OC(0)R', -C(0)OR', -C(0)NH 2 , -C(0)NHR', - C(0)N(R') 2 -NHC(0)R', -SO 3 R', -S(0) 2 R', -S(0)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), - N(R') 2 and -CN; where each R' is independently selected from H, -Ci-Cs alkyl and aryl
  • Ci-Ce alkyl refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 6 carbon atoms.
  • Representative “Ci-Ce alkyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -and n-hexyl; while branched Ci-Ce alkyls include, but are not limited to, -isopropyl, -sec-butyl, - isobutyl, -tert-butyl, -isopentyl, and 2-methylbutyl; unsaturated Ci-Ce alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylenyl, -1-pentenyl, -2-penten
  • C 1 -C4 alkyl refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 4 carbon atoms.
  • Representative “C 1 -C4 alkyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl; while branched C 1 -C4 alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl;
  • unsaturated C 1 -C4 alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylenyl.
  • a C 1 -C4 alkyl group can be unsubstituted or substituted with one or more groups, as described above for Ci-Cs alkyl group.
  • Alkoxy is an alkyl group singly bonded to an oxygen.
  • exemplary alkoxy groups include, but are not limited to, methoxy (-OCH 3 ) and ethoxy (-OCH 2 CH 3 ).
  • a "C 1 -C5 alkoxy” is an alkoxy group with 1 to 5 carbon atoms. Alkoxy groups may can be unsubstituted or substituted with one or more groups, as described above for alkyl groups.
  • Alkenyl is C2-CI8 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp 2 double bond.
  • C 2 -C 8 alkenyl is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp 2 double bond.
  • Alkynyl is C2-C18 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond. Examples include, but are not limited to: acetylenic (-C ⁇ CH) and propargyl (-CH 2 C ⁇ CH).
  • a "C 2 - Cs alkynyl” is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • Typical alkylene radicals include, but are not limited to: methylene (-CH 2 -) 1,2-ethyl (-CH 2 CH 2 -), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like.
  • Ci-Cio alkylene is a straight chain, saturated hydrocarbon group of the formula -(CH 2 )HO-.
  • Examples of a Ci-Cio alkylene include methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, ocytylene, nonylene and decalene.
  • alkenylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2- 18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • Alkynylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • Typical alkynylene radicals include, but are not limited to: acetylene (-C ⁇ C-), propargyl
  • Aryl refers to a carbocyclic aromatic group.
  • aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl.
  • a carbocyclic aromatic group or a heterocyclic aromatic group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-C 8 alkyl, -0-(d-C 8 alkyl), -aryl, -C(0)R', -OC(0)R', - C(0)OR ⁇ -C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 -NHC(0)R', -S(0) 2 R', -S(0)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; wherein each R' is independently selected from H, -Ci-C 8 alkyl and aryl.
  • a "C 5 -C 2 o aryl” is an aryl group with 5 to 20 carbon atoms in the carbocyclic aromatic rings. Examples of C 5 -C 2 o aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A Cs-C 2 o aryl group can be substituted or unsubstituted as described above for aryl groups.
  • a "C5-C14 aryl” is an aryl group with 5 to 14 carbon atoms in the carbocyclic aromatic rings. Examples of C5-C14 aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl.
  • a C 5 -Ci4 aryl group can be substituted or unsubstituted as described above for aryl groups.
  • arylene is an aryl group which has two covalent bonds and can be in the ortho, meta, or para configurations as shown in the following structures:
  • the phenyl group can be unsubstituted or substituted with up to four groups including, but not limited to, -Ci-Cg alkyl, -0-(d-C 8 alkyl), -aryl, -C(0)R', -OC(0)R', -C(0)OR', - C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 -NHC(0)R ⁇ -S(0) 2 R', -S(0)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; wherein each R' is independently selected from H, -Ci-C 8 alkyl and aryl.
  • Arylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl radical.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, 2- phenylethen-l-yl, naphthylmethyl, 2-naphthylethan-l-yl, 2-naphthylethen-l-yl, naphthobenzyl, 2- naphthophenylethan-l-yl and the like.
  • the arylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.
  • Heteroarylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heteroaryl radical.
  • Typical heteroarylalkyl groups include, but are not limited to, 2- benzimidazolylmethyl, 2-furylethyl, and the like.
  • the heteroarylalkyl group comprises 6 to 20 carbon atoms, e.g.
  • the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the heteroarylalkyl group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S.
  • the heteroaryl moiety of the heteroarylalkyl group may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.
  • Substituted alkyl means alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a substituent.
  • Heteroaryl and “heterocycle” refer to a ring system in which one or more ring atoms is a heteroatom, e.g. nitrogen, oxygen, and sulfur.
  • the heterocycle radical comprises 3 to 20 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S.
  • a heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.
  • heterocycles are described, e.g., in Paquette, Leo A., "Principles of Modern Heterocyclic Chemistry” (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566.
  • heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, bis- tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, bis-t
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2- pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3 -pyridazinyl, 4-pyridazinyl, 5 -pyridazinyl, 6- pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5 -pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5 -pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5 -thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1 -aziridyl, 1 -azetedyl, 1 -pyrrolyl, 1 -imidazolyl, 1 - pyrazolyl, and 1 -piperidinyl.
  • C3-C8 heterocycle refers to an aromatic or non-aromatic C3-C8 carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N.
  • C3-C8 heterocycle examples include, but are not limited to, benzofuranyl, benzothiophene, indolyl, benzopyrazolyl, coumarinyl, isoquinolinyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl, isoxazolyl and tetrazolyl.
  • a C3-C8 heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -Ci-Cg alkyl, -0-(Ci-C 8 alkyl), -aryl, -C(0)R ⁇ -OC(0)R ⁇ -C(0)OR ⁇ -C(0)NH 2 , - C(0)NHR', -C(0)N(R') 2 -NHC(0)R', -S(0) 2 R', -S(0)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), - N(R') 2 and -CN; wherein each R' is independently selected from H, -Ci-Cs alkyl and aryl.
  • C 3 -Cs heterocyclo refers to a C3-C8 heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond.
  • a C3-C8 heterocyclo can be unsubstituted or substituted with up to six groups including, but not limited to, -Ci-Cs alkyl, - 0-(Ci-Cg alkyl), -aryl, -C(0)R ⁇ -OC(0)R ⁇ -C(0)OR ⁇ -C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 - NHC(0)R', -S(0) 2 R', -S(0)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; wherein each R' is independently selected from H, -Ci-Cs alkyl and aryl.
  • C 3 -C 2 o heterocycle refers to an aromatic or non-aromatic C 3 -C8 carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N.
  • a C 3 -C 2 o heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -Ci-Cs alkyl, -0-(Ci-Cs alkyl), -aryl, -C(0)R', - OC(0)R ⁇ -C(0)OR ⁇ -C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 -NHC(0)R', -S(0) 2 R', -S(0)R', - OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; wherein each R' is independently selected from H, -Ci-Cs alkyl and aryl.
  • C3-C 2 o heterocyclo refers to a C3-C 2 o heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond.
  • Carbocycle means a saturated or unsaturated ring having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle.
  • Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g. arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system.
  • Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1 -cyclopent-l-enyl, l-cyclopent-2-enyl, l -cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l -cyclohex-3-enyl, cycloheptyl, and cyclooctyl.
  • a "C3-C8 carbocycle” is a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocyclic ring.
  • Representative C3-C8 carbocycles include, but are not limited to, - cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1 ,3- cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1 ,3-cycloheptadienyl, -1 ,3,5- cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl.
  • a C3-C8 carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-Cs alkyl, - 0-(Ci-Cg alkyl), -aryl, -C(0)R', -OC(0)R ⁇ -C(0)OR', -C(0)NH 2 , -C(0)NHR', -C(0)N(R') 2 - NHC(0)R', -S(0) 2 R', -S(0)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN; where each R' is independently selected from H, -Ci-Cs alkyl and aryl.
  • C3-C8 carbocyclo refers to a C3-C8 carbocycle group defined above wherein one of the carbocycle groups' hydrogen atoms is replaced with a bond.
  • Linker refers to a chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches an antibody to a drug moiety.
  • linkers include a divalent radical such as an alkyldiyl, an aryldiyl, a heteroaryldiyl, moieties such as: -(CR 2 ) n O(CR 2 ) n -, repeating units of alkyloxy (e.g. polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g.
  • linkers can comprise one or more amino acid residues, such as valine, phenylalanine, lysine, and homolysine.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • Enantiomers refer to two stereoisomers of a compound which are non- superimposable mirror images of one another.
  • Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light.
  • the prefixes D and L, or R and S are used to denote the absolute configuration of the molecule about its chiral center(s).
  • the prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory.
  • a compound prefixed with (+) or d is dextrorotatory.
  • these stereoisomers are identical except that they are mirror images of one another.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • racemic mixture A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • racemic mixture and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • leaving group refers to a functional group that can be substituted by another functional group. Certain leaving groups are well known in the art, and examples include, but are not limited to, a halide ⁇ e.g., chloride, bromide, iodide), methanesulfonyl (mesyl), p- toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate.
  • a halide ⁇ e.g., chloride, bromide, iodide
  • methanesulfonyl methanesulfonyl
  • p- toluenesulfonyl tosyl
  • triflate trifluoromethylsulfonate
  • protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound.
  • an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound.
  • Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
  • the invention is based, in part, on antibodies that bind to Lg 5 and immunoconjugates comprising such antibodies.
  • Antibodies and immunoconjugates of the invention are useful, e.g., for the diagnosis or treatment of LgR5 -positive cancers.
  • the invention provides isolated antibodies that bind to LgPv5.
  • LgR5 is is a seven-transmembrane protein found, for example, on the surface of actively cycling intestinal stem cells. As demonstrated herein, LgR5 is expressed in about 77% of colon tumor sections examined.
  • SEQ ID NO: 67 An exemplary naturally occurring human LgR5 precursor protein sequence, with signal sequence (amino acids 1-21) is provided in SEQ ID NO: 67, and the corresponding mature LgR5 protein sequence is shown in SEQ ID NO: 68 (corresponding to amino acids 22-907 of SEQ ID NO: 67).
  • an anti-LgR5 antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within amino acids 22-555 of SEQ ID NO: 67; (b) binds LgR5 with an affinity of ⁇ 5 nM, or ⁇ 4 nM, or ⁇ 3 nM, or ⁇ 2 nM, or ⁇ 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM; (c) does not significantly disrupt the binding of R-spondin (RSPO) to LgR5; (d) does not significantly disrupt beta-catenin signaling; (e) does not significantly disrupt RSPO activation of LgR5 signaling; (f) activates caspase 3 cleavage; (g) recognizes both human and rodent LgR5; (h) recognizes human LgR5 but not rodent LgR5; (i) does not significantly inhibit tumor
  • the anti-LgR5 antibody is 8E11 and humanized variants thereof, such as hu8El l.v2; YW353; 2H6; and 3G12.
  • LgR5 is human LgR5.
  • LgR5 is selected from human, cynomolgus monkey, mouse, and rat LgR5.
  • binding of an anti-LgR5 antibody to an epitope of LgR5 may be determined by expressing LgR5 polypeptides with N- and C-terminal deletions in 293 cells and testing by FACS as described in Example I binding of the antibody to the truncated polypeptides.
  • LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
  • the epitope of LgR5 comprises the lucine rich N-terminal domain of LgR5 ⁇ e.g., amino acid residues 25-66 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises one or more lucine rich repeats (LRR) of LgR5 ⁇ e.g., amino acid residues 67-446 of SEQ ID NO:67; LRRs 1-16 of LgR5). ). In some embodiments, the epitope of LgR5 comprises LRR 1 of LgR5 ⁇ e.g., amino acid residues 67-90 of SEQ ID NO:67).
  • LRR lucine rich repeats
  • the epitope of LgR5 comprises LRR 2 of LgR5 ⁇ e.g., amino acid residues 91-112 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 3 of LgR5 ⁇ e.g., amino acid residues 115-136 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 4 of LgR5 (e.g., amino acid residues 139-160 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 5 of LgR5 (e.g., amino acid residues 163-184 of SEQ ID NO:67).
  • the epitope of LgR5 comprises LRR 6 of LgR5 (e.g., amino acid residues 187-208 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 7 of LgR5 (e.g., amino acid residues 211-232 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 8 of LgR5 (e.g., amino acid residues 235-256 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 9 of LgR5 (e.g., amino acid residues 258-279 of SEQ ID NO:67).
  • the epitope of LgR5 comprises LRR 10 of LgR5 (e.g., amino acid residues 282-303 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 11 of LgR5 (e.g., amino acid residues 306- 328 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 12 of LgR5 (e.g., amino acid residues 329-350 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 13 of LgR5 (e.g., amino acid residues 353-374 of SEQ ID NO:67).
  • the epitope of LgR5 comprises LRR 14 of LgR5 (e.g., amino acid residues 375- 396 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 15 of LgR5 (e.g., amino acid residues 399-420 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 16 of LgR5 (e.g., amino acid residues 423-446 of SEQ ID NO:67).
  • the epitope of LgR5 comprises any of LRRl to LRRl 1, LRR2 to LRRl 1, LRR3 to LRRl l, LLR1 to LLR3, LLR2 to LLR3, LLR2 to LLR8, LLR3 to LL7, or LLR4 to LLR6.
  • the epitope of LgR5 comprises an epitope within amino acids 22-555 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-424 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-123 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-323 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 324-555 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 324-424 of SEQ ID NO: 67.
  • (b) binds LgR5 with an affinity of ⁇ 5 iiM. or ⁇ 4 iiM. or ⁇ 3 iiM. or ⁇ 2 iiM. or ⁇ l iiM. and optionally > 0.0001 iiM. or > 0.001 iiM. or > 0.01 nM
  • binding affinity may be determined according to a BIAcore ® assay as described herein in Example E.
  • Kd may be measured using surface plasmon resonance assays using a BIACORE -3000 (BIAcore, Inc., Piscataway, NJ).
  • BIAcoreTM research grade CM5 chips may be activated with l-ethyl-3-(3-dimethylaminopropyl)
  • Goat anti-human Fc IgGs may be coupled to the chips to achieve approximately 10,000 response units (RU) in each flow cell. Unreacted coupling groups may be blocked with 1M ethanolamine.
  • anti-LGR5 antibodies may be captured to achieve approximately 300 RU.
  • Two-fold serial dilutions of human LgR5 ECD may be injected in HBS-P buffer (0.01M HEPES pH7.4, 0.15M NaCl, 0.005% surfactant P20) at 25°C with a flow rate of 30 ⁇ /min.
  • association rates (k on ) and dissociation rates (k off ) may be calculated using a 1 : 1 Langmuir binding model (BIAcoreTM Evaluation Software version 3.2).
  • a spectrometer such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000- series SLM-Aminco ® spectrophotometer (ThermoSpectronic) with a stirred cuvette.
  • the anti-LgR5 antibody binds LgR5 with an affinity of about any of ⁇ 5 nM, or ⁇ 4 nM, or ⁇ 3 nM, or ⁇ 2 nM, or ⁇ 1 nM. In some embodiments, the anti-LgR5 antibody binds LgR5 with an affinity of about ⁇ 5. In some embodiments, the anti- LgR5 antibody binds LgR5 with an affinity of about ⁇ 4 nM. In some embodiments, the anti- LgR5 antibody binds LgR5 with an affinity of about ⁇ 3 nM.
  • the anti- LgR5 antibody binds LgR5 with an affinity of about ⁇ 2 nM.
  • LgR5 is human LgR5.
  • LgR5 is human LgR5 or cynomolgus monkey LgR5.
  • Methods of determining the ability of an anti-LgR5 antibody to disrupt the binding of an RSPO to LgR5 are known in the art.
  • the ability of an anti- LgR5 antibody to significantly disrupt the binding of an R-spondon (RSPO) to LgR5 may be determined by flow cytometry.
  • 293 cells expressing LgR5 may be contacted with fluorescently-labeled RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, in the presence and absence of an anti-LgR5 antibody. Binding of RSPO to the 293 cells may be detected using fluorescence-activated cell sorting (FACS).
  • FACS fluorescence-activated cell sorting
  • a decrease in RSPO binding in the presence of an anti-LgR5 antibody of less than about 25% relative to RSPO binding in the presence of a control antibody indicates that the anti-LgR5 antibody does not significantly disrupt binding of RSPO to LgR5.
  • the ability of an anti-LgR5 antibody to significantly disrupt the binding of an R-spondon (RSPO) to LgR5 may be determined by BIAcore assay.
  • LgR5 extracellular domain may be immobilized on CM5 chips, e.g., as described herein, and binding of RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, to the immobilized LgR5 may be determined in the presence and absence of an anti-LgR5 antibody.
  • a decrease in RSPO binding in the presence of an anti-LgR5 antibody of less than about 25% relative to RSPO binding in the presence of a control antibody indicates that the anti-LgR5 antibody does not significantly disrupt binding of RSPO to LgR5.
  • the RSPO is selected from RSPOl, RSP02, RSP03, and RSP04.
  • the antibody disrupts binding by less than about 25%, less than about 20%, less than about 15%, or less than about 10%.
  • the antibody does not detectably disrupt binding of an RSPO to LgR5.
  • LgR5 is human LgR5.
  • LgR5 is human LgR5 or cynomolgus monkey LgR5.
  • Methods of determining ability of an anti-LgR5 antibody to disrupt wnt/beta- catenin signaling are known in the art.
  • the ability of an anti-LgR5 antibody to significantly disrupt wnt/beta-catenin signaling may be determined using a reporter gene assay.
  • a reporter construct comprising a reporter gene (such as, for example, a luciferase gene) under the control of a wnt/beta-catenin responsive promoter (such as, for example, a promoter comprising multimerized TCF/LEF DNA-binding sites) may be transfected into cells that express LgR5.
  • the cells are then contacted with a Wnt ligand, such as Wnt3a, and an RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, in the presence and absence of an anti-LgR5 antibody, and luciferase expression is measured.
  • a decrease in luciferase expression in the presence of antibody of less than about 25% relative to luciferase expression in the presence of a control antibody indicates that the anti- LgR5 antibody does not significantly disrupt beta-catenin signaling.
  • the antibody disrupts beta-catenin signaling by less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, the antibody does not detectably disrupt beta-catenin signaling.
  • LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
  • a reporter construct comprising a reporter gene (such as, for example, a luciferase gene) under the control of a beta-catenin responsive promoter (such as, for example, a promoter comprising multimerized TCF/LEF DNA- binding sites) may be transfected into cells that express LgR5.
  • a reporter gene such as, for example, a luciferase gene
  • a beta-catenin responsive promoter such as, for example, a promoter comprising multimerized TCF/LEF DNA- binding sites
  • the cells may be then contacted with a Wnt ligand, such as Wnt3a, in the presence and absence of an RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, and the activation of LgR5 signaling may be measured as the increase in luciferase expression in the presence of the RSPO.
  • RSPO RSPOl
  • RSP02 RSP03
  • RSP04 RSP04
  • LgR5 signaling may be measured as the increase in luciferase expression in the presence of the RSPO.
  • the activation of LgR5 signaling may also be measured in the presence and absence of an anti-LgR5 antibody.
  • a decrease in the activation of LgR5 signaling in the presence of RSPOl, RSP02, RSP03, and/or RSP04 of less than about 25% when the cells are contacted with an anti-LgR5 antibody versus a control antibody indicates that the anti-LgR5 antibody does not significantly disrupt RSPO activation of LgR5 signaling.
  • the RSPO is selected from RSPOl, RSP02, RSP03, and RSP04.
  • the antibody disrupts RSPO activation of LgR5 signaling by less than about 25%, less than about 20%, less than about 15%, or less than about 10%.
  • the antibody does not detectably disrupt RSPO activation of LgR5 signaling.
  • LgR5 is human LgR5.
  • LgR5 is human LgR5 or cynomolgus monkey LgR5.
  • Methods of determining ability of an anti-LgR5 antibody to activate caspase 3 cleavage are known in the art.
  • the ability of an anti-LgR5 antibody to activate caspase 3 cleavage may be determined in a rodent xenograft model, e.g., as described in Example N.
  • the presence of cleaved caspase 3 may be measured as a function of tumor area, for example, in formalin fixed paraffin embedded (FFPE) small intestine and colon tissue collected from intestinal tumorogenesis model mice that were administered an anti-LgR5 antibody.
  • FFPE formalin fixed paraffin embedded
  • caspase 3 cleavage may be determined as a percent positive tumor area, e.g., as shown in Example N and Figure 18.
  • an anti-LgR5 antibody increases the percentage of caspase 3 positive tumor area according to the assay described in Example N by about any of at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% (i.e., the percentage of positive tumor area doubles).
  • rodent LgR5 is mouse or rat LgR5. In some embodiments, rodent LgR5 is mouse LgR5.
  • rodent LgR5 is mouse or rat LgR5.
  • rodent LgR5 is mouse LgR5.
  • an anti-LgR5 antibody determines the ability of an anti-LgR5 antibody to inhibit tumor growth in its unconjugated form.
  • a rodent xenograft model such as the D5124 pancreatic cancer xenograft model described in Example M is used.
  • an anti-LgR5 antibody does not significantly inhibit tumor growth in its unconjugated form in a LoVo colon cancer cell line xenograft model, for example, as described in Example L.
  • an anti-LgR5 antibody does not significantly inhibit tumor growth in its unconjugated form in a murine intestinal tumorigenesis model, for example, as described in Example N. Inhibition of tumor growth in a xenograft model or murine intestinal tumorigenesis model is determined relative to a vehicle control or control antibody.
  • an anti-LgR5 antibody inhibits tumor growth in its unconjugated form by less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, an anti-LgR5 antibody does not detectably inhibit tumor growth in its unconjugated form.
  • stem cell differentiation may be assayed by determining ability to differentiation of crypt base columnar cells (CBCs), which are fast-cycling stem cells in the small intestine that express LgR5, into, for example, enterocytes, goblet cells, and/or enteroendocrine cells, in the presence and absence of an anti-LgR5 antibody
  • CBCs crypt base columnar cells
  • an anti-LgR5 antibody is considered to not induce stem cell differentiation if about any of less than 25%, less than 20%, less than 15%, or less than 10% of a population of CBCs differentiates in the presence of the anti-LgR5 antibody under conditions in which a control antibody also induces stem cell differentiation in less than about 25% of a population of CBCs.
  • an anti-LgR5 antibody immunoconjugate inhibits tumor growth through a primary mechanism that is not inducing stem cell differentiation. In some such embodiments, the anti-LgR5 antibody immunoconjugate inhibits tumor growth through cytotoxic activity mediated through a cytotoxic agent conjugated to the antibody in the immunoconjugate.
  • the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30
  • HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31
  • HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32
  • HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27
  • HVR-L2 comprising
  • the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31.
  • the antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
  • the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 32; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 ; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • an anti-LgR5 antibody is humanized.
  • an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework.
  • the human acceptor framework is the human VL kappa IV consensus (VL K iv) framework and/or the VH framework V3 ⁇ 4.
  • the human acceptor framework is the human VL kappa IV consensus (VL K rv) framework and/or the VH framework V3 ⁇ 4 comprising an R71S mutation and an A78V mutation in heavy chain framework region FR3.
  • an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a heavy chain framework FR3 sequence selected from SEQ ID NOs: 40 to 43.
  • an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a heavy chain framework FR3 sequence of SEQ ID NO: 41.
  • the heavy chain variable domain framework is a modified human V3 ⁇ 4 framework having an FR3 sequence selected from SEQ ID NOs: 40 to 43.
  • the heavy chain variable domain framework is a modified human VHi framework having an FR3 sequence of SEQ ID NO: 41.
  • an anti-Lg 5 antibody comprises HVRs as in any of the above embodiments, and further comprises a light chain framework FR3 sequence of SEQ ID NO: 36.
  • the heavy chain variable domain framework is a modified VL kappa IV consensus (VL K iv) framework having an FR3 sequence of SEQ ID NO: 36.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20.
  • VH heavy chain variable domain
  • a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in a sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20.
  • a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in a sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20.
  • substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12.
  • an anti- LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18.
  • an anti- LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20.
  • the anti-LgR5 antibody comprises the VH sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20, including post-translational modifications of that sequence.
  • the VH comprises one, two or three HVRs selected from: (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 , and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
  • an anti-LgR5 antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11 , 13, 15, 17, and 19.
  • VL light chain variable domain
  • a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 1 1 , 13, 15, 17, and 19 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11 , 13, 15, 17, and 19.
  • a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11 , 13, 15, 17, and 19.
  • the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
  • an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5.
  • an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7.
  • an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9.
  • an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 1.
  • an anti- LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13.
  • an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15.
  • an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17.
  • an anti- LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19.
  • the anti-LgR5 antibody comprises the VL sequence of an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, and 19, including post-translational modifications of that sequence.
  • the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
  • an anti-LgR5 antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 6 and SEQ ID NO: 5, respectively, including post-translational modifications of those sequences.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 8 and SEQ ID NO: 7, respectively, including post-translational modifications of those sequences.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 10 and SEQ ID NO: 9, respectively, including post-translational modifications of those sequences.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 12 and SEQ ID NO: 11, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 14 and SEQ ID NO: 13, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 16 and SEQ ID NO: 15, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 18 and SEQ ID NO: 17, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 20 and SEQ ID NO: 19, respectively, including post-translational modifications of those sequences.
  • the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein.
  • an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 22-323.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 1-312.
  • an anti-LgR5 antibody is a monoclonal antibody, including a chimeric, humanized or human antibody.
  • an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment.
  • the antibody is a substantially full length antibody, e.g., an IgGl antibody or other antibody class or isotype as defined herein.
  • an anti-LgR5 antibody may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
  • the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60
  • HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61
  • HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62
  • HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57
  • the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61.
  • the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:62.
  • the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 , and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 59.
  • an anti-LgR5 antibody is a human antibody.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 26.
  • VH heavy chain variable domain
  • a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 26 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • substitutions e.g., conservative substitutions
  • insertions, or deletions relative to the reference sequence but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 26.
  • a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 26.
  • the anti-LgR5 antibody comprises the VH sequence of SEQ ID NO: 26, including post-translational modifications of that sequence.
  • the VH comprises one, two or three HVRs selected from: (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 60, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 , and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62.
  • an anti-LgR5 antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 25.
  • VL light chain variable domain
  • a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 25 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • the anti-LgR5 antibody comprises the VL sequence of SEQ ID NO: 25, including post-translational modifications of that sequence.
  • the VL comprises one, two or three HVRs selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
  • an anti-LgR5 antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 26 and SEQ ID NO: 25, respectively, including post-translational modifications of those sequences.
  • the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein.
  • an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 22-123.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 1 -102.
  • an anti-LgR5 antibody is a monoclonal antibody, including a human antibody.
  • an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment.
  • the antibody is a substantially full length antibody, e.g. , an IgG2a antibody or other antibody class or isotype as defined herein.
  • an anti-LgR5 antibody may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
  • the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48
  • HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49
  • HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50
  • HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45
  • HVR-L2 comprising
  • the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
  • VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49.
  • the antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
  • the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 48, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 50; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • an anti-LgR5 antibody is humanized.
  • an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework.
  • the human acceptor framework is the human VL kappa consensus (VL K ) framework and/or the human VH subgroup 3 consensus (VH 3 ) framework.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22.
  • VH heavy chain variable domain
  • a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 22 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 22.
  • a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 22.
  • the anti-LgR5 antibody comprises the VH sequence of SEQ ID NO: 22, including post-translational modifications of that sequence.
  • the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 48, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
  • an anti-LgR5 antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21.
  • VL light chain variable domain
  • a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 21 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 21. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 21. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
  • the anti-LgR5 antibody comprises the VL sequence of SEQ ID NO: 21 , including post-translational modifications of that sequence.
  • the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 45; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
  • an anti-LgR5 antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 22 and SEQ ID NO: 21 , respectively, including post-translational modifications of those sequences.
  • the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein.
  • an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 22 and a VL sequence of SEQ ID NO: 21.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-423.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-402.
  • an antibody that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-555. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-534.
  • an anti-LgR5 antibody is a monoclonal antibody, including a chimeric, humanized or human antibody.
  • an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment.
  • the antibody is a substantially full length antibody, e.g., an IgGl antibody or other antibody class or isotype as defined herein.
  • an anti-LgR5 antibody may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
  • the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 51; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54
  • HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55
  • HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56
  • HVR-L1 comprising the amino acid sequence of SEQ ID NO: 51
  • HVR-L2 comprising
  • the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
  • VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
  • the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55.
  • the antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
  • the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51 ; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51 ; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 56; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51 ; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • an anti-LgR5 antibody is humanized.
  • an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework.
  • the human acceptor framework is the human VL kappa consensus (VL K ) framework and/or the human VH subgroup 3 (VH 3 ) framework.
  • an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 24.
  • VH heavy chain variable domain
  • a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 24 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 24.
  • a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 24.
  • the anti-LgR5 antibody comprises the VH sequence of SEQ ID NO: 24, including post-translational modifications of that sequence.
  • the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
  • an anti-LgR5 antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23.
  • VL light chain variable domain
  • a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 23 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5.
  • a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 23. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 23. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
  • the anti-LgR5 antibody comprises the VL sequence of the amino acid sequence of SEQ ID NO: 23, including post-translational modifications of that sequence.
  • the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 51 ; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
  • an anti-LgR5 antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
  • the antibody comprises the VH and VL sequences in SEQ ID NO: 24 and SEQ ID NO: 23, respectively, including post-translational modifications of those sequences.
  • the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein.
  • an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 24 and a VL sequence of SEQ ID NO: 23.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-423.
  • an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-402.
  • an antibody that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-555. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-534.
  • an anti-Lg 5 antibody is a monoclonal antibody, including a chimeric, humanized or human antibody.
  • an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment.
  • the antibody is a substantially full length antibody, e.g., an IgGl antibody or other antibody class or isotype as defined herein.
  • an anti-LgR5 antibody may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
  • an antibody provided herein has a dissociation constant (Kd) of ⁇ ⁇ ⁇ , ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM, and optionally is > 10 "13 M. (e.g. 10 "8 M or less, e.g. from 10 "8 M to 10 "13 M, e.g., from 10 "9 M to 10 "13 M).
  • Kd dissociation constant
  • Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay.
  • Solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of ( 125 I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)).
  • MICROTITER multi-well plates (Thermo Scientific) are coated overnight with 5 ⁇ g/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23°C).
  • a non-adsorbent plate (Nunc #269620)
  • 100 pM or 26 pM [ 125 I] -antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res. 57:4593-4599 (1997)).
  • the Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN- 20 ® ) in PBS. When the plates have dried, 150 ⁇ /well of scintillant (MICROSCINT-20TM;
  • Kd is measured using surface plasmon resonance assays using a BIACORE ® -2000 or a BIACORE ® -3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with immobilized antigen CM5 chips at -10 response units (RU).
  • CM5 carboxymethylated dextran biosensor chips
  • EDC N-ethyl- N'- (3-dimethylaminopropyl)-carbodiimide hydrochloride
  • NHS N-hydroxysuccinimide
  • Antigen is diluted with 10 niM sodium acetate, pH 4.8, to 5 ⁇ g/ml (-0.2 ⁇ ) before injection at a flow rate of 5 ⁇ /minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN- 20TM) surfactant (PBST) at 25°C at a flow rate of approximately 25 ⁇ /min.
  • TWEEN- 20TM polysorbate 20
  • association rates (k on ) and dissociation rates (k 0 ff) are calculated using a simple one-to-one Langmuir binding model (BIACORE Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams.
  • the equilibrium dissociation constant (Kd) is calculated as the ratio k 0 ff/k on See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 10 6
  • an antibody provided herein is an antibody fragment.
  • Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, and other fragments described below.
  • Fab fragment antigen
  • Fab' fragment antigen binding domain
  • Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161 ; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).
  • Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
  • Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
  • a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 Bl).
  • Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
  • recombinant host cells e.g. E. coli or phage
  • an antibody provided herein is a chimeric antibody.
  • Certain chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)).
  • a chimeric antibody comprises a non-human variable region (e.g. , a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region.
  • a chimeric antibody is a "class switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
  • a chimeric antibody is a humanized antibody.
  • a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
  • a humanized antibody comprises one or more variable domains in which HV s, e.g. , CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
  • a humanized antibody optionally will also comprise at least a portion of a human constant region.
  • some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
  • a non-human antibody e.g., the antibody from which the HVR residues are derived
  • Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit” method ⁇ see, e.g., Sims et al. J.
  • an antibody provided herein is a human antibody.
  • Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
  • Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous
  • Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. ⁇ See, e.g., Kozbor J. Immunol, 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006).
  • Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human- human hybridomas).
  • Human hybridoma technology Trioma technology
  • Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3): 185-91 (2005).
  • Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
  • Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described, e.g., in the McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol.
  • repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PC ) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., Ann. Rev. Immunol, 12: 433-455 (1994).
  • Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
  • Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas.
  • the naive repertoire can be cloned (e.g.
  • naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol, 227: 381-388 (1992).
  • Patent publications describing human antibody phage libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.
  • Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
  • an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody.
  • Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites.
  • one of the binding specificities is for LgR5 and the other is for any other antigen.
  • one of the binding specificities is for LgR5 and the other is for CD3. See, e.g., U.S. Patent No. 5,821,337.
  • bispecific antibodies may bind to two different epitopes of LgR5.
  • Bispecific antibodies may also be used to localize cytotoxic agents to cells which express LgR5.
  • Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
  • Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities ⁇ see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole” engineering ⁇ see, e.g., U.S. Patent No.
  • Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments ⁇ see, e.g., US Patent No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies ⁇ see, e.g., Kostelny et al., J. Immunol, 148(5):1547-1553 (1992)); using "diabody” technology for making bispecific antibody fragments ⁇ see, e.g., Hollinger et al., Proc. Natl. Acad. Sci.
  • Engineered antibodies with three or more functional antigen binding sites are also included herein ⁇ see, e.g. US 2006/0025576A1).
  • the antibody or fragment herein also includes a "Dual Acting FAb” or “DAF” comprising an antigen binding site that binds to Lg 5 as well as another, different antigen (see, US 2008/0069820, for example).
  • amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
  • Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
  • antibody variants having one or more amino acid substitutions are provided.
  • Sites of interest for substitutional mutagenesis include the HVRs and FRs.
  • Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions.” More substantial changes are provided in Table 1 under the heading of "exemplary substitutions,” and as further described below in reference to amino acid side chain classes.
  • Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased
  • Amino acids may be grouped according to common side-chain properties:
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
  • substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody).
  • a parent antibody e.g. a humanized or human antibody
  • the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody.
  • An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g. , using phage display -based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
  • Alterations may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR "hotspots," i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity.
  • HVR "hotspots” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity.
  • Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g. , in Hoogenboom
  • affinity maturation diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g. , error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
  • a secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity.
  • Another method to introduce diversity involves HVR- directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
  • substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
  • conservative alterations e.g., conservative substitutions as provided herein
  • Such alterations may be outside of HVR "hotspots" or SDRs.
  • each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
  • a useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by
  • a residue or group of target residues e.g., charged residues such as arg, asp, his, lys, and glu
  • a neutral or negatively charged amino acid e.g., alanine or polyalanine
  • Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions.
  • a crystal structure of an antigen-antibody complex is used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • terminal insertions include an antibody with an N-terminal methionyl residue.
  • Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
  • ADEPT enzyme
  • an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated.
  • Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
  • the carbohydrate attached thereto may be altered.
  • Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997).
  • the oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the "stem" of the biantennary oligosaccharide structure.
  • modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.
  • antibody variants having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
  • the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%.
  • the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example.
  • Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd).
  • Examples of publications related to "defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng.
  • Examples of cell lines capable of producing defucosylated antibodies include Led 3 CHO cells deficient in protein fucosylation ( ipka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 Al, Presta, L; and
  • WO 2004/056312 Al Adams et al., especially at Example 11
  • knockout cell lines such as alpha- 1,6-fucosyltransferase gene, FUT8, knockout CHO cells ⁇ see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003/085107).
  • Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean- Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided.
  • Such antibody variants may have improved CDC function.
  • Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 ( aju, S.); and WO 1999/22764 (Raju, S.).
  • one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant.
  • the Fc region variant may comprise a human Fc region sequence ⁇ e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification ⁇ e.g. a substitution) at one or more amino acid positions.
  • the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
  • In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
  • Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
  • NK cells express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII and Fc(RIII.
  • FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991).
  • Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Patent No. 5,500,362 ⁇ see, e.g. Hellstrom, I. et al. Proc. Nat 'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc.
  • non-radioactive assays methods may be employed ⁇ see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96 ® non-radioactive cytotoxicity assay (Promega, Madison, WI).
  • Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
  • ADCC activity of the molecule of interest may be assessed in vivo, e.g. , in a animal model such as that disclosed in Clynes et al. Proc. Natl Acad. Sci. USA 95:652-656 (1998).
  • Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
  • a CDC assay may be performed ⁇ see, for example, Gazzano-Santoro et al., J. Immunol.
  • FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., Int 'l. Immunol. 18(12):1759-1769 (2006)).
  • Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056).
  • Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).
  • an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
  • alterations are made in the Fc region that result in altered (i.e., either improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No. 6,194,551, WO 99/51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
  • CDC Complement Dependent Cytotoxicity
  • Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826). [0274] See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No.
  • cysteine engineered antibodies e.g., "thioMAbs”
  • one or more residues of an antibody are substituted with cysteine residues.
  • the substituted residues occur at accessible sites of the antibody.
  • reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein.
  • any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
  • Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent No. 7,521,541.
  • An exemplary hu8El 1.v2 light chain (LC) V205C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 64 and 74, respectively.
  • An exemplary hu8El l.v2 heavy chain (HC) Al 18C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 75 and 63, respectively.
  • An exemplary hu8El l .v2 heavy chain (HC) S400C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 76 and 63, respectively.
  • An exemplary YW353 light chain (LC) V205C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 66 and 77, respectively.
  • An exemplary YW353 heavy chain (HC) Al 18C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 78 and 65, respectively.
  • An exemplary YW353 heavy chain (HC) S400C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 79 and 65, respectively.
  • V205C cysteine engineered thiomabs comprise a light chain comprising a variable region selected from SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 and a constant region of SEQ ID NO: 80; and a heavy chain comprising a variable region selected from SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 and a human heavy chain constant region, such as an IgGl .
  • Al 18C cysteine engineered thiomabs comprise a light chain comprising a variable region selected from SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 and a human light chain constant region, such as a kappa light chain constant region; and a heavy chain comprising a variable region selected from SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 and a constant region of SEQ ID NO: 81.
  • S400C cysteine engineered thiomabs comprise a light chain comprising a variable region selected from SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 and a human light chain constant region, such as a kappa light chain constant region; and a heavy chain comprising a variable region selected from SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 and a constant region of SEQ ID NO: 82.
  • an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
  • the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
  • Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol,
  • carboxymethylcellulose dextran
  • polyvinyl alcohol polyvinyl pyrrolidone
  • poly-1, 3-dioxolane poly-l,3,6-trioxane
  • ethylene/maleic anhydride copolymer polyaminoacids (either
  • polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
  • the polymer may be of any molecular weight, and may be branched or unbranched.
  • the number of polymers attached to the antibody may vary, and if more than one polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
  • conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided.
  • the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)).
  • the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.
  • Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No. 4,816,567.
  • isolated nucleic acid encoding an anti-LgPv5 antibody described herein is provided.
  • Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody).
  • one or more vectors e.g., expression vectors
  • a host cell comprising such nucleic acid is provided.
  • a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
  • the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NSO, Sp20 cell).
  • a method of making an anti-Lg 5 antibody comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
  • nucleic acid encoding an antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
  • nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
  • Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
  • antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
  • U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in E. coli.
  • the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
  • Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. [0286] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos.
  • Vertebrate cells may also be used as hosts.
  • mammalian cell lines that are adapted to grow in suspension may be useful.
  • useful mammalian host cell lines are monkey kidney CVl line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.
  • monkey kidney cells (CVl); African green monkey kidney cells (VEPvO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al Annals N Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells.
  • Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR " CHO cells (Urlaub et al Proc. Natl. Acad. Sci.
  • Anti-LgR5 antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
  • an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, BIACore ® , FACS, or Western blot.
  • competition assays may be used to identify an antibody that competes with any of the antibodies described herein for binding to LgR5.
  • such a competing antibody binds to the same epitope ⁇ e.g., a linear or a conformational epitope) that is bound by an antibody described herein.
  • epitope e.g., a linear or a conformational epitope
  • Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).
  • immobilized LgR5 is incubated in a solution comprising a first labeled antibody that binds to LgR5 ⁇ e.g. , any of the antibodies described herein) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to LgR5.
  • the second antibody may be present in a hybridoma supernatant.
  • immobilized LgR5 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to LgR5, excess unbound antibody is removed, and the amount of label associated with immobilized LgR5 is measured.
  • the invention also provides immunoconjugates comprising an anti-LgR5 antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins ⁇ e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes (i.e., a radioconjugate).
  • cytotoxic agents such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins ⁇ e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof
  • toxins ⁇ e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof
  • radioactive isotopes i.e., a radioconjugate
  • Immunoconjugates allow for the targeted delivery of a drug moiety to a tumor, and, in some embodiments intracellular accumulation therein, where systemic administration of unconjugated drugs may result in unacceptable levels of toxicity to normal cells (Polakis P. (2005) Current Opinion in Pharmacology 5:382-387).
  • ADC Antibody-drug conjugates
  • ADC are targeted chemotherapeutic molecules which combine properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to antigen-expressing tumor cells (Teicher, B.A. (2009) Current Cancer Drug Targets 9:982-1004), thereby enhancing the therapeutic index by maximizing efficacy and minimizing off-target toxicity (Carter, P.J. and Senter P.D. (2008) The Cancer Jour. 14(3): 154-169; Chari, R.V. (2008) Acc. Chem. Res. 41 :98-107 .
  • the ADC compounds of the invention include those with anticancer activity.
  • the ADC compounds include an antibody conjugated, i.e. covalently attached, to the drug moiety.
  • the antibody is covalently attached to the drug moiety through a linker.
  • the antibody-drug conjugates (ADC) of the invention selectively deliver an effective dose of a drug to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved while increasing the therapeutic index ("therapeutic window").
  • the drug moiety (D) of the antibody-drug conjugates (ADC) may include any compound, moiety or group that has a cytotoxic or cytostatic effect.
  • Drug moieties may impart their cytotoxic and cytostatic effects by mechanisms including but not limited to tubulin binding, DNA binding or intercalation, and inhibition of R A polymerase, protein synthesis, and/or topoisomerase.
  • Exemplary drug moieties include, but are not limited to, a maytansinoid, dolastatin, auristatin, calicheamicin, pyrrolobenzodiazepine (PBD), nemorubicin and its derivatives, PNU- 159682, anthracycline, duocarmycin, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinafide, and stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity.
  • PNU- 159682 anthracycline, duocarmycin, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinafide, and stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity.
  • Nonlimiting examples of such immunoconjugates are discussed in further detail below. .
  • An exemplary embodiment of an antibody-drug conjugate (ADC) compound comprises an antibody (Ab) which targets a tumor cell, a drug moiety (D), and a linker moiety (L) that attaches Ab to D.
  • the antibody is attached to the linker moiety (L) through one or more amino acid residues, such as lysine and/or cysteine.
  • An exemplary ADC has Formula I:
  • the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine residues.
  • free cysteine residues are introduced into the antibody amino acid sequence by the methods described herein.
  • Exemplary ADC of Formula I include, but are not limited to, antibodies that have 1, 2, 3, or 4 engineered cysteine amino acids (Lyon, . et al (2012) Methods in Enzym. 502:123-138).
  • one or more free cysteine residues are already present in an antibody, without the use of engineering, in which case the existing free cysteine residues may be used to conjugate the antibody to a drug.
  • an antibody is exposed to reducing conditions prior to conjugation of the antibody in order to generate one or more free cysteine residues.
  • a “Linker” (L) is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties (D) to an antibody (Ab) to form an antibody-drug conjugate (ADC) of Formula I.
  • antibody-drug conjugates (ADC) can be prepared using a Linker having reactive functionalities for covalently attaching to the drug and to the antibody.
  • a cysteine thiol of an antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.
  • a linker has a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond.
  • reactive functionalities include maleimide, haloacetamides, a-haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates.
  • a linker has a functionality that is capable of reacting with an electrophilic group present on an antibody.
  • electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups.
  • a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit.
  • Nonlimiting exemplary such reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
  • a linker may comprise one or more linker components.
  • exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP”), valine-citrulline (“val-cit” or “vc”), alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (a "PAB”), N- Succinimidyl 4-(2-pyridylthio) pentanoate (“SPP”), and 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (“MCC”).
  • MC 6-maleimidocaproyl
  • MP maleimidopropanoyl
  • val-cit valine-citrulline
  • alanine-phenylalanine ala-phe
  • PAB p-aminobenzyloxycarbonyl
  • SPP N- Succinimidyl 4-(2-pyridylthio) pen
  • a linker may be a "cleavable linker," facilitating release of a drug.
  • Nonlimiting exemplary cleavable linkers include acid- labile linkers (e.g., comprising hydrazone), protease- sensitive ⁇ e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research 52: 127-131 (1992); US 5208020).
  • a linker has the following Formula II:
  • A is a "stretcher unit", and a is an integer from 0 to 1 ; W is an “amino acid unit”, and w is an integer from 0 to 12; Y is a "spacer unit”, and y is 0, 1, or 2.
  • An ADC comprising the linker of Formula II has the Formula 1(A): Ab-(A a -W w -Y y -D)p, wherein Ab, D, and p are defined as above for Formula I. Exemplary embodiments of such linkers are described in U.S. Patent No. 7,498,298, which is expressly incorporated herein by reference.
  • a linker component comprises a "stretcher unit" (A) that links an antibody to another linker component or to a drug moiety.
  • stretcher units are shown below (wherein the wavy line indicates sites of covalent attachment to an antibody, drug, or additional linker components):
  • a linker component comprises an "amino acid unit" (W).
  • the amino acid unit allows for cleavage of the linker by a protease, thereby facilitating release of the drug from the immunoconjugate upon exposure to intracellular proteases, such as lysosomal enzymes (Doronina et al. (2003) Nat. Biotechnol. 21 :778-784).
  • Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides.
  • Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or phe-lys);
  • phenylalanine-homolysine phe-homolys
  • methylalanine-val-cit N-methyl-valine-citrulline
  • Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly).
  • An amino acid unit may comprise amino acid residues that occur naturally and/or minor amino acids and/or non-naturally occurring amino acid analogs, such as citrulline.
  • Amino acid units can be designed and optimized for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.
  • peptide-type linkers can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments.
  • Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (e.g., E. Schroder and K. Liibke (1965) "The Peptides", volume 1, pp 76-136, Academic Press).
  • a linker component comprises a "spacer unit” (Y) that links the antibody to a drug moiety, either directly or through a stretcher unit and/or an amino acid unit.
  • a spacer unit may be "self-immolative” or a "non-self-immolative.”
  • a "non-self- immolative" spacer unit is one in which part or all of the spacer unit remains bound to the drug moiety upon cleavage of the ADC. Examples of non-self-immolative spacer units include, but are not limited to, a glycine spacer unit and a glycine-glycine spacer unit.
  • enzymatic cleavage of an ADC containing a glycine-glycine spacer unit by a tumor-cell associated protease results in release of a glycine-glycine-drug moiety from the remainder of the ADC.
  • the glycine-glycine-drug moiety is subjected to a hydrolysis step in the tumor cell, thus cleaving the glycine-glycine spacer unit from the drug moiety.
  • a "self-immolative" spacer unit allows for release of the drug moiety.
  • a spacer unit of a linker comprises a p-aminobenzyl unit. In some such
  • a p-aminobenzyl alcohol is attached to an amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is made between the benzyl alcohol and the drug (Hamann et al. (2005) Expert Opin. Ther. Patents (2005) 15: 1087-1103).
  • the spacer unit comprises p-aminobenzyloxycarbonyl (PAB).
  • PAB p-aminobenzyloxycarbonyl
  • an ADC comprising a self-immolative linker has the structure:
  • Q is -Ci-Cs alkyl, -0-(Ci-Cs alkyl), -halogen, -nitro, or -cyano;
  • m is an integer ranging from 0 to 4;
  • X may be one or more additional spacer units or may be absent; and
  • p ranges from 1 to about 20. In some embodiments, p ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4.
  • Nonlimiting exemplary X spacer units include: independently selected from H and Ci-Ce alkyl.
  • Rl and R2 are each -CH 3 .
  • self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazol-5- methanol derivatives (U.S. Patent No. 7,375,078; Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho- or para-aminobenzylacetals.
  • spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4- aminobutyric acid amides ( odrigues et al (1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) J. Amer. Chem. Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) J. Org. Chem. 55:5867).
  • Linkage of a drug to the a-carbon of a glycine residue is another example of a self- immolative spacer that may be useful in ADC (Kingsbury et al (1984) J. Med. Chem. 27: 1447).
  • linker L may be a dendritic type linker for covalent attachment of more than one drug moiety to an antibody through a branching, multifunctional linker moiety (Sun et al (2002) Bioorganic & Medicinal Chemistry Letters 12:2213-2215; Sun et al (2003) Bioorganic & Medicinal Chemistry 11 :1761-1768).
  • Dendritic linkers can increase the molar ratio of drug to antibody, i.e. loading, which is related to the potency of the ADC.
  • an antibody bears only one reactive cysteine thiol group, a multitude of drug moieties may be attached through a dendritic linker.
  • Nonlimiting exemplary linkers are shown below in the context of an ADC of
  • R 2 are independently selected from H and Ci-Ce alkyl. In some embodiments, Rl and R2 are each -
  • n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8.
  • each is independently H or Ci-Ce alkyl; and n is 1 to 12.
  • a linker is substituted with groups that modulate solubility and/or reactivity.
  • a charged substituent such as sulfonate (-S0 3 ⁇ ) or ammonium may increase water solubility of the linker reagent and facilitate the coupling reaction of the linker reagent with the antibody and/or the drug moiety, or facilitate the coupling reaction of Ab-L (antibody-linker intermediate) with D, or D-L (drug-linker intermediate) with Ab, depending on the synthetic route employed to prepare the ADC.
  • a portion of the linker is coupled to the antibody and a portion of the linker is coupled to the drug, and then the Ab-(linker portion) a is coupled to drug-(linker portion) 13 to form the ADC of Formula I.
  • the compounds of the invention expressly contemplate, but are not limited to, ADC prepared with the following linker reagents: bis-maieimido-trioxyethylene glycol (BMPEO), N-(P-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS), ⁇ -( ⁇ - maleimidocaproyloxy) succinimide ester (EMCS), N-fy-maleimidobutyryloxy] succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N- maleimidomethyl)cyclohexane- 1 -carboxy-(6-amidocaproate) (LC-SMCC), m-maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bro), ⁇
  • imidoesters such as dimethyl adipimidate HC1
  • active esters such as disuccinimidyl suberate
  • aldehydes such as glutaraldehyde
  • bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine
  • bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)- ethylenediamine
  • diisocyanates such as toluene 2,6-diisocyanate
  • bis-active fluorine compounds such as l,5-difluoro-2,4-dinitrobenzene
  • bis-maleimide reagents allow the attachment of the thiol group of a cysteine in the antibody to a thiol-containing drug moiety, linker, or linker-drug intermediate.
  • Other functional groups that are reactive with thiol groups include, but are not limited to, iodoacetamide, bromoacetamide, vinyl pyridine, disulfi
  • Certain useful linker reagents can be obtained from various commercial sources, such as Pierce Biotechnology, Inc. ( ockford, IL), Molecular Biosciences Inc.(Boulder, CO), or synthesized in accordance with procedures described in the art; for example, in Toki et al (2002) J. Org. Chem. 67:1866-1872; Dubowchik, et al. (1997) Tetrahedron Letters, 38:5257-60; Walker, M.A. (1995) J. Org. Chem. 60:5352-5355; Frisch et al (1996) Bioconjugate Chem.
  • an immunoconjugate comprises an antibody conjugated to one or more maytansinoid molecules.
  • Maytansinoids are derivatives of maytansine, and are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Patent No. 3896111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos.
  • Maytansinoid drug moieties are attractive drug moieties in antibody-drug conjugates because they are: (i) relatively accessible to prepare by fermentation or chemical modification or derivatization of fermentation products, (ii) amenable to derivatization with functional groups suitable for conjugation through non-disulfide linkers to antibodies, (iii) stable in plasma, and (iv) effective against a variety of tumor cell lines.
  • Certain maytansinoids suitable for use as maytansinoid drug moieties are known in the art and can be isolated from natural sources according to known methods or produced using genetic engineering techniques (see, e.g., Yu et al (2002) PNAS 99:7968-7973). Maytansinoids may also be prepared synthetically according to known methods.
  • Exemplary maytansinoid drug moieties include, but are not limited to, those having a modified aromatic ring, such as: C-19-dechloro (US Pat. No. 4256746) (prepared, for example, by lithium aluminum hydride reduction of ansamytocin P2); C-20-hydroxy (or C-20- demethyl) +/-C-19-dechloro (US Pat. Nos. 4361650 and 4307016) (prepared, for example, by demethylation using Streptomyces ox Actinomyces or dechlorination using LAH); and C-20- demethoxy, C-20-acyloxy (-OCOR), +/-dechloro (U.S. Pat. No. 4,294,757) (prepared, for example, by acylation using acyl chlorides), and those having modifications at other positions of the aromatic ring.
  • C-19-dechloro (US Pat. No. 4256746) (prepared, for example, by lithium aluminum hydride reduction of ansamyto
  • Exemplary maytansinoid drug moieties also include those having modifications such as: C-9-SH (US Pat. No. 4424219) (prepared, for example, by the reaction of maytansinol with H 2 S or P 2 S 5 ); C-14-alkoxymethyl(demethoxy/CH 2 OR)(US 4331598); C-14-hydroxymethyl or acyloxymethyl (CH 2 OH or CH 2 OAc) (US Pat. No. 4450254) (prepared, for example, from Nocardia); C-15-hydroxy/acyloxy (US 4364866) (prepared, for example, by the conversion of maytansinol by Streptomyces); C-15-methoxy (US Pat. Nos.
  • an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques.
  • the reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group.
  • the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.
  • Maytansinoid drug moieties include those having the structure:
  • Each R may independently be H or a Ci-Ce alkyl.
  • the alkylene chain attaching the amide group to the sulfur atom may be methanyl, ethanyl, or propyl, i.e., m is 1, 2, or 3 (US 633410; US 5208020; Chari et al (1992) Cancer Res. 52: 127-131 ; Liu et al (1996) Proc. Natl. Acad. Sci USA 93:8618-8623).
  • the maytansinoid drug moiety has the following stereochemistry:
  • Exemplary embodiments of maytansinoid drug moieties include, but are not limited to, DM
  • exemplary maytansinoid antibody-drug conjugates have the following structures and abbreviations (wherein Ab is antibody and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4):
  • Exemplary antibody-drug conjugates where DM1 is linked through a BMPEO linker to a thiol group of the antibody have the structure and abbreviation:
  • Ab is antibody; n is 0, 1, or 2; and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4.
  • Immunoconjugates containing maytansinoids, methods of making the same, and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020 and 5,416,064; US 2005/0276812 Al ; and European Patent EP 0 425 235 Bl, the disclosures of which are hereby expressly incorporated by reference. See also Liu et al. Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996); and Chari et al. Cancer Research 52:127-131 (1992).
  • antibody-maytansinoid conjugates may be prepared by chemically linking an antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. See, e.g., U.S. Patent No. 5,208,020 (the disclosure of which is hereby expressly incorporated by reference).
  • ADC with an average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody. In some instances, even one molecule of toxin/antibody is expected to enhance cytotoxicity over the use of naked antibody.
  • Exemplary linking groups for making antibody -maytansinoid conjugates include, for example, those described herein and those disclosed in U.S. Patent No. 5208020; EP Patent 0 425 235 Bl ; Chari et al. Cancer Research 52: 127-131 (1992); US 2005/0276812 Al; and US 2005/016993 Al, the disclosures of which are hereby expressly incorporated by reference.
  • Drug moieties include dolastatins, auristatins, and analogs and derivatives thereof (US 5635483; US 5780588; US 5767237; US 6124431).
  • Auristatins are derivatives of the marine mollusk compound dolastatin-10. While not intending to be bound by any particular theory, dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al (2001) Antimicrob. Agents and Chemother. 45(12):3580-3584) and have anticancer (US 5663149) and antifungal activity (Pettit et al (1998) Antimicrob. Agents Chemother.
  • the dolastatin/auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172; Doronina et al (2003) Nature Biotechnology
  • Exemplary auristatin embodiments include the N-terminus linked
  • R 2 is selected from H and Ci-Cs alkyl
  • R 3 is selected from H, Ci-Cs alkyl, C3-C8 carbocycle, aryl, Ci-Cs alkyl-aryl, Ci-Cs alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and Ci-Cs alkyl-(C3-Cs heterocycle);
  • R 4 is selected from H, Ci-Cs alkyl, C3-C8 carbocycle, aryl, Ci-Cs alkyl-aryl, Ci-Cs alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and Ci-Cs alkyl-(C3-Cs heterocycle);
  • R 5 is selected from H and methyl
  • R 4 and R 5 jointly form a carbocyclic ring and have the formula -(CR a R b ) n - wherein R a and R b are independently selected from H, Ci-Cs alkyl and C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6;
  • R 6 is selected from H and Ci-Cs alkyl
  • R 7 is selected from H, Ci-Cs alkyl, C3-C8 carbocycle, aryl, Ci-Cs alkyl-aryl, Ci-Cs alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and Ci-Cs alkyl-(C3-Cs heterocycle);
  • each R 8 is independently selected from H, OH, Ci-Cs alkyl, C3-C8 carbocycle and 0-(Ci- C 8 alkyl);
  • R 9 is selected from H and Ci-Cs alkyl
  • R 10 is selected from aryl or C3-C8 heterocycle
  • Z is O, S, NH, or NR 12 , wherein R 12 is Ci-Cg alkyl;
  • R 11 is selected from H, Ci-C 20 alkyl, aryl, C 3 -C 8 heterocycle, -(R 13 0) m -R 14 , or -(R 13 0) m - CH(R 15 ) 2 ;
  • n is an integer ranging from 1-1000;
  • R 13 is C 2 -Cs alkyl
  • R 14 is H or Ci-Cg alkyl
  • each occurrence of R 15 is independently H, COOH, -(CH 2 ) n -N(R 16 ) 2 , -(CH 2 ) n -S0 3 H, or -(CH 2 ) n -S0 3 -C 1 -C 8 alkyl;
  • each occurrence of R 16 is independently H, Ci-Cg alkyl, or -(CH 2 ) n -COOH;
  • R 18 is selected from -C(R 8 ) 2 -C(R 8 ) 2 -aryl, -C(R 8 ) 2 -C(R 8 ) 2 -(C 3 -C 8 heterocycle), and -C(R 8 ) 2 -C(R 8 ) 2 -(C 3 -C 8 carbocycle); and
  • n is an integer ranging from 0 to 6.
  • R 3 , R 4 and R 7 are independently isopropyl or sec-butyl and R 5 is -H or methyl. In an exemplary embodiment, R 3 and R 4 are each isopropyl, R 5 is -H, and R 7 is sec-butyl.
  • R 2 and R 6 are each methyl, and R 9 is -H.
  • each occurrence of R 8 is -OCH 3 .
  • R 3 and R 4 are each isopropyl, R 2 and R 6 are each methyl, R 5 is -H, R 7 is sec-butyl, each occurrence of R 8 is -OCH 3 , and R 9 is -H.
  • Z is -O- or -NH-.
  • R 10 is aryl
  • R 10 is -phenyl
  • R 11 is -H, methyl or t-butyl.
  • R 11 is -CH(R 15 ) 2 , wherein R 15 is -(CH 2 ) n - N(R 16 ) 2 , and R 16 is -Ci-Cg alkyl or -(CH 2 ) n -COOH.
  • R 11 is -CH(R 15 ) 2 , wherein R 15 is -(CH 2 ) n -
  • An exemplary auristatin embodiment of formula D E is MMAE, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:
  • An exemplary auristatin embodiment of formula D F is MMAF, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:
  • Other exemplary embodiments include monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008848) and monomethylvaline compounds having phenylalanine sidechain modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008603).
  • Nonlimiting exemplary embodiments of ADC of Formula I comprising MMAE or MMAF and various linker components have the following structures and abbreviations (wherein “Ab” is an antibody; p is 1 to about 8, “Val-Cit” is a valine-citrulline dipeptide; and “S” is a sulfur atom:
  • Nonlimiting exemplary embodiments of ADCs of Formula I comprising MMAF and various linker components further include Ab-MC-PAB-MMAF and Ab-PAB-MMAF.
  • Immunoconjugates comprising MMAF attached to an antibody by a linker that is not proteolytically cleavable have been shown to possess activity comparable to immunoconjugates comprising MMAF attached to an antibody by a proteolytically cleavable linker (Doronina et al. (2006) Bioconjugate Chem. 17:114-124). In some such embodiments, drug release is believed to be effected by antibody degradation in the cell.
  • peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments.
  • Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (see, e.g., E. Schroder and K. Liibke, "The Peptides", volume 1, pp 76-136, 1965, Academic Press).
  • Auristatin/dolastatin drug moieties may, in some embodiments, be prepared according to the methods of: US 7498298; US 5635483; US 5780588; Pettit et al (1989) J. Am. Chem. Soc.
  • auristatin/dolastatin drug moieties of formulas D E such as MMAE, and D F , such as MMAF, and drug-linker intermediates and derivatives thereof, such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF, and MC-vc-PAB-MMAE may be prepared using methods described in US 7498298; Doronina et al. (2006) Bioconjugate Chem. 17:114-124; and Doronina et al. (2003) Nat. Biotech. 21 :778-784and then conjugated to an antibody of interest.
  • the immunoconjugate comprises an antibody conjugated to one or more calicheamicin molecules.
  • the calicheamicin family of antibiotics, and analogues thereof, are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., (1993) Cancer Research 53:3336-3342; Lode et al., (1998) Cancer Research 58:2925-2928).
  • Calicheamicin has intracellular sites of action but, in certain instances, does not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody- mediated internalization may, in some embodiments, greatly enhances their cytotoxic effects.
  • Nonlimiting exemplary methods of preparing antibody-drug conjugates with a calicheamicin drug moiety are described, for example, in US 5712374; US 5714586; US 5739116; and US 5767285.
  • an ADC comprises a pyrrolobenzodiazepine (PBD).
  • PDB dimers recognize and bind to specific DNA sequences.
  • the natural product anthramycin, a PBD was first reported in 1965 (Leimgruber, et al., (1965) J. Am. Chem. Soc, 87:5793-5795; Leimgruber, et al., (1965) J. Am. Chem. Soc, 87:5791-5793). Since then, a number of PBDs, both naturally-occurring and analogues, have been reported (Thurston, et al., (1994) Chem. Rev.
  • dimers of the tricyclic PBD scaffold (US 6884799; US 7049311; US 7067511 ; US 7265105; US 7511032; US 7528126; US 7557099).
  • the dimer structure imparts the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In Antibiotics III. Springer- Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, (1986) Acc. Chem. Res., 19:230-237).
  • PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties.
  • Nonlimiting exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598).
  • the wavy line indicates the covalent attachment site to the linker
  • the dotted lines indicate the optional presence of a double bond between CI and C2 or C2 and C3;
  • R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', N0 2 , Me 3 Sn and halo;
  • R 7 is independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', N0 2 , MesSn and halo;
  • Q is independently selected from O, S and NH;
  • R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
  • R and R' are each independently selected from optionally substituted Ci_s alkyl, C 2 alkyl, C 3 - 8 heterocyclyl, C 3 _ 2 o heterocycle, and C 5 _ 2 o aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
  • R 12 , R 16 , R 19 and R 17 are as defined for R 2 , R 6 , R 9 and R 7 respectively;
  • R" is a C 3 _i 2 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted; and
  • X and X' are independently selected from O, S and N(H).
  • R and R' are each independently selected from optionally substituted Ci_i 2 alkyl, C 3 _ 2 o heterocycle, and C 5 _ 2 o aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring.
  • R 9 and R 19 are H.
  • R 6 and R 16 are H.
  • R 7 are R 17 are both OR 7A , where R 7A is optionally substituted C 1 -4 alkyl.
  • R 7A is Me.
  • R 7A is is (3 ⁇ 4 ⁇ 1 ⁇ , where Ph is a phenyl group.
  • X is O.
  • R 11 is H.
  • each group may independently have either confi uration shown below:
  • R" is a C3 alkylene group or a C 5 alkylene group.
  • n 0 or 1.
  • an exemplary PBD dimer component of an ADC has the
  • an exemplary PBD dimer component of an ADC has the structure o
  • n 0 or 1.
  • n is 0. In some embodiments, n is 1. In some
  • R E and/or R E is H. In some embodiments, R E and R E are H. In some
  • R E and/or R E is R D , wherein R D is optionally substituted C 2 alkyl. In some embodiments, R E and/or R E is R D , wherein R D is methyl.
  • an exemplary PBD dimer component of an ADC has the
  • Ar 1 and Ar 2 are each independently optionally substituted C 5 _2o aryl; wherein Ar 1 and Ar 2 may be the same or different; and wherein n is 0 or 1.
  • an exemplary PBD dimer component of an ADC has the structure of Formula A(V):
  • Ar 1 and Ar 2 are each independently optionally substituted C 5 _2o aryl; wherein Ar 1 and Ar 2 may be the same or different; and
  • n 0 or 1.
  • Ar 1 and Ar 2 are each independently selected from optionally substituted phenyl, furanyl, thiophenyl and pyridyl. In some embodiments, Ar 1 and Ar 2 are each independently optionally substituted phenyl. In some embodiments, Ar 1 and Ar 2 are each independently optionally substituted thien-2-yl or thien-3-yl. In some embodiments, Ar 1 and Ar 2 are each independently optionally substituted quinolinyl or isoquinolinyl. The quinolinyl or isoquinolinyl group may be bound to the PBD core through any available ring position.
  • the quinolinyl may be quinolin-2-yl, quinolin-3-yl, quinolin-4yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl.
  • the quinolinyl is selected from quinolin-3-yl and quinolin-6-yl.
  • the isoquinolinyl may be isoquinolin-l-yl, isoquinolin-3- yl, isoquinolin-4yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl.
  • the isoquinolinyl is selected from isoquinolin-3-yl and isoquinolin-6-yl.
  • the wavy line indicates the covalent attachment site to the linker
  • R vl and v2 are independently selected from H, methyl, ethyl and phenyl (which phenyl may be optionally substituted with fluoro, particularly in the 4 position) and C 5 _ 6 heterocyclyl; wherein R vl and R v2 may be the same or different; and
  • n 0 or 1.
  • R are independently selected from H, phenyl, and 4-fluorophenyl.
  • a linker may be attached at one of various sites of the PBD dimer drug moiety, including the N10 imine of the B ring, the C-2 endo/exo position of the C ring, or the tether unit linking the A rings (see structures C(I) and C(II) below).
  • Nonlimiting exemplary PBD dimer components of ADCs include Formulas C(I) and C(II):
  • Formulas C(I) and C(II) are shown in their N10-C11 imine form.
  • Exemplary PBD drug moieties also include the carbinolamine and protected carbinolamine forms as well, as shown in the table below:
  • Z and Z' are independently selected from OR and NR 2 , where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;
  • Ri, R'i, R 2 and R'2 are each independently selected from H, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C5-20 aryl (including substituted aryls), C5-20 heteroaryl groups, -NH 2 , -NHMe, - OH, and -SH, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;
  • R 3 and R'3 are independently selected from H, OR, NHR, and NR 2 , where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;
  • R4 and R'4 are independently selected from H, Me, and OMe;
  • R 5 is selected from Ci-Cs alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C5- 20 aryl (including aryls substituted by halo, nitro, cyano, alkoxy, alkyl, heterocyclyl) and C 5 _ 2 o heteroaryl groups, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;
  • R 11 is H, Ci-Cs alkyl, or a protecting group (such as acetyl, trifluoroacetyl, t- butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citrulline-PAB);
  • a protecting group such as acetyl, trifluoroacetyl, t- butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citrulline-PAB
  • R 12 is is H, Ci-Cs alkyl, or a protecting group
  • Exemplary PDB dimer portions of ADC include, but are not limited to (the wavy line indicates the site of covalent attachment to the linker):
  • n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8. In some embodiments, n is selected from 4, 5, 6, 7, and 8.
  • linkers of PBD dimer-val-cit-PAB-Ab and the PBD dimer-Phe-Lys-PAB-Ab are protease cleavable, while the linker of PBD dimer-maleimide-acetal is acid- labile.
  • PBD dimers and ADC comprising PBD dimers may be prepared according to methods known in the art. See, e.g., WO 2009/016516; US 2009/304710; US 2010/047257; US
  • an ADC comprising anthracycline.
  • Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. While not intending to be bound by any particular theory, studies have indicated that anthracyclines may operate to kill cells by a number of different mechanisms, including: 1) intercalation of the drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; 2) production by the drug of free radicals which then react with cellular macromolecules to cause damage to the cells, and/or 3) interactions of the drug molecules with the cell membrane ⁇ see, e.g., C. Peterson et al., "Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia" in
  • Nonlimiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al (2006) Current Med. Chem. 13:477-523; Jeffrey et al (2006) Bioorganic & Med. Chem. Letters 16:358-362; Torgov et al (2005) Bioconj. Chem. 16:717-721; Nagy et al (2000) Proc. Natl. Acad. Sci. USA 97:829-834; Dubowchik et al (2002) Bioorg. & Med. Chem. Letters 12:1529-1532; King et al
  • PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri, et al. (2005) Clinical Cancer Research 11(4): 1608-1617).
  • Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino of doxorubicin and has been under clinical evaluation (Grandi et al (1990) Cancer Treat. Rev. 17:133; ipamonti et al (1992) Brit. J. Cancer 65:703; ), including phase II/III trials for hepatocellular carcinoma (Sun et al (2003) Proceedings of the American Society for Clinical Oncology 22, Absl448; Quintieri
  • a nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula la:
  • Ri is hydrogen atom, hydroxy or methoxy group and R 2 is a C 1 -C5 alkoxy group, or a pharmaceutically acceptable salt thereof;
  • Li and Z together are a linker (L) as described herein;
  • T is an antibody (Ab) as described herein;
  • n is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.
  • Ri and R 2 are both methoxy (-OMe).
  • a further nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula lb:
  • Ri is hydrogen atom, hydroxy or methoxy group and R 2 is a C 1 -C5 alkoxy group, or a pharmaceutically acceptable salt thereof;
  • L 2 and Z together are a linker (L) as described herein;
  • T is an antibody (Ab) as described herein;
  • n is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.
  • Ri and R 2 are both methoxy (-OMe).
  • the nemorubicin component of a nemorubicin-containing ADC is PNU- 159682.
  • the drug portion of the ADC may have one of the following structures:
  • Anthracyclines including PNU-159682, may be conjugated to antibodies through several linkage sites and a variety of linkers (US 2011/0076287; WO2009/099741 ; US 2011/0076287; WO2009/099741 ; US 2011/0076287; WO2009/099741 ; US 2011/0076287; WO2009/099741 ; US 2011/0076287; WO2009/099741 ; US
  • Exemplary ADCs comprising a nemorubicin and linker include, but are not limited
  • PNU-159682-val-cit-PAB-spacer( 1 2 )-Ab wherein: P i and 2 are independently selected from H and Ci-Ce alkyl; and
  • linker of PNU-159682 maleimide acetal-Ab is acid-labile, while the linkers of PNU-159682-val-cit-PAB-Ab, PNU-159682-val-cit-PAB-spacer-Ab, and PNU-159682-val- cit-PAB-spacer(R 1 R 2 )-Ab are protease cleavable.
  • Drug moieties also include geldanamycin (Mandler et al (2000) J. Nat. Cancer Inst. 92(19):1573-1581 ; Mandler et al (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al (2002) Bioconjugate Chem.
  • enzymatically active toxins and fragments thereof including, but not limited to, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, e.g., WO 93/21232.
  • Drug moieties also include compounds with nucleolytic activity ⁇ e.g., a ribonuclease or a DNA endonuclease).
  • an immunoconjugate may comprise a highly radioactive atom.
  • a variety of radioactive isotopes are available for the production of radioconjugated antibodies. Examples include At 211 , 1 131 , 1 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu.
  • an immunoconjugate when used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc" or I 123 , or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as zirconium-89, iodine-123, iodine-131, indium-I l l, fluorine- 19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
  • NMR nuclear magnetic resonance
  • zirconium-89 zirconium-89, iodine-123, iodine-131, indium-I l l, fluorine- 19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
  • Zirconium-89 may be complexed to various metal chelating agents and conjugated to antibodies, e.g., for PET imaging (WO 2011/056983).
  • radio- or other labels may be incorporated in the immunoconjugate in known ways.
  • a peptide may be biosynthesized or chemically synthesized using suitable amino acid precursors comprising, for example, one or more fluorine- 19 atoms in place of one or more hydrogens.
  • labels such as Tc", I 123 , Re 186 , Re 188 and In 111 can be attached via a cysteine residue in the antibody.
  • yttrium-90 can be attached via a lysine residue of the antibody.
  • the IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes certain other methods.
  • an immunoconjugate may comprise an antibody conjugated to a prodrug-activating enzyme.
  • a prodrug-activating enzyme converts a prodrug ⁇ e.g., a peptidyl chemotherapeutic agent, see WO 81/01145) to an active drug, such as an anti-cancer drug.
  • ADEPT antibody-dependent enzyme-mediated prodrug therapy
  • Enzymes that may be conjugated to an antibody include, but are not limited to, alkaline phosphatases, which are useful for converting phosphate-containing prodrugs into free drugs; arylsulfatases, which are useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase, which is useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5- fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), which are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, which are useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as ⁇ -galactosidase and neuraminidase, which are useful for converting glycosy
  • Drug loading is represented by p, the average number of drug moieties per antibody in a molecule of Formula I. Drug loading may range from 1 to 20 drug moieties (D) per antibody.
  • ADCs of Formula I include collections of antibodies conjugated with a range of drug moieties, from 1 to 20. The average number of drug moieties per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as mass spectroscopy, ELISA assay, and HPLC. The quantitative distribution of ADC in terms of p may also be determined. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
  • p may be limited by the number of attachment sites on the antibody.
  • an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached.
  • higher drug loading e.g. p >5
  • the average drug loading for an ADC ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. Indeed, it has been shown that for certain ADCs, the optimal ratio of drug moieties per antibody may be less than 8, and may be about 2 to about 5 (US 7498298).
  • an antibody may contain, for example, lysine residues that do not react with the drug-linker intermediate or linker reagent, as discussed below. Generally, antibodies do not contain many free and reactive cysteine thiol groups which may be linked to a drug moiety; indeed most cysteine thiol residues in antibodies exist as disulfide bridges.
  • an antibody may be reduced with a reducing agent such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP), under partial or total reducing conditions, to generate reactive cysteine thiol groups.
  • DTT dithiothreitol
  • TCEP tricarbonylethylphosphine
  • an antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine.
  • the loading (drug/antibody ratio) of an ADC may be controlled in different ways, and for example, by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.
  • the resulting product is a mixture of ADC compounds with a distribution of one or more drug moieties attached to an antibody.
  • the average number of drugs per antibody may be calculated from the mixture by a dual ELISA antibody assay, which is specific for antibody and specific for the drug.
  • Individual ADC molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography (see, e.g., McDonagh et al (2006) Prot. Engr. Design & Selection 19(7):299-307; Hamblett et al (2004) Clin. Cancer Res.
  • An ADC of Formula I may be prepared by several routes employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reaction of a nucleophilic group of an antibody with a bivalent linker reagent to form Ab-L via a covalent bond, followed by reaction with a drug moiety D; and (2) reaction of a nucleophilic group of a drug moiety with a bivalent linker reagent, to form D-L, via a covalent bond, followed by reaction with a nucleophilic group of an antibody. Exemplary methods for preparing an ADC of Formula I via the latter route are described in US 7498298, which is expressly incorporated herein by reference.
  • Nucleophilic groups on antibodies include, but are not limited to: (i) N- terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated.
  • Amine, thiol, and hydroxyl groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; and (iii) aldehydes, ketones, carboxyl, and maleimide groups. Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges.
  • Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP), such that the antibody is fully or partially reduced.
  • a reducing agent such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP)
  • TCEP tricarbonylethylphosphine
  • Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles.
  • Additional nucleophilic groups can be introduced into antibodies through modification of lysine residues, e.g., by reacting lysine residues with 2-iminothiolane (Traut's reagent), resulting in conversion of an amine into a thiol.
  • Reactive thiol groups may also be introduced into an antibody by introducing one, two, three, four, or more cysteine residues (e
  • Antibody-drug conjugates of the invention may also be produced by reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, with a nucleophilic group on a linker reagent or drug.
  • an electrophilic group on an antibody such as an aldehyde or ketone carbonyl group
  • nucleophilic groups on a linker reagent or drug include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
  • an antibody is modified to introduce electrophilic moieties that are capable of reacting with nucleophilic substituents on the linker reagent or drug.
  • the sugars of glycosylated antibodies may be oxidized, e.g. with periodate oxidizing reagents, to form aldehyde or ketone groups which may react with the amine group of linker reagents or drug moieties.
  • the resulting imine Schiff base groups may form a stable linkage, or may be reduced, e.g. by borohydride reagents to form stable amine linkages.
  • reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug
  • antibodies containing N- terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate Chem. 3:138-146; US 5362852).
  • Such an aldehyde can be reacted with a drug moiety or linker nucleophile.
  • nucleophilic groups on a drug moiety include, but are not limited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups.
  • active esters such as NHS esters, HOBt esters, haloformates, and acid halides
  • alkyl and benzyl halides such as haloacetamides
  • aldehydes ketones, carboxyl, and maleimide groups.
  • Nonlimiting exemplary cross-linker reagents that may be used to prepare ADC are described herein in the section titled "Exemplary Linkers.” Methods of using such cross- linker reagents to link two moieties, including a proteinaceous moiety and a chemical moiety, are known in the art.
  • a fusion protein comprising an antibody and a cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis.
  • a recombinant DNA molecule may comprise regions encoding the antibody and cytotoxic portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.
  • an antibody may be conjugated to a "receptor” (such as streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand” (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a drug or radionucleotide).
  • a receptor such as streptavidin
  • any of the anti-Lg 5 antibodies provided herein is useful for detecting the presence of LgR5 in a biological sample.
  • the term “detecting” as used herein encompasses quantitative or qualitative detection.
  • a “biological sample” comprises, e.g., a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic, or ovarian tissue).
  • an anti-LgR5 antibody for use in a method of diagnosis or detection is provided.
  • a method of detecting the presence of LgR5 in a biological sample is provided.
  • the method comprises contacting the biological sample with an anti-LgR5 antibody as described herein under conditions permissive for binding of the anti-LgR5 antibody to LgR5, and detecting whether a complex is formed between the anti-LgR5 antibody and LgR5 in the biological sample.
  • Such method may be an in vitro or in vivo method.
  • an anti-LgR5 antibody is used to select subjects eligible for therapy with an anti-LgR5 antibody, e.g.
  • the biological sample is a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic, or ovarian tissue).
  • tissue e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic, or ovarian tissue.
  • an anti-LgR5 antibody is used in vivo to detect, e.g., by in vivo imaging, an LgR5 -positive cancer in a subject, e.g., for the purposes of diagnosing, prognosing, or staging cancer, determining the appropriate course of therapy, or monitoring response of a cancer to therapy.
  • an LgR5 -positive cancer in a subject
  • a subject e.g., for the purposes of diagnosing, prognosing, or staging cancer, determining the appropriate course of therapy, or monitoring response of a cancer to therapy.
  • immuno-PET immuno- positron emission tomography
  • a method for detecting an LgR5-positive cancer in a subject comprising administering a labeled anti-LgR5 antibody to a subject having or suspected of having an LgR5-positive cancer, and detecting the labeled anti-LgR5 antibody in the subject, wherein detection of the labeled anti-LgR5 antibody indicates an LgR5 -positive cancer in the subject.
  • the labeled anti-LgR5 antibody comprises an anti-LgR5 antibody conjugated to a positron emitter, such as 68 Ga, 18 F, ⁇ Cu, 86 Y, 76 Br, 89 Zr, and 124 I.
  • the positron emitter is 89 Zr.
  • a method of diagnosis or detection comprises contacting a first anti-LgR5 antibody immobilized to a substrate with a biological sample to be tested for the presence of LgR5, exposing the substrate to a second anti-LgR5 antibody, and detecting whether the second anti-LgR5 is bound to a complex between the first anti-LgR5 antibody and LgR5 in the biological sample.
  • a substrate may be any supportive medium, e.g., glass, metal, ceramic, polymeric beads, slides, chips, and other substrates.
  • a biological sample comprises a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic or ovarian tissue).
  • the first or second anti-LgR5 antibody is any of the antibodies described herein.
  • the second anti-LgR5 antibody may be 8E11 or antibodies derived from 8E11, e.g., as described herein.
  • the second anti-LgR5 antibody may be YW353 or antibodies derived from YW353, e.g., as described herein.
  • the first or second anti-LgR5 antibody is selected from 3G12 and 2H6 and antibodies derived from 3G12 and/or 2H6, e.g., as described herein.
  • Exemplary disorders that may be diagnosed or detected according to any of the above embodiments include LgR5-positive cancers, such as LgR5-positive colorectal cancer (including adenocarcinoma), LgR5 -positive small intestine cancer (including adenocarcinoma, sarcoma (e.g., leiomyosarcoma), carcinoid tumors, gastrointestnal stromal tumor, and lymphoma) LgPv5-positive ovarian cancer (including ovarian serous adenocarcinoma), LgR5-positive pancreatic cancer (including pancreatic ductal adenocarcinoma), and LgR5 -positive endometrial cancer.
  • LgR5-positive cancers such as LgR5-positive colorectal cancer (including adenocarcinoma), LgR5 -positive small intestine cancer (including adenocarcinoma, sarcoma (e.g., lei
  • an LgR5 -positive cancer is a cancer that receives an anti-LgR5 immunohistochemistry (IHC) or in situ hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example B.
  • an LgR5-positive cancer expresses LgR5 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example B.
  • an LgR5 -positive cancer is a cancer that expresses LgR5 according to a reverse- transcriptase PCR (RT-PCR) assay that detects LgR5 mRNA.
  • the RT-PCR is quantitative RT-PCR.
  • labeled anti-LgR5 antibodies include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction.
  • Exemplary labels include, but are not limited to, the radioisotopes 32 P, 14 C, 125 1, 3 H, and 131 I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No.
  • luciferin 2,3-dihydrophthalazinediones
  • horseradish peroxidase HRP
  • alkaline phosphatase alkaline phosphatase
  • ⁇ -galactosidase glucoamylase
  • lysozyme saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase
  • heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP
  • HRP horseradish peroxidase
  • a label is a positron emitter.
  • Positron emitters include but are not limited to 68 Ga, 18 F, ⁇ Cu, 86 Y, 76 Br, 89 Zr, and 124 I.
  • a positron emitter is 89 Zr.
  • compositions of an anti-LgR5 antibody or immunoconjugate as described herein are prepared by mixing such antibody or immunoconjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride;
  • hexamethonium chloride benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3- pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides;
  • proteins such as serum albumin, gelatin, or immunoglobulins
  • hydrophilic polymers such as polyvinylpyrrolidone
  • amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine
  • chelating agents such as EDTA
  • sugars such as sucrose, mannitol, trehalose or sorbitol
  • salt-forming counter-ions such as sodium
  • metal complexes e.g. Zn-protein complexes
  • non-ionic surfactants such as polyethylene glycol (PEG).
  • Exemplary pharmaceutically acceptable carriers herein further include insterstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX ® , Baxter International, Inc.).
  • sHASEGP soluble neutral-active hyaluronidase glycoproteins
  • rHuPH20 HYLENEX ® , Baxter International, Inc.
  • Certain exemplary sHASEGPs and methods of use, including rHuPH20 are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968.
  • a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
  • Exemplary lyophilized antibody or immunoconjugate formulations are described in US Patent No. 6,267,958.
  • Aqueous antibody or immunoconjugate formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
  • the formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • Avastin® bevacizumab
  • Lg 5-positive cancer such as LgR5 -positive colon cancer or LgR5 -positive colorectal cancer.
  • Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules
  • Sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody or immunoconjugate, which matrices are in the form of shaped articles, e.g. films, or microcapsules. [0419] The formulations to be used for in vivo administration are generally sterile.
  • Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
  • any of the anti-Lg 5 antibodies or immunoconjugates provided herein may be used in methods, e.g., therapeutic methods.
  • an anti-LgR5 antibody or immunoconjugate provided herein is used in a method of inhibiting proliferation of an LgR5-positive cell, the method comprising exposing the cell to the anti-LgR5 antibody or immunoconjugate under conditions permissive for binding of the anti-LgR5 antibody or immunoconjugate to LgR5 on the surface of the cell, thereby inhibiting the proliferation of the cell.
  • the method is an in vitro or an in vivo method.
  • the cell is a colon, colorectal, small intestine, ovarian, pancreatic, or endometrial cell.
  • an anti-LgR5 antibody or immunoconjugate provided herein is used in a method of treating cancer that comprises a mutation in a Kras gene and/or a mutation in an adenomatous polyposis coli (APC) gene in at least a portion of the cells of the cancer.
  • the cancer is selected from colon, colorectal, small intestine, ovarian, pancreatic, and endometrial cancer.
  • an anti-LgR5 antibody or immunoconjugate provided herein is used in a method of treating a colon or colorectal cancer that comprises a mutation in a Kras gene and/or a mutation in an APC gene in at least a portion of the cells of the cancer.
  • Nonlimiting exemplary Kras mutations found in cancers include mutations at Kras codon 12 (e.g., G12D, G12V, G12R, G12C, G12S, and G12A), codon 13 (e.g., G13D and G13C), codon 61 (e.g., G61H, G61L, G61E, and G61K), and codon 146. See, e.g., Yokota, Anticancer Agents Med. Chem., 12: 163-171 (2012); Wicki et al., Swiss Med. Wkly, 140: wl3112 (2010).
  • Nonlimiting exemplary APC mutations found in cancers include mutations in the mutation cluster region (MCR), such as stop codons and frameshift mutations that result in a truncated APC gene product.
  • MCR mutation cluster region
  • a method of treating cancer comprises administering an anti-LgR5 antibody or immunoconjugate to a subject, wherein the subject has a cancer comprising a Kras mutation and/or an APC mutation in at least a portion of the cancer cells.
  • the cancer is selected from colon, colorectal, small intestine, ovarian, pancreatic, and endometrial cancer.
  • the cancer is colon and/or colorectal cancer.
  • the subject has previously been determined to have a cancer comprising a Kras mutation and/or an APC mutation in at least a portion of the cancer cells.
  • the cancer is LgR5 -positive.
  • Presence of various biomarkers in a sample can be analyzed by a number of methodologies, many of which are known in the art and understood by the skilled artisan, including, but not limited to, immunohistochemistry ("IHC"), Western blot analysis,
  • Typical protocols for evaluating the status of genes and gene products are found, for example in Ausubel et al, eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunob lotting) and 18 (PCR Analysis). Multiplexed immunoassays such as those available from Rules Based Medicine or Meso Scale Discovery (“MSD”) may also be used.
  • MSD Meso Scale Discovery
  • Inhibition of cell proliferation in vitro may be assayed using the CellTiter-GloTM Luminescent Cell Viability Assay, which is commercially available from Promega (Madison, WI). That assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells. See Crouch et al. (1993) J. Immunol. Meth. 160:81-88, US Pat. No. 6602677. The assay may be conducted in 96- or 384-well format, making it amenable to automated high-throughput screening (HTS). See Cree et al. (1995) Anticancer Drugs 6:398-404.
  • HTS high-throughput screening
  • the assay procedure involves adding a single reagent (CellTiter- Glo ® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction.
  • the luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device.
  • the luminescence output is expressed as relative light units (RLU).
  • an anti-LgR5 antibody or immunoconjugate for use as a medicament is provided.
  • an anti-LgR5 antibody or immunoconjugate for use in a method of treatment is provided.
  • an anti-LgR5 antibody or immunoconjugate for use in treating LgR5-positive cancer is provided.
  • the invention provides an anti-LgR5 antibody or immunoconjugate for use in a method of treating an individual having an LgR5-positive cancer, the method comprising administering to the individual an effective amount of the anti-LgR5 antibody or immunoconjugate.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
  • the invention provides for the use of an anti-LgR5 antibody or immunoconjugate in the manufacture or preparation of a medicament.
  • the medicament is for treatment of LgR5 -positive cancer.
  • the medicament is for use in a method of treating LgR5-positive cancer, the method comprising administering to an individual having LgR5-positive cancer an effective amount of the medicament.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
  • the invention provides a method for treating LgR5-positive cancer.
  • the method comprises administering to an individual having such LgR5-positive cancer an effective amount of an anti-LgR5 antibody or immunoconjugate.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below.
  • An LgR5 -positive cancer may be, e.g., LgR5-positive colon or colorectal cancer (including adenocarcinoma), LgR5-positive small intestine cancer (including adenocarcinoma, sarcoma (e.g., leiomyosarcoma), carcinoid tumors, gastrointestnal stromal tumor, and lymphoma).
  • LgR5-positive ovarian cancer including ovarian serous adenocarcinoma
  • LgR5 -positive pancreatic cancer including pancreatic ductal adenocarcinoma
  • LgR5-positive endometrial cancer e.g., LgR5-positive colon or colorectal cancer (including adenocarcinoma), LgR5-positive small intestine cancer (including adenocarcinoma, sarcoma (e.g., leiomyosarcoma), carcinoid tumors, gastro
  • an LgR5- positive cancer is a cancer that receives an anti-LgR5 immunohistochemistry (IHC) or in situ hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example B.
  • an LgR5-positive cancer expresses LgR5 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example B.
  • an LgR5-positive cancer is a cancer that expresses LgR5 according to a reverse-transcriptase PCR (RT-PCR) assay that detects LgR5 mRNA.
  • the RT-PCR is quantitative RT-PCR.
  • An "individual” according to any of the above embodiments may be a human.
  • the invention provides pharmaceutical formulations comprising any of the anti-LgR5 antibodies or immunoconjugate provided herein, e.g., for use in any of the above therapeutic methods.
  • a pharmaceutical formulation comprises any of the anti-LgR5 antibodies or immunoconjugates provided herein and a pharmaceutically acceptable carrier.
  • a pharmaceutical formulation comprises any of the anti-LgR5 antibodies or immunoconjugates provided herein and at least one additional therapeutic agent, e.g., as described below.
  • Antibodies or immunoconjugates of the invention can be used either alone or in combination with other agents in a therapy.
  • an antibody or immunoconjugate of the invention may be co-administered with at least one additional therapeutic agent.
  • an additional therapeutic agent is Avastin® (bevacizumab), e.g., for the treatment of LgR5-positive cancer such as LgR5-positive colon cancer or LgR5-positive colorectal cancer.
  • Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody or immunoconjugate of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.
  • Antibodies or immunoconjugates of the invention can also be used in combination with radiation therapy.
  • An antibody or immunoconjugate of the invention can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
  • Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
  • Antibodies or immunoconjugates of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the antibody or immunoconjugate need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody or
  • immunoconjugate present in the formulation the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
  • an antibody or immunoconjugate of the invention when used alone or in combination with one or more other additional therapeutic agents, will depend on the type of disease to be treated, the type of antibody or immunoconjugate, the severity and course of the disease, whether the antibody or immunoconjugate is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody or immunoconjugate, and the discretion of the attending physician.
  • the antibody or immunoconjugate is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 ⁇ g/kg to 15 mg/kg (e.g.
  • O.lmg/kg-lOmg/kg) of antibody or immunoconjugate can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
  • One typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
  • One exemplary dosage of the antibody or immunoconjugate would be in the range from about 0.05 mg/kg to about 10 mg/kg.
  • one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
  • Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody).
  • An initial higher loading dose, followed by one or more lower doses may be administered.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
  • an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the disorder and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is an antibody or immunoconjugate of the invention.
  • the label or package insert indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody or immunoconjugate of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
  • the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution.
  • BWFI bacteriostatic water for injection
  • Ringer's solution such as bacterio
  • Figure 1 is a graphic representation of human LgR5 gene expression in various tissues. The scale on the y-axis indicates gene expression levels based on hybridization signal intensity. Dots appear both to the left and to the right of the line extending from the name of each listed tissue. The dots appearing to the left of the line represent gene expression in normal tissue, and the dots appearing to the right of the line represent gene expression in tumor and diseased tissue. Figure 1 shows increased LgR5 gene expression in certain tumor or diseased tissues relative to their normal counterparts.
  • LgR5 is substantially overexpressed in colorectal, endometrial, and ovarian tumors.
  • Figure 1, inset shows that LgR5 is overexpressed in at least the following colon tumors: adenocarcinoma, benign tumors, and metastatic colon tumors, and also in tissue with a colon tumor content of less than 50% ("low tumor” in Figure 1 inset); but is not overexpressed in normal colon, Crohn's disease, or ulcerative colitis.
  • Human LgR5 expression is much lower in normal tissues, with low levels of expression in normal brain, muscle, ovarian, and placental tissues.
  • Tissue microarrays were assembled using duplicate cores as described in Bubendorf L, et al., J Pathol. 2001 Sep;195(l):72-9, and included five normal colorectal mucosa samples from matched cases.
  • oligonucleotide probes shown in Table 2. See, e.g., Jubb AM, et al., Methods Mol Biol 2006; 326:255-64.
  • ISH for ⁇ -actin was used to confirm mRNA integrity in colorectal cancer tissues prior to analysis.
  • LgR5 hybridization intensity was scored by a trained pathologist according to the scheme below, taking into account the intensity (silver grains) as well as breadth of staining.
  • Sense probes were used to control for the specificity of hybridization.
  • Figure 2 shows exemplary colon tumor sections with 1+, 2+, and 3+ levels of staining.
  • the top panels show dark field images and the bottom panels show bright field images.
  • the deposition of silver grains in the dark field images indicates hybridization of the probe and expression of LgR5 mRNA.
  • -77% (41/53) of colon tumor sections analyzed were LgR5 positive, showing staining at the 1+, 2+, or 3+ levels, with 34% (18/53) showing 2+ or 3+ staining.
  • Four of the 57 samples analyzed were noninformative for LgR5 expression.
  • Tissue microarrays were constructed with one core of normal mucosa and three cores of adenocarcinoma per patient as described in Bubendorf L, et al., J Pathol. 2001 Sep;195(l):72-9. ISH was performed and scored as described above.
  • the heterogeneity of expression across three cores from the same tumor was also determined, and is expressed as the proportion of tumors that showed a particular level of discordance in one of the three cores. For example, if three cores had scores of +1, +3, and +3, one of the three cores from that tumor is discordant by 2.
  • Figure 3 A shows the prevalence of 0, 1+, 2+, and 3+ levels of LgR5 staining in the colon tumor tissue microarray, measured by in situ hybridization. 75% of the colon tumor tissues showed staining at the 1+, 2+, or 3+ levels, with 37% showing 2+ or 3+ staining.
  • Figure 3B shows the heterogeneity of LgR5 expression. 67% of tumors showed no heterogeneity across the three cores. 32% shows a discordance of 1 in one of the three cores, and only 1% showed a discordance greater than 1.
  • Monoclonal antibodies against human LgR5 were generated using the following procedures.
  • Human LgR5 extracellular domain (ECD; amino acids 22-557) with a C-terminal His-tagged Fc was expressed from a baculovirus expression system, and purified on a Ni-NTA column (Qiagen), followed by gel filtration on a Superdex 200 column in 20mM MES pH 6.0, 6M guanidine HC1 as previously described (Kirchhofer et al., 2003) and dialysis into PBS for storage at -80°C.
  • mice (Charles River Laboratories International, Inc., Hollister, CA, USA) were injected with either huLgR5 plasmid DNA in lactated Ringer's solution (via tail vein) or with recombinant human LgR5 ECD as described above (via rear footpads) in adjuvant containing metabolizable squalene (4% v/v), Tween 80 (0.2 % v/v), trehalose 6,6-dimycolate (0.05% w/v) and monophosphoryl lipid A (0.05% w/v; Sigma Aldrich, USA).
  • huLgR5 plasmid DNA in lactated Ringer's solution (via tail vein) or with recombinant human LgR5 ECD as described above (via rear footpads) in adjuvant containing metabolizable squalene (4% v/v), Tween 80 (0.2 % v/v), trehalose 6,6-dimycolate
  • Serum titers were evaluated by standard enzyme linked immunosorbant assay (ELISA) and FACS following 6-9 injections.
  • Splenic B cells harvested from a total of 5 mice were fused with mouse myeloma cells (X63.Ag8.653; American Type Culture Collection, Manassas, VA, USA) by electrofusion (Hybrimune; Harvard Apparatus, Inc., Holliston, MA, USA). After 10-14 days, hybridoma supernatants were screened for antibody secretion by ELISA.
  • Hybridoma clones 8E11.1.1 (identified from the DNA immunized mice), and 2H6.3.5 and 3G12.2.1 (both from the protein immunized mice) showed high immunobinding after two rounds of subcloning (by limiting dilution) and were scaled up for purification in INTEGRA CELLine 1000 bioreactors (INTEGRA Biosciences AG, Zizers, Switzerland).
  • Supematants were then purified by affinity chromatography, sterile-filtered, and stored at 4°C in PBS.
  • the isotypes of the mAbs were determined to be IgGl (kappa light chain) using the Isostrip Mouse mAb Isotyping Kit (Roche Applied Biosciences, Indianapolis, IN, USA).
  • Figure 4 shows certain monoclonal antibodies generated, along with certain properties, some of which will be described in further detail below.
  • the variable light (VL) and variable heavy (VH) domains were amplified using RT-PCR with degenerate primers to the heavy and light chains.
  • the forward primers were specific for the N-terminal amino acid sequence of the VL and VH regions.
  • the LC and HC reverse primers were designed to anneal to a region in the constant light (CL) and constant heavy domain 1 (CHI), which are highly conserved across species.
  • the polynucleotide sequence of the inserts was determined using routine sequencing methods.
  • the 8E11 VL and VH amino acid sequences are shown in Figures 5 and 6, respectively (SEQ ID NOs: 3 and 4, respectively).
  • the 3G12 and 2H6 VL and VH amino acid sequences are shown in Figures 7 and 8, respectively.
  • the VL and VH sequences of antibody 3G12 are shown in SEQ ID NOs: 21 and 22, respectively, and the VL and VH sequences of antibody 2H6 are shown in SEQ ID NOs: 23 and 24, respectively.
  • Each antibody was chimerized by cloning the mouse heavy chain variable region onto a human IgGl heavy chain constant region and cloning the light chain variable region onto a human kappa light chain constant region.
  • Monoclonal antibody 8E11 was humanized as described below. Residue numbers are according to Kabat et al., Sequences of proteins of immunological interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Direct hypervariable region gra fts onto the acceptor human consensus framework
  • VL KIV human VH subgroup I
  • V3 ⁇ 4 human VH subgroup I
  • positions 24-34 (LI), 50-56 (L2) and 89-97 (L3) were grafted into VL K rv-
  • positions 26-35 (HI), 49-65 (H2) and 95-102 (H3) were grafted into V3 ⁇ 4.
  • positions 71 and 78 in framework III of VH were retained from the mouse sequence in 8E11.vl .
  • Those residues were found to be part of the framework residues acting as "Vernier" zone, which may adjust CDR structure and fine-tune the antigen fit. See, e.g., Foote and Winter, J. Mol. Biol. 224: 487-499 (1992) ( Figures 5 and 6).
  • CDR definitions include positions defined by their sequence hypervariability (Wu, T. T. & Kabat, E. A. (1970)), their structural location (Chothia, C. & Lesk, A. M. (1987)) and their involvement in antigen-antibody contacts (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)).
  • 8E11 variants were generated to evaluate the contributions of other Vernier positions, such as position 68 in the light chain, and positions 67 and 69 in the heavy chain.
  • Humanized 8E11.v2 was generated by retaining two addition mouse residues, at positions 67 and 69 of the heavy chain variable region.
  • the light chain variable region sequence and heavy chain variable region sequence for 8E11.v2, and other variants, are shown in Figures 5 and 6, respectively.
  • the humanized variants of 8E11 were generated by Kunkel mutagenesis using a separate oligonucleotide for each hypervariable region. Correct clones were identified by DNA sequencing.
  • IgG variants were initially produced in 293 cells.
  • Vectors coding for VL and VH were transfected into 293 cells.
  • IgG was purified from cell culture media by protein A affinity chromatography.
  • each 8E11 IgG variant for human LgR5 was determined by surface plasmon resonance using a BIAcoreTM-3000.
  • BIAcoreTM research grade CM5 chips were activated with l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N- hydroxysuccinimide (NHS) reagents according to the supplier's instructions.
  • EDC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
  • NHS N- hydroxysuccinimide
  • the human acceptor framework used for humanization of 8E11 is based on the human VL kappa IV consensus (VL K iv) and the acceptor VH framework V3 ⁇ 4.
  • Eight humanized variants of mu8El 1 were produced and tested for LgR5 affinity by BIAcoreTM.
  • the light chain variable regions and heavy chain variable regions of each of the variants is shown in Figures 5 and 6, respectively.
  • the results of the affinity measurements are shown in Figure 9.
  • Variant hu8El 1.v2 was generated by changing positions 67 and 69 of the hu8El 1.vl heavy chain to the residues found at those positions in mu8El 1.
  • the affinity (K D ) of hu8El 1.v2 was found to be about the same as the parental ch8El 1 antibody.
  • the 6 murine 8E11 CDRs (defined as positions 24-34 (LI), 50-56 (L2) and 89-97 (L3), 26-35 (HI), 49-65 (H2) and 93-102 (H3)) were grafted into the human consensus VL K iv and VHi acceptor domains. Positions 67, 69, 71, and 78 were changed back to murine residues from mu8E 11. Humanized 8E 11.v2 has comparable affinity for LgR5 to chimeric 8E 11.
  • mouse monoclonal antibodies 8E11, 2H6, and 3G12 are referred to in the alternative as 8E11, m8El 1, or mu8El 1; and 2H6, m2H6 or mu2H6; and 3G12, m3G12, or mu3G12; respectively.
  • Chimeric monoclonal antibodies 8E11, 2H6, and 3G12 are referred to as chimeric 8E11 or ch8El 1; chimeric 2H6 or ch2H6; and chimeric 3G12 or ch3G12; respectively.
  • Humanized monoclonal antibody 8E11.v2 may also be referred to as 8E1 lv2, h8El lv.2, or hu8El lv.2.
  • Nunc 96-well MaxiSorp immnoplates (Nunc) were coated overnight at 4°C with LgR5 ECD protein (10 ⁇ g/ml) and blocked for 1 hour with PBST buffer (PBS, 0.05% Tween 20) supplemented with 1% BSA. The antibody phage libraries were added and incubated overnight at room temperature. The plates were washed with PBST buffer and bound phage were eluted with 50 mM HCL/500 mM NaCl for 30 minutes and neutralized with an equal volume of 1M Tris base. Recovered phages were amplified in E.coli XL-1 blue cells.
  • FIG. 12A to C shows an alignment between human (SEQ ID NO: 67), cynomolgus monkey (SEQ ID NO: 69), rat (SEQ ID NO: 70) and mouse (SEQ ID NO: 72) LgR5. Residues that are identical among all four species are indicated by asterisks (*).
  • Figure 4 shows the results of FACS analysis of 293 cells stably transfected with gD epitope-tagged LgR5 (human, cynomolgus monkey, rat, or mouse LgR5); stained with 10 ⁇ g/ml YW353, ch8El 1, hu8El l.v2, 2H6, or 3G12 antibody; and detected with R-Phycoerythrin conjugated goat anti-human antibody.
  • Untransfected 293 cells do not normally express LgR5.
  • YW353 antibody binds human and cynomolgus monkey LgR5, but not rat or mouse LgR5.
  • Ch8El 1 and hu8El 1.v2 antibodies bind all four species of LgR5, although binding to rat LgR5 is not as strong as binding to human, cynomolgus monkey, or mouse LgR5.
  • 2H6 antibody binds to human and mouse LgR5, and was not tested for binding to cynomolgus monkey or rat LgR5.
  • 3G12 antibody shows strong binding to human LgR5, less strong binding to mouse LgR5, and was not tested for binding to cynomolgus monkey or rat LgR5.
  • YW353 antibody bound to human LgR5 with an affinity of 1.6 nM.
  • Ch8El 1 and hu8El l.v2 antibodies bound to human LgR5 with affinities of 2.4 nm and 3.1 nm, respectively.
  • 2H6 and 3G12 antibodies bound to human LgR5 with affinities of 208 nM and 72 nM, respectively.
  • Anti-Lgr5 antibodies were [I 125 ] labeled using the indirect Iodogen method.
  • the [I 125 ] labeled anti-Lgr5 antibodies were purified from free 125 I-Na by gel filtration using a NAP-5 column (GE Healthcare); the purified iodinated anti-Lgr5 antibodies had a range of specific activities of 13.92 to 19.01 Competition assay mixtures of 50 volume containing a fixed concentration of [I 125 ] labeled antibody and decreasing concentrations of serially diluted, unlabeled antibody were placed into 96-well plates. 293 cells stably expression human, rat, or mouse Lgr5 were cultured in growth media at 37°C in 5% CO 2 .
  • binding buffer which consisted of Dulbecco's Modified Eagle Medium (DMEM) with 2% fetal bovine serum (FBS), 50 mM HEPES (pH 7.2) and 0.1% sodium azide.
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • HEPES 50 mM HEPES
  • 0.1% sodium azide 0.1% sodium azide.
  • the washed cells were added to the 96 well plates at a density of 250,000 cells in 0.2 mL of binding buffer.
  • the final concentration of the [I 125 ] labeled antibody in each well was 200 pM.
  • the final concentration of the unlabeled antibody in the competition assay ranged from 500 nM through ten 2-fold diluation steps to a 0 nM buffer-only assay. Competition assays were carried out in triplicate.
  • Competition assays were incubated for 2 hours at room temperature. After the 2-hour incubation, the competition assays were transferred to a Millipore Multiscreen filter plate (Billerica, MA) and washed 4 times with binding buffer to separate the free from bound [I 125 ] labeled antibody. The filters were counted on a Wallac Wizard 1470 gamma counter (PerkinElmer Life and Analytical Sciences Inc.;
  • YW353 bound to gD-tagged human LgR5 expressed on stably transfected 293 cells with an affinity of 0.2 nM.
  • Ch8El 1 bound to gD-tagged human LgR5 and gD-tagged mouse LgR5 expressed on stably transfected 293 cells with affinities of 0.4 nM and 0.2 nM, respectively.
  • Hu8El lv2 bound to gD-tagged human LgR5, gD-tagged mouse LgR5, and gD-tagged rat LgR5 expressed on stably transfected 293 cells with affinities 0.3-0.7 nM, 0.5- 0.6 nM, and 2.4-2.8 nM, respectively.
  • Kd values were generally lower than those determined by BIAcore ® .
  • Antibodies YW353 and 8E11 both bound to to gD epitope-tagged LgR5 22 -323 (amino acids 22-323 of SEQ ID NO: 67) with a C-terminal GPI anchor, but antibodies 2H6 and 3G12 did not. Finally, none of the antibodies bound to gD epitope-tagged LgR5424-907 (amino acids 424-907 of SEQ ID NO: 67).
  • Figure 4 summarizes those results in the column titled "epitope region.”
  • antibody YW353 binds to an epitope in the region of amino acids 22 to 123 of SEQ ID NO: 67
  • antibody 8E11 and its humanized variants bind to an epitope in the region of amino acids 22 to 323 of SEQ ID NO: 67
  • antibodies 2H6 and 3G12 bind to an epitope in the region of amino acids 324 to 423 of SEQ ID NO: 67.
  • antibodies were produced in CHO cells.
  • Vectors coding for VL and VH were transfected into CHO cells and IgG was purified from cell culture media by protein A affinity chromatography.
  • Anti-LgR5 antibody-drug conjugates were produced by conjugating YW353 (IgGl heavy chain and kappa light chain sequences shown in SEQ ID NOs: 66 and 65, respectively), hu8El lv2 (IgGl heavy chain and kappa light chain sequences shown in SEQ ID NOs: 64 and 63, respectively), mu8El 1, ch8El 1, 2H6, ch2H6, 3G12, and ch3G12 to the drug- linker moiety MC-vc-PAB-MMAE, which is depicted herein.
  • the drug-linker moiety MC-vc-PAB-MMAE is sometimes referred to in these Examples and in the Figures as "vcMMAE” or "VCE.”
  • the antibodies Prior to conjugation, the antibodies were partially reduced with TCEP using standard methods in accordance with the methodology described in WO 2004/010957 A2.
  • the partially reduced antibodies were conjugated to the drug-linker moiety using standard methods in accordance with the methodology described, e.g., in Doronina et al. (2003) Nat. Biotechnol. 21 :778-784 and US 2005/0238649 Al . Briefly, the partially reduced antibodies were combined with the drug- linker moiety to allow conjugation of the drug-linker moiety to reduced cysteine residues of the antibody.
  • the conjugation reactions were quenched, and the ADCs were purified.
  • the drug load (average number of drug moieties per antibody) for each ADC was determined and was between 3.3 and 4.0 for the anti-LgR5 antibodies.
  • Anti-LgR5 antibody-PNU drug conjugates were produced by conjugating YW353 Al 18C thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 78 and 65, respectively) or hu8El lv2 thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 75 and 63, respectively) to PNU drug-linker moieties.
  • DTT dithiothreitol
  • This process also reduces the interchain disulfide bonds of the antibody.
  • the reduced antibody was purified to remove the released blocking groups and the interchain disulfides were reoxidized using dehydro- ascorbic acid (dhAA).
  • Anti-LgR5 antibody-PBD drug conjugates were produced by conjugating YW353 Al 18C thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 78 and 65, respectively) or hu8El lv2 thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 75 and 63, respectively) to PBD drug-linker moieties.
  • DTT dithiothreitol
  • This process also reduces the interchain disulfide bonds of the antibody.
  • the reduced antibody was purified to remove the released blocking groups and the interchain disulfides were reoxidized using dehydro-ascorbic acid (dhAA).
  • LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229).
  • LgR5 is highly expressed in LoVo cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Five million LoVo cells (LgR5 -positive by FACS using YW353) in HBSS-matrigel were injected
  • mice subcutaneously into the dorsal flank of NCR nude mice and six days post- inoculation mice were given a single intravenous injection of 5 mg/kg murine anti-gpl20-vcMMAE control antibody- drug conjugate, human anti-gD 5B6-vcMMAE control antibody-drug conjugate, huYW353- vcMMAE antibody-drug conjugate, mu8El 1-vcMMAE antibody-drug conjugate, mu2H6- vcMMAE antibody-drug conjugate, or mu3G12-vcMMAE antibody-drug conjugate; or with vehicle (PBS) alone.
  • the presence of the antibodies was confirmed by PK bleeds one day post injection.
  • LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot.
  • mice Twenty to 30 mm 3 D5124 tumor fragments (LgR5-positive by FACS using YW353 and 8E11) were implanted subcutaneously into the dorsal flank area of NCR nude mice and 18 days post-transplantation the mice were given a single intravenous injection of 6 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate, 3 mg/kg or 6 mg/kg huYW353-vcMMAE antibody-drug conjugate, 3 mg/kg or 6 mg/kg ch8El 1-vcMMAE antibody- drug conjugate, 3 mg/kg or 6 mg/kg ch2H6-vcMMAE antibody-drug conjugate, or 3 mg/kg or 6 mg/kg ch3G12-vcMMAE antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5; "HB#8" in Figure 14) alone.
  • AKV mice The efficacy of mu8El 1 and mu8El 1-vcMMAE was investigated in a murine intestinal tumorigenesis model, APC min/+ ; LSL-Kras G12D ; VillinCre ("AKV mice”). AKV mice are the result of crossing APC min/+ ; VillinCre ("AV mice") with LSL-Kras G12D mice. While AV mice develop 0-4 adenomas in the colon and 100 adenomas in the small intestine, AKV mice develop an average of 140 adenomas in the colon and 100 adenomas in the small intestine (data not shown).
  • LgR5 mRNA expression was measured in normal tissue and polyps of AV and AKV mice, and LgR5 was found to be significantly overexpressed in polyps from both the small intestine and colon in AKV mice ( Figure 16).
  • AKV mice were crossed with mice having a cassette containing an enhanced green fluorescent protein (EGFP) linked in frame to human diphtheria toxin receptor cDNA located in the Lgr5 gene. See Tian et al., Nature, 478: 255-260 (2011).
  • EGFP enhanced green fluorescent protein
  • mice An overall survival study was carried out with AKV mice to determine whether anti-LgR5 antibody can increase survival.
  • Ten AKV mice were administered 15 mg/kg mu8El 1- MC-vc-PAB-MMAE; six AKV mice were administered 15 mg/kg mu8El 1, and 9 mice were administered 15 mg/kg control antibody anti-gpl20-MC-vc-MMAE.
  • the antibodies and ADCs were administered weekly beginning at 6 weeks of age until the mice either died or were deemed moribund (as determined by standard criteria related to signs of severe lethargy, weight loss and anemia), in which case the mice were sacrificed.
  • the results of the overall survival study are shown in Figure 17.
  • the untreated control data represents historical survival rates for 22 AKV mice.
  • AKV mice administered either mu8El 1 or mu8El 1-MC-vc-PAB-MMAE had significantly longer survival times than untreated AKV mice or AKV mice administered a control ADC. Based on these results, additional animals were evaluated as described above.
  • the results of that experiment are shown in Figure 19.
  • AKV mice administered mu8El 1-MC-vc-PAB- MMAE had significantly longer survival times than untreated AKV mice or AKV mice administered a control ADC, and also had a longer survival time than mice administered mu8El 1.
  • the AKV mice administered control ADC and anti-LgR5-ADC had similar numbers and sizes of polyps, suggesting that anti-LgR5-ADC may slow the disease and thereby extend survival.
  • cleaved caspase 3 was measured as a function of tumor area.
  • Formalin fixed paraffin embedded (FFPE) small intestine and colon tissue collected at time of death were subjected to immunohistochemical staining for cleaved caspase 3 (Cell Signaling Technologies; Danvers, MA, cat# 9661L). Images of the stained slides were acquired by the Olympus Nanozoomer automated slide scanning platform and manually identified tumor-specific areas were analyzed in the Matlab software package
  • AKV Lgr5 mRJ+ mice were administered 15 mg/kg mu8El 1-MC-vc-PAB-MMAE or 15 mg/kg control antibody anti-gpl20-MC-vc-MMAE (day 1). On day 4, the mice were sacrificed and tumors from the gastrointestinal tract (small and large intestine) were visualized for expression of EGFP and cleaved caspase 3. The amount of CC3+GFP+ area per total cellular area was then determined.
  • FIG. 21 A shows exemplary immunohistochemical staining from control ADC treated mice (left panels) and anti-LgR5-ADC treated mice (right panels). These results demonstrate a trend towards increased apoptosis in LgR5 -expressing cells upon anti-LgR5-ADC treatment.
  • Ki67 is a nuclear protein associated with cellular
  • Ki67 antibodies for immunohistochemical staining were obtained from Neomarker. The results of that experiment are shown in Figure 22. There was significantly less proliferating cell area, as measured by Ki67 staining, in tumors from AKV Lgr5 mRJ+ mice treated with anti- LgR5-ADC than control ADC, in both the GFP+ and GFP- cell populations. These results suggest that anti-LgR5-ADC reduces proliferation and/or inhibits formation of proliferative progeny.
  • LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot.
  • LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229), and subline LoVoXl.l was derived for optimal growth in mice. Briefly, mice were inoculated with LoVo cells. Once tumors were growing, a tumor with a desirable growth rate was harvested. The tumor was minced and grown in culture to establish cell line LoVoXl .l .
  • LgR5 is expressed in LoVoXl.l cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot.
  • Five million LoVoXl. l cells in HBSS-matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCIDmice and 13 days post-inoculation mice were given a single intravenous injection of 3 mg/kg or 6 mg/kg huYW353-vcMMAE antibody-drug conjugate, 3 mg/kg or 6 mg/kg hu8El 1V2-VCMMAE antibody-drug conjugate; 15 mg/kg hu8El lv2 antibody; 15 mg/kg humanized anti-gD 5B6 control antibody; or 6 mg/kg humanized anti-gD 5B6-vcMMAE control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02%
  • LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot.
  • mice Twenty to 30 mm 3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 26 days post-transplantation the mice were given a single intravenous injection of 1 mg/kg huYW353-vcMMAE antibody-drug conjugate, 1 mg/kg huYW353-vcPNU antibody-drug conjugate, 1 mg/kg huYW353 -PNU antibody-drug conjugate, 1 mg/kg huYW353-acetal-PNU antibody-drug conjugate; or 1 mg/kg humanized anti-gD 5B6-vcPNU control antibody-drug conjugate, 1 mg/kg humanized anti-gD 5B6-PNU control antibody-drug conjugate, or 1 mg/kg humanized anti-gD 5B6-acetal-PNU control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 niM sucrose,
  • LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229), and subline LoVoXl.l was derived for optimal growth in mice. Briefly, mice were inoculated with LoVo cells. Once tumors were growing, a tumor with a desirable growth rate was harvested. The tumor was minced and grown in culture to establish cell line LoVoXl .l .
  • LgR5 is expressed in LoVoXl.l cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot.
  • Five million LoVoXl. l cells in HBSS-matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCID mice and 11 days post-inoculation mice were given a single intravenous injection of 2 mg/kg hu8El lv2-vcMMAE antibody-drug conjugate, 2 mg/kg hu8El 1V2-VCPNU, 2 mg/kg hu8El lv2- acetal-PNU, or 2 mg/kg hu8El Iv2-PNU; or 2 mg/kg humanized anti-gD 5B6-vcPNU control antibody-drug conjugate, 2 mg/kg humanized anti-gD 5B6-acetal-PNU control antibody drug conjugate, or 2 mg/kg humanized anti-gD 5B6-P
  • the LoVoXl .l colorectal adenocarcinoma model was tested with a different control antibody-drug conjugate (that binds to a different antigen not expressed on the surface of LoVo cells), and with administration of an excess of anti-gD control antibody to block possible nonspecific antibody binding sites on the tumor cells.
  • vehicle histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5
  • LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229), and subline LoVoXl .l was derived for optimal growth in mice. Briefly, mice were inoculated with LoVo cells. Once tumors were growing, a tumor with a desirable growth rate was harvested. The tumor was minced and grown in culture to establish cell line LoVoXl .l . LgR5 is expressed in LoVoXl.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.

Description

ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES
FIELD OF THE INVENTION
[001] The present invention relates to anti-LgR5 antibodies and immunoconjugates and methods of using the same.
BACKGROUND
[002] Leucine-rich repeat-containing G protein-coupled receptor 5 (LgR5) is a seven- transmembrane protein found on the surface of actively cycling intestinal stem cells (ISCs). LgR5-expressing ISCs are sensitive to Wnt modulation and are primarily responsible for homeostatic regeneration of the intestinal epithelium. Elimination of LgR5-expressing cells in mice does not affect homeostasis of intestinal epithelium, however, suggesting that other cell types can compensate for loss of this cell population. Tian et al., Nature 478: 255-259 (2011). R- spondins enhance WNT signaling by WNT3A, and all four R-spondins, RSPOl, RSP02, RSP03, and RSP04, are able to bind to LgR5. Lau et al., Nature 476: 293-297 (2011).
[003] Human LgR5 is a 907 amino acid protein, of which -540 amino acids are predicted to be in the extracellular space following cleavage of the amino-terminal signal sequence. LgR5 comprises 17 imperfect leucine-rich repeat motifs in the ectodomain, and a cysteine-rich region located between the leucine-rich repeats and the first transmembrane domain.
[004] There is a need in the art for agents that target LgR5 for the diagnosis and treatment of LgR5 -associated conditions, such as cancer. The invention fulfills that need and provides other benefits.
SUMMARY
[005] The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
[006] In some embodiments, an isolated antibody that binds to LgR5 is provided. In some embodiments, the antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within amino acids 22-555 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 22-123 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 22-323 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 22-424 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 324-555 of SEQ ID NO: 67 and/or binds to an epitope within amino acids 324-424 of SEQ ID NO: 67; (b) binds LgR5 with an affinity of < 5 nM, or < 4 nM, or < 3 nM, or < 2 nM, or < 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM; (c) does not significantly disrupt the binding of R-spondin (RSPO) to LgR5; (d) does not significantly disrupt beta-catenin signaling; (e) does not significantly disrupt RSPO activation of LgR5 signaling; (f) activates caspase 3 cleavage; (g) recognizes both human and rodent LgR5; (h) recognizes human LgR5 but not rodent LgR5; (i) does not significantly inhibit tumor growth in its unconjugated form; and (J) does not induce stem cell differentiation.
[007] In some embodiments, the isolated anti-LgR5 antibody binds to an epitope within amino acids 22-323 of SEQ ID NO: 67 with an affinity of < 5 nM, or < 4 nM, or < 3 nM, or < 2 nM, or < 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM. .
[008] In some embodiments, the isolated anti-LgR5 antibody binds to an epitope within amino acids 22-123 of SEQ ID NO: 67 with an affinity of < 5 nM, or < 4 nM, or < 3 nM, or < 2 nM, or < 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM.
[009] In some embodiments, the isolated anti-LgR5 antibody binds to an epitope within amino acids 324-424 of SEQ ID NO: 67 with an affinity of < 5 nM, or < 4 nM, or < 3 nM, or < 2 nM, or < 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM.
[010] In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not significantly disrupt the binding of R-spondin (RSPO) to LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not significantly disrupt wnt/beta-catenin signaling. In some embodiments of any of the isolated anti- LgR5 antibodies, the anti-LgR5 antibody does not significantly disrupt RSPO activation of LgR5 signaling. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody activates caspase 3 cleavage. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody recognizes both human and rodent LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody recognizes human LgR5 but not rodent LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not significantly inhibit tumor growth in its unconjugated form. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody does not induce stem cell differentiation.
[011] In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody is a monoclonal antibody. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody is a human, humanized, or chimeric antibody. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody antibody is an IgGl, IgG2a or IgG2b antibody. In some embodiments of any of the isolated anti-LgR5 antibodies, the anti-LgR5 antibody is an antibody fragment that binds LgR5. In some embodiments of any of the isolated anti-LgR5 antibodies, LgR5 is human LgR5 of SEQ ID NO: 67. [012] In some embodiments, an antibodythat binds LgR5 binds an epitope within amino acids 22-323 of SEQ ID NO: 67. In some embodiments, the antibody binds to LgR5 with an affinity of < 5 nM. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a human, humanized, or chimeric antibody. In some embodiments, the antibody is an IgGl, IgG2a or IgG2b antibody. In some embodiments, the antibody is an antibody fragment that binds LgR5. In some embodiments, LgR5 is human LgR5 of SEQ ID NO: 67.
[013] In some embodiments, the antibody comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31. In some embodiments, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (c) HVR- H3 comprising the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody further comprises a heavy chain framework FR3 sequence of SEQ ID NO: 41. In some embodiments, the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29. In some embodiments, an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27,
(b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29. In some embodiments, the antibody further comprises a light chain framework FR3 sequence of SEQ ID NO: 35.
[014] In some embodiments, an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7; or
(c) a VH sequence as in (a) and a VL sequence as in (b). In some embodiments, the antibody comprises a VH sequence of SEQ ID NO: 8. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 7. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7.
[015] In some embodiments, an antibody that binds LgR5 comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55. In some embodiments, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56. In some embodiments, the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53. In some embodiments, an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51,
(b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
[016] In some embodiments, an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:23; or
(c) a VH sequence as in (a) and a VL sequence as in (b). In some embodiments, the antibody comprises a VH sequence of SEQ ID NO: 24. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 23. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 24 and a VL sequence of SEQ ID NO: 23.
[017] In some embodiments, an antibody that binds LgR5 comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO:495. In some embodiments, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 48, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50. In some embodiments, the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47. In some embodiments, an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45,
(b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
[018] In some embodiments, an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:21; or
(c) a VH sequence as in (a) and a VL sequence as in (b). In some embodiments, the antibody comprises a VH sequence of SEQ ID NO: 22. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 21. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 22 and a VL sequence of SEQ ID NO: 21.
[019] In some embodiments, an antibody that binds LgR5 comprises (a)HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, (b) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59, and (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the antibody further comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57, (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, an isolated antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57,
(b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
[020] In some embodiments, an isolated antibody comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26; or (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:25; or
(c) a VH sequence as in (a) and a VL sequence as in (b). In some embodiments, the antibody comprises a VH sequence of SEQ ID NO: 26. In some embodiments, the antibody comprises a VL sequence of SEQ ID NO: 25. In some embodiments, and isolated antibody comprises a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25.
[021] In some embodiments, an isolated nucleic acid that encodes an antibody described herein is provided. In some embodiments, a host cell comprising the nucleic acid is provided. In some embodiments, a method of producing an antibody described herein is provided. In some embodiments, the method comprises culturing the host cell comprising the nucleic acid that encodes an antibody.
[022] In some embodiments, immunoconjugates are provided. In some embodiments, an immunoconjugate comprises an anti-LgR5 antibody and a cytotoxic agent. In some embodiments, an immunoconjugate has the formula Ab-(L-D)p, wherein: (a) Ab is an antibody described herein; (b) L is a linker; (c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and (d) p ranges from 1-8. In some embodiments, D is an auristatin. In some such embodiments, D has formula DE
wherein R2 and R6 are each methyl, R3 and R4 are each isopropyl, R5 is H, R7 is sec-butyl, each R8 is independently selected from CH3, 0-CH3, OH, and H; R9 is H; and R18 is -C(R8)2-C(R8)2- aryl. In some embodiments, D is MMAE having the structure:
wherein the dotted lines indicate the optional presence of a double bond between CI and C2 or C2 and C3; R2 is independently selected from H, OH, =0, =CH2, CN, R, OR, =CH-RD, =C(RD)2, O-SO2-R, CO2R and COR, and optionally further selected from halo or dihalo, wherein RD is independently selected from R, C02R, COR, CHO, C02H, and halo; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', N02, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', N02, Me3Sn and halo; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation; R and R' are each independently selected from optionally substituted Ci-s alkyl, Ci_i2 alkyl, C3-8 heterocyclyl, C3_2o heterocyclyl, and C5_2o aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring ; R12, R16, R19 and R17 are as defined for R2, R6, R9 and R7 respectively; R" is a€3-12 alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings that are optionally substituted; and X a ' are independently selected from O, S and N(H). In some such embodiments, D is
wherein n is 0 or 1.
[024] In some embodiments, D is a nemorubicin derivative. In some embodiments, D has a structure selected from:
[025] In some embodiments, an immunoconjugate comprises a linker that is cleavable by a protease. In some embodiments, the linker comprises a val-cit dipeptide or a Phe-Lys dipeptide. In some embodiments, an immunoconjugate comprises a linker that is acid-labile. In some such embodiments, the linker comprises hydrazone.
wherein S is a sulfur atom;
In some embodiments, p ranges from 2-5.
[027] In some embodiments, an immunoconjugate comprises an antibody that comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29. In some embodiments, an
immunoconjugate comprises an antibody that comprises a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7.
[028] In some embodiments, pharmaceutical formulations are provided. In some such embodiments, a pharmaceutical formulation comprises an immunoconjugate comprising an antibody that binds LgR5, e.g., as described herein. In some embodiments, a pharmaceutical formulation further comprises an additional therapeutic agent. In some embodiments, the additional therapeutic agent is Avastin® (bevacizumab).
[029] In some embodiments, methods of treating individuals having LgR5 positive cancers are provided. In some such embodiments, a method comprises administering a pharmaceutical formulation comprising an immunoconjugate comprising an antibody that binds LgR5, e.g., as described herein. In some embodiments, the LgR5-positive cancer is selected from colorectal cancer, pancreatic cancer, ovarian cancer, and endometrial cancer. In some embodiments, the LgR5 -positive cancer is a small intestine cancer. In some embodiments, a small intestine cancer is a cancer of the duodenum, jejunum, and/or ilium. In some embodiments, a small intestine cancer is a cancer of the jejunum and/or ilium. In some embodiments, an LgR5- positive cancer comprises a Kras mutation, an APC mutation, or both a Kras mutation and an APC mutation (e.g., in at least a portion of the cancer cells). In some embodiments, a method comprises administering an additional therapeutic agent to the individual. In some such embodiments, the additional therapeutic agent is Avastin® (bevacizumab).
[030] In some embodiments, methods of inhibiting proliferation of an LgR5 -positive cell are provided. In some embodiments, the method comprising exposing the cell to an immunoconjugate comprising an antibody that binds LgR5 under conditions permissive for binding of the immunoconjugate to LgR5 on the surface of the cell. In some embodiments, an antibody that binds LgR5 is an antibody described herein. In some embodiments, proliferation of the cell is thereby inhibited. In some embodiments, the cell is a colorectal, small intestine, pancreatic, ovarian, or endometrial cancer cell.
[031] In some embodiments, an antibody that binds LgR5 is conjugated to a label. In some embodiments, an antibody that binds LgR5 is an antibody described herein. In some embodiments, the label is a positron emitter. In some embodiments, the positron emitter is 89Zr.
[032] In some embodiments, a method of detecting human LgR5 in a biological sample is provided. In some embodiments, a method comprises contacting the biological sample with an anti-LgR5 antibody under conditions permissive for binding of the anti-LgR5 antibody to a naturally occurring human LgR5, and detecting whether a complex is formed between the anti- LgR5 antibody and a naturally occurring human LgR5 in the biological sample. In some embodiments, an anti-LgR5 antibody is an antibody described herein. In some embodiments, the biological sample is a colorectal cancer sample, small intestine cancer sample, pancreatic cancer sample, ovarian cancer sample, or endometrial cancer sample.
[033] In some embodiments, a method for detecting an LgR5-positive cancer is provided. In some such embodiments, a method comprises (i) administering a labeled anti-LgR5 antibody to a subject having or suspected of having an LgR5 -positive cancer, and (ii) detecting the labeled anti-LgR5 antibody in the subject, wherein detection of the labeled anti-LgR5 antibody indicates a LgR5-positive cancer in the subject. In some embodiments, an anti-LgR5 antibody is an antibody described herein.
BRIEF DESCRIPTION OF THE FIGURES
[034] Figure 1 shows a graphic representation of the levels of human LgR5 gene expression in various tissues, as described in Example A. The inset in Figure 1 shows a graphic representation of the levels of human LgR5 gene expression in normal colon tissues and colon tumors, as described in Example A.
[035] Figure 2 shows expression of LgR5 in colon tumors by in situ hybridization, as described in Example B. [036] Figure 3 shows (A) the prevalence of various levels of LgR5 expression in a colon tumor tissue microarray, and (B) the heterogeneity of LgR5 expression in three cores from each colorectal adenocarcinoma sample, both determined by in situ hybridization, as described in Example B.
[037] Figure 4 shows the properties of certain anti-LgR5 monoclonal antibodies developed as described in Examples C through F.
[038] Figure 5 shows an alignment of the light chain variable region sequences of murine antibody mu8El 1 and humanized variants thereof (hu8El 1.vl to hu8El 1.v8). The three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
[039] Figure 6 shows an alignment of the heavy chain variable region sequences of murine antibody mu8El 1 and humanized variants thereof (hu8El 1.vl to hu8El 1.v8). The three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
[040] Figure 7 shows the light chain variable region sequences of murine antibodies 3G12 and 2H6. The three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
[041] Figure 8 shows the heavy chain variable region sequences of murine antibodies 3G12 and 2H6. The three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
[042] Figure 9 shows affinity measurements of chimeric antibody ch8El 1 and various humanized variants, as described in Example E.
[043] Figure 10 shows the light chain variable region sequence of human antibody YW353. The three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
[044] Figure 11 shows the heavy chain variable region sequence of human antibody YW353. The three hypervariable regions (HVRs: HVRl, HVR2, HVR3) are indicated by boxes in the sequences.
[045] Figure 12A-C show an alignment of LgR5 from human, cynomolgus monkey, rat, and mouse.
[046] Figure 13 shows that anti-LgR5 immunoconjugates demonstrate efficacy in LoVo colon cancer xenografts, as described in Example L.
[047] Figure 14 shows that anti-LgR5 immunoconjugates demonstrate efficacy in D5124 pancreatic cancer xenografts, as described in Example M.
[048] Figure 15 shows that huYW353-vcMMAE immunoconjugate demonstrates efficacy at 3, 6, and 12 mg/kg in D5124 pancreatic cancer xenografts, as described in Example M. [049] Figure 16 shows Lg 5 mR A expression in normal tissue and polyps from colons of AV and AKV mice, as described in Example N.
[050] Figure 17 shows survival of AKV mice administered anti-LgR5 antibody and anti-LgR5 antibody-drug conjugate have longer survival times than control AKV mice, as described in Example N.
[051] Figure 18 shows percentage of tumor area that is positive for cleaved caspase 3 in AKV mice administered a control ADC, an anti-LgR5 ADC, or an anti-LgR5 antibody, as described in Example N.
[052] Figure 19 shows AKV mice administered anti-LgR5 antibody-drug conjugate have longer survival times than untreated AKV mice and AKV mice administered gpl20-ADC or anti-LgR5, as described in Example N.
[053] Figure 20 shows LgR5+ area in small intestine polyps and colon polyps in AKV LgR5OTRJ+ mice, as described in Example N.
[054] Figure 21 shows (A) CC3+GFP+ area per cellular area in control ADC and anti- LgR5-ADC treated AKV LgR5OTRJ+ mice, and (B) exemplary immunohistochemistry staining in the control ADC and anti-LgR5-ADC treated AKV LgR5mR/+ mice, as described in Example N.
[055] Figure 22 shows Ki67+ area per cellular area (either GFP+ cells or GFP- cells) in control ADC and anti-LgR5-ADC treated AKV LgR5mBJ+ mice, as described in Example N.
[056] Figure 23 shows the ratio of GFP intensity to GFP+ area in crypts and tumors of AKV LgR5mw+ mice, as described in Example N.
[057] Figure 24 shows that huYW353-vcMMAE, hu8El 1V2-VCMMAE, and ch8El 1- vcMMAE immunoconjugate demonstrates efficacy in D5124 pancreatic cancer xenografts, as described in Example O.
[058] Figure 25 shows that hu8El 1V2-VCMMAE immunoconjugate demonstrates efficacy in D5124 pancreatic cancer xenografts, as described in Example O.
[059] Figure 26 shows that huYW353-vcMMAE and hu8El 1V2-VCMMAE
immunoconjugates demonstrate efficacy in LoVoXl .l colon cancer xenografts, as described in Example P.
[060] Figure 27 shows that hu8El 1V2-VCMMAE immunoconjugate demonstrates efficacy in LoVoXl .l colon cancer xenografts, as described in Example P.
[061] Figure 28 shows that huYW353-vcMMAE, huYW353-acetal-PNU, and huYW353-vcPNU immunoconjugates demonstrate efficacy in D5124 pancreatic cancer xenografts, as described in Example Q. [062] Figure 29 shows that hu8El lv2-acetal-PNU, hu8El 1V2-VCPNU, and hu8El lv2- PNU immunoconjugates demonstrate in D5124 pancreatic cancer xenografts, as described in Example .
[063] Figure 30 shows the results of administering certain hu8El lv2
immunoconjugates and control antibody immunoconjugates in LoVoXl . l colon cancer xenografts, as described in Example S.
[064] Figure 31 that hu8El lv2-acetal-PNU immunoconjugate demonstrates efficacy in LoVoXl . l colon cancer xenografts in mice coadminstered excess control antibody, as described in Example S.
[065] Figure 32 shows that an anti-LgR5 huYW353 PBD immunoconjugate demonstrates efficacy in D5124 pancreatic cancer xenografts, as described in Example T.
[066] Figure 33 shows that an anti-LgR5 hu8El lv2 PBD immunoconjugate demonstrate efficacy in D5124 pancreatic cancer xenografts, as described in Example T.
[067] Figure 34 shows that an anti-LgR5 hu8El lv2 PBD immunoconjugate demonstrates efficacy in a LoVoXl . l colong cancer cancer xenograft, as described in Example U.
[068] Figure 35 shows the structures of (A) an antibody-vcMMAE immunoconjugate, (B) an antibody-acetal-PNU immunoconjugate, (C) an antibody-acetal-PNU immunoconjugate, (D) an antibody-PNU immunoconjugate, and (E) an antibody-vcPBD immunoconjugate.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
I. DEFINITIONS
[069] An "acceptor human framework" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
[070] "Affinity" refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1 :1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
[071] An "affinity matured" antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
[072] The terms "anti-LgR5 antibody" and "an antibody that binds to LgR5" refer to an antibody that is capable of binding LgR5 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting LgR5. In one embodiment, the extent of binding of an anti-LgR5 antibody to an unrelated, non-LgR5 protein is less than about 10% of the binding of the antibody to LgR5 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to LgR5 has a dissociation constant (Kd) of < 1 μΜ, < 100 nM, < 10 nM, , < 5 Nm, , < 4 nM, , < 3 nM, , < 2 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10"8 M or less, e.g. from 10"8 M to 10"13 M, e.g., from 10"9 M to 10"13 M). In certain embodiments, an anti-LgR5 antibody binds to an epitope of LgR5 that is conserved among LgR5 from different species.
[073] The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
[074] An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody and that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.
[075] An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. An exemplary competition assay is provided herein.
[076] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, small intestine cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.
[077] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
[078] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGi, IgG2, IgG3, IgG4, IgAi, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[079] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, 1131, 1125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.
[080] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
[081] An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. [082] The term "epitope" refers to the particular site on an antigen molecule to which an antibody binds.
[083] The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[084] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FRl, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[085] The terms "full length antibody," "intact antibody," and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
[086] The term "glycosylated forms of LgR5" refers to naturally occurring forms of LgR5 that are post-translationally modified by the addition of carbohydrate residues.
[087] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
[088] A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non- human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
[089] A "human consensus framework" is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al supra.
[090] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs {e.g. , CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non- human antibody, refers to an antibody that has undergone humanization.
[091] The term "hypervariable region" or "HVR," as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops"). Generally, native four-chain antibodies comprise six HVRs; three in the VH (HI, H2, H3), and three in the VL (LI, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the
"complementarity determining regions" (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (LI), 50-52 (L2), 91-96 (L3), 26-32 (HI), 53-55 (H2), and 96-101 (H3). (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of LI, 50-56 of L2, 89-97 of L3, 31-35B of HI, 50-65 of H2, and 95-102 of H3. (Kabat et al Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).) With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. CDRs also comprise "specificity determining residues," or "SDRs," which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-Ll, a-CDR-L2, a-CDR-L3, a-CDR-Hl, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of LI, 50-55 of L2, 89-96 of L3, 31-35B of HI, 50-58 of H2, and 95-102 of H3. {See Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008).) Unless otherwise indicated, HVR residues and other residues in the variable domain {e.g., FR residues) are numbered herein according to Kabat et al supra. [092] An "immune-conjugate" is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
[093] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
[094] An "isolated antibody" is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[095] An "isolated nucleic acid" refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[096] "Isolated nucleic acid encoding an anti-LgR5 antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.
[097] The term "LgR5," as used herein, refers to any native, mature LgR5 which results from processing of an LgR5 precursor protein in a cell. The term includes LgR5 from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally occurring variants of LgR5, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary human LgR5 precursor protein, with signal sequence (amino acids 1-21) is shown in SEQ ID NO: 67. The amino acid sequence of an exemplary mature human LgR5 is shown in SEQ ID NO: 68. The predicted sequence for amino acids 33 to 907 of an exemplary cynomolgus monkey LgR5 is shown in SEQ ID NO: 69. The amino acid sequences for exemplary rat LgR5 precursor (with signal sequence, amino acids 1-21) and mature sequences are shown in SEQ ID NOs: 70 and 71, respectively. The amino acid sequences for exemplary mouse LgR5 precursor (with signal sequence, amino acids 1-21) and mature sequences are shown in SEQ ID NOs: 72 and 73, respectively. [098] The term "Lg 5 -positive cancer" refers to a cancer comprising cells that express LgR5 on their surface. For the purposes of determining whether a cell expresses LgR5 on the surface, LgR5 mRNA expression is considered to correlate to LgR5 expression on the cell surface. In some embodiments, expression of LgR5 mRNA is determined by a method selected from in situ hybridization and RT-PCR (including quantitative RT-PCR). Alternatively, expression of LgR5 on the cell surface can be determined, for example, using antibodies to LgR5 in a method such as immunohistochemistry, FACS, etc.
[099] The term "LgR5 -positive cell" refers to a cell that expresses LgR5 on its surface.
[0100] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier
"monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
[0101] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.
[0102] "Native antibodies" refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.
[0103] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
[0104] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTA ) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[0105] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
[0106] The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
[0107] A "pharmaceutically acceptable carrier" refers to an ingredient in a
pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
[0108] As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
[0109] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (F s) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880- 887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0110] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as
"expression vectors."
[0111] "Alkyl" is C1-C18 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1 -propyl (n-Pr, n-propyl, - CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1 -butyl (n-Bu, n-butyl, - CH2CH2CH2CH3), 2-methyl-l -propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, - CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, - CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2- methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3 -methyl- 1 -butyl (-CH2CH2CH(CH3)2), 2-methyl-l -butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (- CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (- CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3- pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3 -dimethyls- butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3.
[0112] The term "Ci-Cs alkyl," as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 8 carbon atoms. Representative "Ci-Cs alkyl" groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, - n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl; while branched Ci-Cs alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, unsaturated Ci-Cs alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, - 1-pentenyl, -2-pentenyl, -3 -methyl- 1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, 1- hexyl, 2-hexyl, 3-hexyl,-acetylenyl, -propynyl, -1-butynyl, -2-butynyl, -1-pentynyl, -2-pentynyl, - 3-methyl-l butynyl. A Ci-Cs alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-C8 alkyl, -0-(d-C8 alkyl), -aryl, -C(0)R', -OC(0)R', - C(0)OR', -C(0)NH2 , -C(0)NHR', -C(0)N(R')2 -NHC(0)R', -SO3R', -S(0)2R', -S(0)R', -OH, - halogen, -N3 , -NH2, -NH(R'), -N(R')2 and -CN; where each R' is independently selected from H, -Ci-Cs alkyl and aryl.
[0113] The term "C1-C12 alkyl," as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 12 carbon atoms. A C1-C12 alkyl group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-Cs alkyl, -0-(Ci-Cs alkyl), -aryl, -C(0)R', -OC(0)R', -C(0)OR', -C(0)NH2 , -C(0)NHR', - C(0)N(R')2 -NHC(0)R', -SO3R', -S(0)2R', -S(0)R', -OH, -halogen, -N3 , -NH2, -NH(R'), - N(R')2 and -CN; where each R' is independently selected from H, -Ci-Cs alkyl and aryl. [0114] The term "Ci-Ce alkyl," as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 6 carbon atoms. Representative "Ci-Ce alkyl" groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -and n-hexyl; while branched Ci-Ce alkyls include, but are not limited to, -isopropyl, -sec-butyl, - isobutyl, -tert-butyl, -isopentyl, and 2-methylbutyl; unsaturated Ci-Ce alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylenyl, -1-pentenyl, -2-pentenyl, - 3-methyl-l-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, 1-hexyl, 2-hexyl, and 3-hexyl. A Ci-Ce alkyl group can be unsubstituted or substituted with one or more groups, as described above for Ci-Cs alkyl group.
[0115] The term "C1-C4 alkyl," as used herein refers to a straight chain or branched, saturated or unsaturated hydrocarbon having from 1 to 4 carbon atoms. Representative "C1-C4 alkyl" groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl; while branched C1-C4 alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl;
unsaturated C1-C4 alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylenyl. A C1-C4 alkyl group can be unsubstituted or substituted with one or more groups, as described above for Ci-Cs alkyl group.
[0116] "Alkoxy" is an alkyl group singly bonded to an oxygen. Exemplary alkoxy groups include, but are not limited to, methoxy (-OCH3) and ethoxy (-OCH2CH3). A "C1-C5 alkoxy" is an alkoxy group with 1 to 5 carbon atoms. Alkoxy groups may can be unsubstituted or substituted with one or more groups, as described above for alkyl groups.
[0117] "Alkenyl" is C2-CI8 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp2 double bond.
Examples include, but are not limited to: ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2 CH2CH2CH2CH=CH2). A "C2-C8 alkenyl" is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp2 double bond.
[0118] "Alkynyl" is C2-C18 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond. Examples include, but are not limited to: acetylenic (-C≡CH) and propargyl (-CH2C≡CH). A "C2- Cs alkynyl" is a hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.
[0119] "Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH2-) 1,2-ethyl (-CH2CH2-), 1,3-propyl (-CH2CH2CH2-), 1,4-butyl (-CH2CH2CH2CH2-), and the like.
[0120] A "Ci-Cio alkylene" is a straight chain, saturated hydrocarbon group of the formula -(CH2)HO-. Examples of a Ci-Cio alkylene include methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, ocytylene, nonylene and decalene.
[0121] "Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2- 18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene radicals include, but are not limited to: 1 ,2-ethylene (-CH=CH-).
[0122] "Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene radicals include, but are not limited to: acetylene (-C≡C-), propargyl
(-CH2C≡C-), and 4-pentynyl (-CH2CH2CH2C≡C-).
[0123] "Aryl" refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A carbocyclic aromatic group or a heterocyclic aromatic group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-C8 alkyl, -0-(d-C8 alkyl), -aryl, -C(0)R', -OC(0)R', - C(0)OR\ -C(0)NH2 , -C(0)NHR', -C(0)N(R')2 -NHC(0)R', -S(0)2R', -S(0)R', -OH, -halogen, -N3 , -NH2, -NH(R'), -N(R')2 and -CN; wherein each R' is independently selected from H, -Ci-C8 alkyl and aryl.
[0124] A "C5-C2o aryl" is an aryl group with 5 to 20 carbon atoms in the carbocyclic aromatic rings. Examples of C5-C2o aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A Cs-C2o aryl group can be substituted or unsubstituted as described above for aryl groups. A "C5-C14 aryl" is an aryl group with 5 to 14 carbon atoms in the carbocyclic aromatic rings. Examples of C5-C14 aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. A C5-Ci4 aryl group can be substituted or unsubstituted as described above for aryl groups.
[0125] An "arylene" is an aryl group which has two covalent bonds and can be in the ortho, meta, or para configurations as shown in the following structures:
in which the phenyl group can be unsubstituted or substituted with up to four groups including, but not limited to, -Ci-Cg alkyl, -0-(d-C8 alkyl), -aryl, -C(0)R', -OC(0)R', -C(0)OR', - C(0)NH2 , -C(0)NHR', -C(0)N(R')2 -NHC(0)R\ -S(0)2R', -S(0)R', -OH, -halogen, -N3 , -NH2, -NH(R'), -N(R')2 and -CN; wherein each R' is independently selected from H, -Ci-C8 alkyl and aryl.
[0126] "Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, 2- phenylethen-l-yl, naphthylmethyl, 2-naphthylethan-l-yl, 2-naphthylethen-l-yl, naphthobenzyl, 2- naphthophenylethan-l-yl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.
[0127] "Heteroarylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl radical. Typical heteroarylalkyl groups include, but are not limited to, 2- benzimidazolylmethyl, 2-furylethyl, and the like. The heteroarylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the heteroarylalkyl group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. The heteroaryl moiety of the heteroarylalkyl group may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.
[0128] "Substituted alkyl," "substituted aryl," and "substituted arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a substituent. Typical substituents include, but are not limited to, -X, -R, -O" , -OR, -SR, -S", -NR2, -NR3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, NC(=0)R, -C(=0)R, -C(=0)NR2, -S03 "
, -S03H, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P03, -P03 H2, -C(=0)R -C(=0)X, -C(=S)R, -C02R, -C02, -C(=S)OR, -C(=0)SR, -C(=S)SR, -C(=0)NR2, - C(=S)NR2, -C(=NR)NR2, where each X is independently a halogen: F, CI, Br, or I; and each R is independently -H, C2-Cis alkyl, C6-C2o aryl, C3-Ci4 heterocycle, protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups as described above may also be similarly substituted.
[0129] "Heteroaryl" and "heterocycle" refer to a ring system in which one or more ring atoms is a heteroatom, e.g. nitrogen, oxygen, and sulfur. The heterocycle radical comprises 3 to 20 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. A heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.
[0130] Exemplary heterocycles are described, e.g., in Paquette, Leo A., "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566.
[0131] Examples of heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, bis- tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H- 1,2,5-thiadiazinyl, 2H,6H-l,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, lH-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl.
[0132] By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2- pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3 -pyridazinyl, 4-pyridazinyl, 5 -pyridazinyl, 6- pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5 -pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5 -pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5 -thiazolyl. [0133] By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1 -aziridyl, 1 -azetedyl, 1 -pyrrolyl, 1 -imidazolyl, 1 - pyrazolyl, and 1 -piperidinyl.
[0134] A "C3-C8 heterocycle" refers to an aromatic or non-aromatic C3-C8 carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. Representative examples of a C3-C8 heterocycle include, but are not limited to, benzofuranyl, benzothiophene, indolyl, benzopyrazolyl, coumarinyl, isoquinolinyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl, isoxazolyl and tetrazolyl. A C3-C8 heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -Ci-Cg alkyl, -0-(Ci-C8 alkyl), -aryl, -C(0)R\ -OC(0)R\ -C(0)OR\ -C(0)NH2 , - C(0)NHR', -C(0)N(R')2 -NHC(0)R', -S(0)2R', -S(0)R', -OH, -halogen, -N3 , -NH2, -NH(R'), - N(R')2 and -CN; wherein each R' is independently selected from H, -Ci-Cs alkyl and aryl.
[0135] "C3-Cs heterocyclo" refers to a C3-C8 heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond. A C3-C8 heterocyclo can be unsubstituted or substituted with up to six groups including, but not limited to, -Ci-Cs alkyl, - 0-(Ci-Cg alkyl), -aryl, -C(0)R\ -OC(0)R\ -C(0)OR\ -C(0)NH2 , -C(0)NHR', -C(0)N(R')2 - NHC(0)R', -S(0)2R', -S(0)R', -OH, -halogen, -N3 , -NH2, -NH(R'), -N(R')2 and -CN; wherein each R' is independently selected from H, -Ci-Cs alkyl and aryl.
[0136] A "C3-C2o heterocycle" refers to an aromatic or non-aromatic C3-C8 carbocycle in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. A C3-C2o heterocycle can be unsubstituted or substituted with up to seven groups including, but not limited to, -Ci-Cs alkyl, -0-(Ci-Cs alkyl), -aryl, -C(0)R', - OC(0)R\ -C(0)OR\ -C(0)NH2 , -C(0)NHR', -C(0)N(R')2 -NHC(0)R', -S(0)2R', -S(0)R', - OH, -halogen, -N3 , -NH2, -NH(R'), -N(R')2 and -CN; wherein each R' is independently selected from H, -Ci-Cs alkyl and aryl.
[0137] "C3-C2o heterocyclo" refers to a C3-C2o heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond.
[0138] "Carbocycle" means a saturated or unsaturated ring having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g. arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1 -cyclopent-l-enyl, l-cyclopent-2-enyl, l -cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l -cyclohex-3-enyl, cycloheptyl, and cyclooctyl.
[0139] A "C3-C8 carbocycle" is a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated non-aromatic carbocyclic ring. Representative C3-C8 carbocycles include, but are not limited to, - cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1 ,3- cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1 ,3-cycloheptadienyl, -1 ,3,5- cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl. A C3-C8 carbocycle group can be unsubstituted or substituted with one or more groups including, but not limited to, -Ci-Cs alkyl, - 0-(Ci-Cg alkyl), -aryl, -C(0)R', -OC(0)R\ -C(0)OR', -C(0)NH2 , -C(0)NHR', -C(0)N(R')2 - NHC(0)R', -S(0)2R', -S(0)R', -OH, -halogen, -N3 , -NH2, -NH(R'), -N(R')2 and -CN; where each R' is independently selected from H, -Ci-Cs alkyl and aryl.
[0140] A "C3-C8 carbocyclo" refers to a C3-C8 carbocycle group defined above wherein one of the carbocycle groups' hydrogen atoms is replaced with a bond.
[0141 ] "Linker" refers to a chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches an antibody to a drug moiety. In various embodiments, linkers include a divalent radical such as an alkyldiyl, an aryldiyl, a heteroaryldiyl, moieties such as: -(CR2)nO(CR2)n-, repeating units of alkyloxy (e.g. polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g. polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide. In various embodiments, linkers can comprise one or more amino acid residues, such as valine, phenylalanine, lysine, and homolysine.
[0142] The term "chiral" refers to molecules which have the property of non- superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.
[0143] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
[0144] "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
[0145] "Enantiomers" refer to two stereoisomers of a compound which are non- superimposable mirror images of one another. [0146] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
[0147] "Leaving group" refers to a functional group that can be substituted by another functional group. Certain leaving groups are well known in the art, and examples include, but are not limited to, a halide {e.g., chloride, bromide, iodide), methanesulfonyl (mesyl), p- toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate.
[0148] The term "protecting group" refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc). For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991, or a later edition.
II. COMPOSITIONS AND METHODS
[0149] In one aspect, the invention is based, in part, on antibodies that bind to Lg 5 and immunoconjugates comprising such antibodies. Antibodies and immunoconjugates of the invention are useful, e.g., for the diagnosis or treatment of LgR5 -positive cancers.
A. Exemplary Anti-LgR5 Antibodies
[0150] In some embodiments, the invention provides isolated antibodies that bind to LgPv5. LgR5 is is a seven-transmembrane protein found, for example, on the surface of actively cycling intestinal stem cells. As demonstrated herein, LgR5 is expressed in about 77% of colon tumor sections examined.
[0151] An exemplary naturally occurring human LgR5 precursor protein sequence, with signal sequence (amino acids 1-21) is provided in SEQ ID NO: 67, and the corresponding mature LgR5 protein sequence is shown in SEQ ID NO: 68 (corresponding to amino acids 22-907 of SEQ ID NO: 67).
[0152] In certain embodiments, an anti-LgR5 antibody has at least one or more of the following characteristics, in any combination: (a) binds to an epitope within amino acids 22-555 of SEQ ID NO: 67; (b) binds LgR5 with an affinity of < 5 nM, or < 4 nM, or < 3 nM, or < 2 nM, or < 1 nM, and optionally > 0.0001 nM, or > 0.001 nM, or > 0.01 nM; (c) does not significantly disrupt the binding of R-spondin (RSPO) to LgR5; (d) does not significantly disrupt beta-catenin signaling; (e) does not significantly disrupt RSPO activation of LgR5 signaling; (f) activates caspase 3 cleavage; (g) recognizes both human and rodent LgR5; (h) recognizes human LgR5 but not rodent LgR5; (i) does not significantly inhibit tumor growth in its unconjugated form; and (J) does not induce stem cell differentiation. In some embodiments, the anti-LgR5 antibody is 8E11 and humanized variants thereof, such as hu8El l.v2; YW353; 2H6; and 3G12. In some embodiments, LgR5 is human LgR5. In some embodiments, LgR5 is selected from human, cynomolgus monkey, mouse, and rat LgR5.
(a) binds to an epitope within amino acids 22-555 of SEQ ID NO: 67
[0153] Methods of determining whether an anti-LgR5 antibody binds to an epitope of LgR5 are known in the art. In some embodiments, binding of an anti-LgR5 antibody to an epitope of LgR5 {e.g., within amino acids 22-555 of SEQ ID NO: 67) may be determined by expressing LgR5 polypeptides with N- and C-terminal deletions in 293 cells and testing by FACS as described in Example I binding of the antibody to the truncated polypeptides. In some embodiments, a substantial reduction (> 70% reduction) or elimination of binding of the antibody to a truncated polypeptide relative to binding to full-length LgR5 expressed in 293 cells indicates that the antibody does not bind to that truncated polypeptide. In some embodiments, LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
[0154] In some embodiments, the epitope of LgR5 comprises the lucine rich N-terminal domain of LgR5 {e.g., amino acid residues 25-66 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises one or more lucine rich repeats (LRR) of LgR5 {e.g., amino acid residues 67-446 of SEQ ID NO:67; LRRs 1-16 of LgR5). ). In some embodiments, the epitope of LgR5 comprises LRR 1 of LgR5 {e.g., amino acid residues 67-90 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 2 of LgR5 {e.g., amino acid residues 91-112 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 3 of LgR5 {e.g., amino acid residues 115-136 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 4 of LgR5 (e.g., amino acid residues 139-160 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 5 of LgR5 (e.g., amino acid residues 163-184 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 6 of LgR5 (e.g., amino acid residues 187-208 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 7 of LgR5 (e.g., amino acid residues 211-232 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 8 of LgR5 (e.g., amino acid residues 235-256 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 9 of LgR5 (e.g., amino acid residues 258-279 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 10 of LgR5 (e.g., amino acid residues 282-303 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 11 of LgR5 (e.g., amino acid residues 306- 328 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 12 of LgR5 (e.g., amino acid residues 329-350 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 13 of LgR5 (e.g., amino acid residues 353-374 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 14 of LgR5 (e.g., amino acid residues 375- 396 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 15 of LgR5 (e.g., amino acid residues 399-420 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises LRR 16 of LgR5 (e.g., amino acid residues 423-446 of SEQ ID NO:67). In some embodiments, the epitope of LgR5 comprises any of LRRl to LRRl 1, LRR2 to LRRl 1, LRR3 to LRRl l, LLR1 to LLR3, LLR2 to LLR3, LLR2 to LLR8, LLR3 to LL7, or LLR4 to LLR6.
[0155] In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-555 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-424 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-123 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 22-323 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 324-555 of SEQ ID NO: 67. In some embodiments, the epitope of LgR5 comprises an epitope within amino acids 324-424 of SEQ ID NO: 67.
[0156] It is understood that aspect and embodiments described herein include
"consisting" and/or "consisting effectially of aspects and embodiments.
(b) binds LgR5 with an affinity of < 5 iiM. or < 4 iiM. or < 3 iiM. or < 2 iiM. or < l iiM. and optionally > 0.0001 iiM. or > 0.001 iiM. or > 0.01 nM
[0157] Methods of determining binding affinity are known in the art. In some embodiments, the binding affinity may be determined according to a BIAcore® assay as described herein in Example E. Specifically, in some embodiments, Kd may be measured using surface plasmon resonance assays using a BIACORE -3000 (BIAcore, Inc., Piscataway, NJ). BIAcore™ research grade CM5 chips may be activated with l-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) reagents according to the supplier's instructions. Goat anti-human Fc IgGs may be coupled to the chips to achieve approximately 10,000 response units (RU) in each flow cell. Unreacted coupling groups may be blocked with 1M ethanolamine. For kinetics measurements, anti-LGR5 antibodies may be captured to achieve approximately 300 RU. Two-fold serial dilutions of human LgR5 ECD (for example, amino acids 22-557 (or a similar fragment, such as 22-555) fused to His-Fc expressed in a baculovirus system, or amino acids 22-558 (or a similar fragment, such as 22-555) fused to Fc expressed from CHO cells; 125 nM to 0.49 nM) may be injected in HBS-P buffer (0.01M HEPES pH7.4, 0.15M NaCl, 0.005% surfactant P20) at 25°C with a flow rate of 30 μΐ/min. Association rates (kon) and dissociation rates (koff) may be calculated using a 1 : 1 Langmuir binding model (BIAcore™ Evaluation Software version 3.2). The equilibrium dissociation constant (Kd) may be calculated as the ratio koff/kon. If the on-rate exceeds 106 M"1 s by the surface plasmon resonance assay above, then the on-rate may be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm;
emission = 340 nm, 16 nm band-pass) at 25°C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000- series SLM-Aminco® spectrophotometer (ThermoSpectronic) with a stirred cuvette.
[0158] In some embodiments, the anti-LgR5 antibody binds LgR5 with an affinity of about any of < 5 nM, or < 4 nM, or < 3 nM, or < 2 nM, or < 1 nM. In some embodiments, the anti-LgR5 antibody binds LgR5 with an affinity of about < 5. In some embodiments, the anti- LgR5 antibody binds LgR5 with an affinity of about < 4 nM. In some embodiments, the anti- LgR5 antibody binds LgR5 with an affinity of about < 3 nM. In some embodiments, the anti- LgR5 antibody binds LgR5 with an affinity of about <2 nM. In some embodiments, LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
[0159] As is understood by one skilled in the art, reference to "about" a value or parameter includes (and describes) embodiments that are direct to that value or parameter per se. For example, description referring to "about X" includes description of "X".
(c) does not significantly disrupt the binding of R-spondin (RSPO) to LgR5
[0160] Methods of determining the ability of an anti-LgR5 antibody to disrupt the binding of an RSPO to LgR5 are known in the art. In some embodiments, the ability of an anti- LgR5 antibody to significantly disrupt the binding of an R-spondon (RSPO) to LgR5 may be determined by flow cytometry. In some embodiments, for example, 293 cells expressing LgR5 may be contacted with fluorescently-labeled RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, in the presence and absence of an anti-LgR5 antibody. Binding of RSPO to the 293 cells may be detected using fluorescence-activated cell sorting (FACS). In some embodiments, a decrease in RSPO binding in the presence of an anti-LgR5 antibody of less than about 25% relative to RSPO binding in the presence of a control antibody, indicates that the anti-LgR5 antibody does not significantly disrupt binding of RSPO to LgR5.
[0161] In some embodiments, the ability of an anti-LgR5 antibody to significantly disrupt the binding of an R-spondon (RSPO) to LgR5 may be determined by BIAcore assay. In some embodiments, for example, LgR5 extracellular domain may be immobilized on CM5 chips, e.g., as described herein, and binding of RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, to the immobilized LgR5 may be determined in the presence and absence of an anti-LgR5 antibody. In some embodiments, a decrease in RSPO binding in the presence of an anti-LgR5 antibody of less than about 25% relative to RSPO binding in the presence of a control antibody, indicates that the anti-LgR5 antibody does not significantly disrupt binding of RSPO to LgR5.
[0162] In some embodiments, the RSPO is selected from RSPOl, RSP02, RSP03, and RSP04. In some embodiments, the antibody disrupts binding by less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, the antibody does not detectably disrupt binding of an RSPO to LgR5. In some embodiments, LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
(d) does not significantly disrupt wnt/beta-catenin signaling
[0163] Methods of determining ability of an anti-LgR5 antibody to disrupt wnt/beta- catenin signaling are known in the art. In some embodiments, the ability of an anti-LgR5 antibody to significantly disrupt wnt/beta-catenin signaling may be determined using a reporter gene assay. In some embodiments, for example, a reporter construct comprising a reporter gene (such as, for example, a luciferase gene) under the control of a wnt/beta-catenin responsive promoter (such as, for example, a promoter comprising multimerized TCF/LEF DNA-binding sites) may be transfected into cells that express LgR5. The cells are then contacted with a Wnt ligand, such as Wnt3a, and an RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, in the presence and absence of an anti-LgR5 antibody, and luciferase expression is measured. In some embodiments, a decrease in luciferase expression in the presence of antibody of less than about 25% relative to luciferase expression in the presence of a control antibody, indicates that the anti- LgR5 antibody does not significantly disrupt beta-catenin signaling.
[0164] In some embodiments, the antibody disrupts beta-catenin signaling by less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, the antibody does not detectably disrupt beta-catenin signaling. In some embodiments, LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
(e) does not significantly disrupt RSPO activation of LgR5 signaling
[0165] Methods of determining ability of an anti-LgR5 antibody to disrupt RSPO activation of LgR5 are known in the art. In some embodiments, the ability of an anti-LgR5 antibody to significantly disrupt RSPO activation of LgR5 signaling may be determined using a reporter gene assay. In some embodiments, for example, a reporter construct comprising a reporter gene (such as, for example, a luciferase gene) under the control of a beta-catenin responsive promoter (such as, for example, a promoter comprising multimerized TCF/LEF DNA- binding sites) may be transfected into cells that express LgR5. The cells may be then contacted with a Wnt ligand, such as Wnt3a, in the presence and absence of an RSPO, such as RSPOl, RSP02, RSP03, and/or RSP04, and the activation of LgR5 signaling may be measured as the increase in luciferase expression in the presence of the RSPO. The activation of LgR5 signaling may also be measured in the presence and absence of an anti-LgR5 antibody. In some embodiments, a decrease in the activation of LgR5 signaling in the presence of RSPOl, RSP02, RSP03, and/or RSP04 of less than about 25% when the cells are contacted with an anti-LgR5 antibody versus a control antibody, indicates that the anti-LgR5 antibody does not significantly disrupt RSPO activation of LgR5 signaling.
[0166] In some embodiments, the RSPO is selected from RSPOl, RSP02, RSP03, and RSP04. In some embodiments, the antibody disrupts RSPO activation of LgR5 signaling by less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, the antibody does not detectably disrupt RSPO activation of LgR5 signaling. In some embodiments, LgR5 is human LgR5. In some embodiments, LgR5 is human LgR5 or cynomolgus monkey LgR5.
(f) activates caspase 3 cleavage
[0167] Methods of determining ability of an anti-LgR5 antibody to activate caspase 3 cleavage are known in the art. In some embodiments, the ability of an anti-LgR5 antibody to activate caspase 3 cleavage may be determined in a rodent xenograft model, e.g., as described in Example N. In some embodiments, the presence of cleaved caspase 3 may be measured as a function of tumor area, for example, in formalin fixed paraffin embedded (FFPE) small intestine and colon tissue collected from intestinal tumorogenesis model mice that were administered an anti-LgR5 antibody. The presence of cleaved caspase 3 may be determined, in some
embodiments, using immunohistochemistry. Further, in some embodiments, caspase 3 cleavage may be determined as a percent positive tumor area, e.g., as shown in Example N and Figure 18. [0168] In some embodiments, an anti-LgR5 antibody increases the percentage of caspase 3 positive tumor area according to the assay described in Example N by about any of at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% (i.e., the percentage of positive tumor area doubles).
(g) recognizes both human and rodent LgR5
[0169] Methods of determining the ability of an anti-LgR5 antibody to bind human and rodent LgR5 are known in the art. In some embodiments, human and rodent LgR5 polypeptides are expressed in 293 cells and binding of the antibody to the LgR5-espressing 293 cells is tested by FACS as described in Example G. In some embodiments, rodent LgR5 is mouse or rat LgR5. In some embodiments, rodent LgR5 is mouse LgR5.
(h) recognizes human LgR5 but not rodent LgR5
[0170] Methods of determining the ability of an anti-LgR5 antibody to bind human but not rodent LgR5 are known in the art. In some embodiments, human and rodent LgR5 polypeptides are expressed in 293 cells and binding of the antibody to the LgR5-espressing 293 cells is tested by FACS as described in Example G. In some embodiments, rodent LgR5 is mouse or rat LgR5. In some embodiments, rodent LgR5 is mouse LgR5.
(i) does not significantly inhibit tumor growth in its unconjugated form
[0171] Methods of determining the ability of an anti-LgR5 antibody to inhibit tumor growth in its unconjugated form are known in the art. In some embodiments, a rodent xenograft model such as the D5124 pancreatic cancer xenograft model described in Example M is used. In some embodiments, an anti-LgR5 antibody does not significantly inhibit tumor growth in its unconjugated form in a LoVo colon cancer cell line xenograft model, for example, as described in Example L. In some embodiments, an anti-LgR5 antibody does not significantly inhibit tumor growth in its unconjugated form in a murine intestinal tumorigenesis model, for example, as described in Example N. Inhibition of tumor growth in a xenograft model or murine intestinal tumorigenesis model is determined relative to a vehicle control or control antibody.
[0172] In some embodiments, an anti-LgR5 antibody inhibits tumor growth in its unconjugated form by less than about 25%, less than about 20%, less than about 15%, or less than about 10%. In some embodiments, an anti-LgR5 antibody does not detectably inhibit tumor growth in its unconjugated form.
(j) does not induce stem cell differentiation
[0173] Methods of determining the ability of an anti-LgR5 antibody to induce stem cell differntiation are known in the art. In some embodiments, stem cell differentiation may be assayed by determining ability to differentiation of crypt base columnar cells (CBCs), which are fast-cycling stem cells in the small intestine that express LgR5, into, for example, enterocytes, goblet cells, and/or enteroendocrine cells, in the presence and absence of an anti-LgR5 antibody In some embodiments, an anti-LgR5 antibody is considered to not induce stem cell differentiation if about any of less than 25%, less than 20%, less than 15%, or less than 10% of a population of CBCs differentiates in the presence of the anti-LgR5 antibody under conditions in which a control antibody also induces stem cell differentiation in less than about 25% of a population of CBCs.
[0174] In some embodiments, an anti-LgR5 antibody immunoconjugate inhibits tumor growth through a primary mechanism that is not inducing stem cell differentiation. In some such embodiments, the anti-LgR5 antibody immunoconjugate inhibits tumor growth through cytotoxic activity mediated through a cytotoxic agent conjugated to the antibody in the immunoconjugate. Antibody 8E11 and other embodiments
[0175] In some embodiments, the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
[0176] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31. In a further embodiment, the antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
[0177] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29. In one embodiment, the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
[0178] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 32; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
[0179] In another aspect, the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 ; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 27; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
[0180] In any of the above embodiments, an anti-LgR5 antibody is humanized. In one embodiment, an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In certain embodiments, the human acceptor framework is the human VL kappa IV consensus (VLKiv) framework and/or the VH framework V¾. In certain embodiments, the human acceptor framework is the human VL kappa IV consensus (VLKrv) framework and/or the VH framework V¾ comprising an R71S mutation and an A78V mutation in heavy chain framework region FR3.
[0181] In some embodiments, an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a heavy chain framework FR3 sequence selected from SEQ ID NOs: 40 to 43. In some embodiments, an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a heavy chain framework FR3 sequence of SEQ ID NO: 41. In some such embodiments, the heavy chain variable domain framework is a modified human V¾ framework having an FR3 sequence selected from SEQ ID NOs: 40 to 43. In some such embodiments, the heavy chain variable domain framework is a modified human VHi framework having an FR3 sequence of SEQ ID NO: 41. [0182] In some embodiments, an anti-Lg 5 antibody comprises HVRs as in any of the above embodiments, and further comprises a light chain framework FR3 sequence of SEQ ID NO: 36. In some such embodiments, the heavy chain variable domain framework is a modified VL kappa IV consensus (VLKiv) framework having an FR3 sequence of SEQ ID NO: 36.
[0183] In another aspect, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in a sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in a sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
[0184] In some embodiments, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 6. In some embodiments, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12. In some embodiments, an anti- LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14. In some embodiments, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18. In some embodiments, an anti- LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 20.
[0185] Optionally, the anti-LgR5 antibody comprises the VH sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31 , and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
[0186] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11 , 13, 15, 17, and 19. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 1 1 , 13, 15, 17, and 19 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11 , 13, 15, 17, and 19. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11 , 13, 15, 17, and 19. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
[0187] In some embodiments, an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 5. In some embodiments, an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 1. In some embodiments, an anti- LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 13. In some embodiments, an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 15. In some embodiments, an anti-LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17. In some embodiments, an anti- LgR5 antibody comprises a light chain variable domain (VL) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19.
[0188] Optionally, the anti-LgR5 antibody comprises the VL sequence of an amino acid sequence selected from SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, and 19, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29.
[0189] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 6 and SEQ ID NO: 5, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 8 and SEQ ID NO: 7, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 10 and SEQ ID NO: 9, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 12 and SEQ ID NO: 11, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 14 and SEQ ID NO: 13, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 16 and SEQ ID NO: 15, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 18 and SEQ ID NO: 17, respectively, including post-translational modifications of those sequences. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 20 and SEQ ID NO: 19, respectively, including post-translational modifications of those sequences.
[0190] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 22-323. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 1-312.
[0191] In a further aspect of the invention, an anti-LgR5 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgGl antibody or other antibody class or isotype as defined herein.
[0192] In a further aspect, an anti-LgR5 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
Antibody YW353 and other embodiments
[0193] In one aspect, the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
[0194] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62. In one embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61. In a further embodiment, the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:62.
[0195] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In one embodiment, the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
[0196] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 , and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
[0197] In another aspect, the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 60; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 ; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 59.
[0198] In any of the above embodiments, an anti-LgR5 antibody is a human antibody.
[0199] In another aspect, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 26. In certain
embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 26 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 26. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 26. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-LgR5 antibody comprises the VH sequence of SEQ ID NO: 26, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 60, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61 , and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62.
[0200] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 25. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 25 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 25. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 25. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-LgR5 antibody comprises the VL sequence of SEQ ID NO: 25, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 57; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
[0201 ] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 26 and SEQ ID NO: 25, respectively, including post-translational modifications of those sequences.
[0202] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 22-123. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 1 -102. [0203] In a further aspect of the invention, an anti-LgR5 antibody according to any of the above embodiments is a monoclonal antibody, including a human antibody. In one embodiment, an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another embodiment, the antibody is a substantially full length antibody, e.g. , an IgG2a antibody or other antibody class or isotype as defined herein.
[0204] In a further aspect, an anti-LgR5 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
Antibody 3G12 and other embodiments
[0205] In some embodiments, the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
[0206] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50. In one
embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49. In a further embodiment, the antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
[0207] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47. In one embodiment, the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
[0208] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 48, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 50; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
[0209] In another aspect, the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 48; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 45; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
[0210] In any of the above embodiments, an anti-LgR5 antibody is humanized. In one embodiment, an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In certain embodiments, the human acceptor framework is the human VL kappa consensus (VLK) framework and/or the human VH subgroup 3 consensus (VH3) framework.
[0211] In another aspect, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 22. In certain
embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 22 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 22. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 22. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). [0212] Optionally, the anti-LgR5 antibody comprises the VH sequence of SEQ ID NO: 22, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 48, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 49, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50.
[0213] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 21. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 21 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 21. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 21. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
[0214] Optionally, the anti-LgR5 antibody comprises the VL sequence of SEQ ID NO: 21 , including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 45; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47.
[0215] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 22 and SEQ ID NO: 21 , respectively, including post-translational modifications of those sequences.
[0216] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 22 and a VL sequence of SEQ ID NO: 21. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-423. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-402. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-555. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-534.
[0217] In a further aspect of the invention, an anti-LgR5 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgGl antibody or other antibody class or isotype as defined herein.
[0218] In a further aspect, an anti-LgR5 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
Antibody 2H6 and other embodiments
[0219] In some embodiments, the invention provides an anti-LgR5 antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 51; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
[0220] In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56. In one
embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56. In another embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56 and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53. In a further embodiment, the antibody comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55. In a further embodiment, the antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
[0221] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51 ; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53. In one embodiment, the antibody comprises (a) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51 ; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
[0222] In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 56; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52, and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
[0223] In another aspect, the invention provides an antibody comprising (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO: 54; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 51 ; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
[0224] In any of the above embodiments, an anti-LgR5 antibody is humanized. In one embodiment, an anti-LgR5 antibody comprises HVRs as in any of the above embodiments, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework. In certain embodiments, the human acceptor framework is the human VL kappa consensus (VLK) framework and/or the human VH subgroup 3 (VH3) framework.
[0225] In another aspect, an anti-LgR5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 24. In certain
embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 24 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti- LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 24. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 24. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). [0226] Optionally, the anti-LgR5 antibody comprises the VH sequence of SEQ ID NO: 24, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 55, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 56.
[0227] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 23 contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-LgR5 antibody comprising that sequence retains the ability to bind to LgR5. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 23. In certain embodiments, a total of 1 to 5 amino acids have been substituted, inserted and/or deleted in the amino acid sequence of SEQ ID NO: 23. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs).
[0228] Optionally, the anti-LgR5 antibody comprises the VL sequence of the amino acid sequence of SEQ ID NO: 23, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 51 ; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 53.
[0229] In another aspect, an anti-LgR5 antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 24 and SEQ ID NO: 23, respectively, including post-translational modifications of those sequences.
[0230] In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-LgR5 antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-LgR5 antibody comprising a VH sequence of SEQ ID NO: 24 and a VL sequence of SEQ ID NO: 23. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-423. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-402. In certain embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 67 from, within, or overlapping amino acids 324-555. In some embodiments, an antibody is provided that binds to an epitope of SEQ ID NO: 68 from, within, or overlapping amino acids 303-534.
[0231 ] In a further aspect of the invention, an anti-Lg 5 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-LgR5 antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In another embodiment, the antibody is a substantially full length antibody, e.g., an IgGl antibody or other antibody class or isotype as defined herein.
[0232] In a further aspect, an anti-LgR5 antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below.
. Antibody Affinity
[0233] In certain embodiments, an antibody provided herein has a dissociation constant (Kd) of < Ι μΜ, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM, and optionally is > 10"13 M. (e.g. 10"8 M or less, e.g. from 10"8 M to 10"13 M, e.g., from 10"9 M to 10"13 M).
[0234] In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay. Solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of (125I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)). To establish conditions for the assay,
MICROTITER multi-well plates (Thermo Scientific) are coated overnight with 5 μg/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23°C). In a non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [125I] -antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN- 20®) in PBS. When the plates have dried, 150 μΐ/well of scintillant (MICROSCINT-20™;
Packard) is added, and the plates are counted on a TOPCOUNT™ gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.
[0235] According to another embodiment, Kd is measured using surface plasmon resonance assays using a BIACORE®-2000 or a BIACORE ®-3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with immobilized antigen CM5 chips at -10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with N-ethyl- N'- (3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 niM sodium acetate, pH 4.8, to 5 μg/ml (-0.2 μΜ) before injection at a flow rate of 5 μΐ/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN- 20™) surfactant (PBST) at 25°C at a flow rate of approximately 25 μΐ/min. Association rates (kon) and dissociation rates (k0ff) are calculated using a simple one-to-one Langmuir binding model (BIACORE Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (Kd) is calculated as the ratio k0ff/kon See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 106
M"l s"l by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25 °C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophometer (Aviv Instruments) or a 8000-series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with a stirred cuvette.
2. Antibody Fragments
[0236] In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthiin, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer- Verlag, New York), pp. 269-315 (1994); see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046. [0237] Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161 ; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).
Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[0238] Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 Bl).
[0239] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
3. Chimeric and Humanized Antibodies
[0240] In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g. , a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0241] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HV s, e.g. , CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
[0242] Humanized antibodies and methods of making them are reviewed, e.g. , in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and are further described, e.g., in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA
86:10029-10033 (1989); US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409;
Kashmiri et al, Methods 36:25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36:43-60 (2005) (describing "F shuffling"); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the "guided selection" approach to FR shuffling).
[0243] Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit" method {see, e.g., Sims et al. J.
Immunol. 151 :2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions {see, e.g. , Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol, 151 :2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions {see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR libraries {see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271 :22611-22618 (1996)).
4. Human Antibodies
[0244] In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[0245] Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous
immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Patent No.
5,770,429 describing HUMAB® technology; U.S. Patent No. 7,041,870 describing K-M
MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.
[0246] Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. {See, e.g., Kozbor J. Immunol, 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human- human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3): 185-91 (2005).
[0247] Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
5. Library-Derived Antibodies
[0248] Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described, e.g., in the McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and Bradbury, in Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073- 1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132(2004).
[0249] In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PC ) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., Ann. Rev. Immunol, 12: 433-455 (1994). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g. , from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al., EMBO J 12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol, 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.
[0250] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
6. Multispecific Antibodies
[0251 ] In certain embodiments, an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for LgR5 and the other is for any other antigen. In certain embodiments, one of the binding specificities is for LgR5 and the other is for CD3. See, e.g., U.S. Patent No. 5,821,337. In certain embodiments, bispecific antibodies may bind to two different epitopes of LgR5.
Bispecific antibodies may also be used to localize cytotoxic agents to cells which express LgR5. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
[0252] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities {see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole" engineering {see, e.g., U.S. Patent No.
5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments {see, e.g., US Patent No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies {see, e.g., Kostelny et al., J. Immunol, 148(5):1547-1553 (1992)); using "diabody" technology for making bispecific antibody fragments {see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444- 6448 (1993)); and using single-chain Fv (sFv) dimers {see,e.g. Gruber et al., J. Immunol, 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al. J. Immunol 147: 60 (1991).
[0253] Engineered antibodies with three or more functional antigen binding sites, including "Octopus antibodies," are also included herein {see, e.g. US 2006/0025576A1). [0254] The antibody or fragment herein also includes a "Dual Acting FAb" or "DAF" comprising an antigen binding site that binds to Lg 5 as well as another, different antigen (see, US 2008/0069820, for example).
7. Antibody Variants
[0255] In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
a) Substitution, Insertion, and Deletion Variants
[0256] In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions," and as further described below in reference to amino acid side chain classes. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased
immunogenicity, or improved ADCC or CDC.
TA BLE I
Original Exemplary Preferred
Residue Substitutions Substitutions
He (I) Leu; Val; Met; Ala; Phe; Norleucine Leu
Leu (L) Norleucine; He; Val; Met; Ala; Phe He
Lys (K) Arg; Gin; Asn Arg
Met (M) Leu; Phe; He Leu
Phe (F) Trp; Leu; Val; He; Ala; Tyr Tyr
Pro (P) Ala Ala
Ser (S) Thr Thr
Thr (T) Val; Ser Ser
Trp (W) Tyr; Phe Tyr
Tyr (Y) Trp; Phe; Thr; Ser Phe
Val (V) He; Leu; Met; Phe; Ala; Norleucine Leu
Amino acids may be grouped according to common side-chain properties:
(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, He;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin;
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
[0257] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0258] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g. , using phage display -based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
[0259] Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR "hotspots," i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g. , in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001).) In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g. , error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR- directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
[0260] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may be outside of HVR "hotspots" or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
[0261] A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by
Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex is used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.
[0262] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody. b) Glycosylation variants
[0263] In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
[0264] Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.
[0265] In one embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ± 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to "defucosylated" or "fucose-deficient" antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Led 3 CHO cells deficient in protein fucosylation ( ipka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 Al, Presta, L; and
WO 2004/056312 Al, Adams et al., especially at Example 11), and knockout cell lines, such as alpha- 1,6-fucosyltransferase gene, FUT8, knockout CHO cells {see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003/085107).
[0266] Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean- Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 ( aju, S.); and WO 1999/22764 (Raju, S.).
c) Fc region variants
[0267] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence {e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification {e.g. a substitution) at one or more amino acid positions.
[0268] In certain embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII and Fc(RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Patent No. 5,500,362 {see, e.g. Hellstrom, I. et al. Proc. Nat 'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat 'lAcad. Sci. USA 82:1499-1502 (1985); 5,821,337 {see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed {see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g. , in a animal model such as that disclosed in Clynes et al. Proc. Natl Acad. Sci. USA 95:652-656 (1998). Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed {see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, M.S. et al., Blood 101 : 1045-1052 (2003); and Cragg, M.S. and M.J. Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., Int 'l. Immunol. 18(12):1759-1769 (2006)).
[0269] Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).
[0270] Certain antibody variants with improved or diminished binding to Fc s are described. (See, e.g., U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al J. Biol. Chem. 9(2): 6591-6604 (2001).)
[0271] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
[0272] In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No. 6,194,551, WO 99/51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
[0273] Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826). [0274] See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No.
5,648,260; U.S. Patent No. 5,624,821 ; and WO 94/29351 concerning other examples of Fc region variants.
d) Cysteine engineered antibody variants
[0275] In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., "thioMAbs," in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent No. 7,521,541.
[0276] An exemplary hu8El 1.v2 light chain (LC) V205C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 64 and 74, respectively. An exemplary hu8El l.v2 heavy chain (HC) Al 18C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 75 and 63, respectively. An exemplary hu8El l .v2 heavy chain (HC) S400C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 76 and 63, respectively.
[0277] An exemplary YW353 light chain (LC) V205C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 66 and 77, respectively. An exemplary YW353 heavy chain (HC) Al 18C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 78 and 65, respectively. An exemplary YW353 heavy chain (HC) S400C thiomab has the heavy chain and light chain sequences of SEQ ID NOs: 79 and 65, respectively.
[0278] Further exemplary V205C cysteine engineered thiomabs comprise a light chain comprising a variable region selected from SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 and a constant region of SEQ ID NO: 80; and a heavy chain comprising a variable region selected from SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 and a human heavy chain constant region, such as an IgGl . Further exemplary Al 18C cysteine engineered thiomabs comprise a light chain comprising a variable region selected from SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 and a human light chain constant region, such as a kappa light chain constant region; and a heavy chain comprising a variable region selected from SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 and a constant region of SEQ ID NO: 81. Further exemplary S400C cysteine engineered thiomabs comprise a light chain comprising a variable region selected from SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23 and a human light chain constant region, such as a kappa light chain constant region; and a heavy chain comprising a variable region selected from SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 and a constant region of SEQ ID NO: 82.
e) Antibody Derivatives
[0279] In certain embodiments, an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol,
carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-l,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either
homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer are attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
[0280] In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.
B. Recombinant Methods and Compositions
[0281] Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-LgPv5 antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NSO, Sp20 cell). In one embodiment, a method of making an anti-Lg 5 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
[0282] For recombinant production of an anti-LgR5 antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
[0283] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in E. coli.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
[0284] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized," resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
[0285] Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. [0286] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos.
5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).
[0287] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CVl line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CVl); African green monkey kidney cells (VEPvO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al Annals N Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR" CHO cells (Urlaub et al Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255- 268 (2003).
C. Assays
[0288] Anti-LgR5 antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
[0289] In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, BIACore®, FACS, or Western blot.
[0290] In another aspect, competition assays may be used to identify an antibody that competes with any of the antibodies described herein for binding to LgR5. In certain
embodiments, such a competing antibody binds to the same epitope {e.g., a linear or a conformational epitope) that is bound by an antibody described herein. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).
[0291] In an exemplary competition assay, immobilized LgR5 is incubated in a solution comprising a first labeled antibody that binds to LgR5 {e.g. , any of the antibodies described herein) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to LgR5. The second antibody may be present in a hybridoma supernatant. As a control, immobilized LgR5 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to LgR5, excess unbound antibody is removed, and the amount of label associated with immobilized LgR5 is measured. If the amount of label associated with immobilized LgR5 is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to LgR5. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
D. Immunoconjugates
[0292] The invention also provides immunoconjugates comprising an anti-LgR5 antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins {e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes (i.e., a radioconjugate).
[0293] Immunoconjugates allow for the targeted delivery of a drug moiety to a tumor, and, in some embodiments intracellular accumulation therein, where systemic administration of unconjugated drugs may result in unacceptable levels of toxicity to normal cells (Polakis P. (2005) Current Opinion in Pharmacology 5:382-387).
[0294] Antibody-drug conjugates (ADC) are targeted chemotherapeutic molecules which combine properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to antigen-expressing tumor cells (Teicher, B.A. (2009) Current Cancer Drug Targets 9:982-1004), thereby enhancing the therapeutic index by maximizing efficacy and minimizing off-target toxicity (Carter, P.J. and Senter P.D. (2008) The Cancer Jour. 14(3): 154-169; Chari, R.V. (2008) Acc. Chem. Res. 41 :98-107 .
[0295] The ADC compounds of the invention include those with anticancer activity. In some embodiments, the ADC compounds include an antibody conjugated, i.e. covalently attached, to the drug moiety. In some embodiments, the antibody is covalently attached to the drug moiety through a linker. The antibody-drug conjugates (ADC) of the invention selectively deliver an effective dose of a drug to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved while increasing the therapeutic index ("therapeutic window").
[0296] The drug moiety (D) of the antibody-drug conjugates (ADC) may include any compound, moiety or group that has a cytotoxic or cytostatic effect. Drug moieties may impart their cytotoxic and cytostatic effects by mechanisms including but not limited to tubulin binding, DNA binding or intercalation, and inhibition of R A polymerase, protein synthesis, and/or topoisomerase. Exemplary drug moieties include, but are not limited to, a maytansinoid, dolastatin, auristatin, calicheamicin, pyrrolobenzodiazepine (PBD), nemorubicin and its derivatives, PNU- 159682, anthracycline, duocarmycin, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinafide, and stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity. Nonlimiting examples of such immunoconjugates are discussed in further detail below. . Exemplary Antibody-drug Conjugates
[0297] An exemplary embodiment of an antibody-drug conjugate (ADC) compound comprises an antibody (Ab) which targets a tumor cell, a drug moiety (D), and a linker moiety (L) that attaches Ab to D. In some embodiments, the antibody is attached to the linker moiety (L) through one or more amino acid residues, such as lysine and/or cysteine.
[0298] An exemplary ADC has Formula I:
Ab-(L-D)p I
where p is 1 to about 20. In some embodiments, the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine residues. In some
embodiments, free cysteine residues are introduced into the antibody amino acid sequence by the methods described herein. Exemplary ADC of Formula I include, but are not limited to, antibodies that have 1, 2, 3, or 4 engineered cysteine amino acids (Lyon, . et al (2012) Methods in Enzym. 502:123-138). In some embodiments, one or more free cysteine residues are already present in an antibody, without the use of engineering, in which case the existing free cysteine residues may be used to conjugate the antibody to a drug. In some embodiments, an antibody is exposed to reducing conditions prior to conjugation of the antibody in order to generate one or more free cysteine residues.
a) Exemplary Linkers
[0299] A "Linker" (L) is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties (D) to an antibody (Ab) to form an antibody-drug conjugate (ADC) of Formula I. In some embodiments, antibody-drug conjugates (ADC) can be prepared using a Linker having reactive functionalities for covalently attaching to the drug and to the antibody. For example, in some embodiments, a cysteine thiol of an antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.
[0300] In one aspect, a linker has a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond. Nonlimiting exemplary such reactive functionalities include maleimide, haloacetamides, a-haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates. See, e.g., the conjugation method at page 766 of Klussman, et al (2004), Bioconjugate Chemistry 15(4):765- 773, and the Examples herein.
[0301] In some embodiments, a linker has a functionality that is capable of reacting with an electrophilic group present on an antibody. Exemplary such electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups. In some embodiments, a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit. Nonlimiting exemplary such reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
[0302] A linker may comprise one or more linker components. Exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl (a "PAB"), N- Succinimidyl 4-(2-pyridylthio) pentanoate ("SPP"), and 4-(N-maleimidomethyl) cyclohexane-1 carboxylate ("MCC"). Various linker components are known in the art, some of which are described below.
[0303] A linker may be a "cleavable linker," facilitating release of a drug. Nonlimiting exemplary cleavable linkers include acid- labile linkers (e.g., comprising hydrazone), protease- sensitive {e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide-containing linkers (Chari et al., Cancer Research 52: 127-131 (1992); US 5208020).
[0304] In certain embodiments, a linker has the following Formula II:
wherein A is a "stretcher unit", and a is an integer from 0 to 1 ; W is an "amino acid unit", and w is an integer from 0 to 12; Y is a "spacer unit", and y is 0, 1, or 2. An ADC comprising the linker of Formula II has the Formula 1(A): Ab-(Aa-Ww-Yy-D)p, wherein Ab, D, and p are defined as above for Formula I. Exemplary embodiments of such linkers are described in U.S. Patent No. 7,498,298, which is expressly incorporated herein by reference.
[0305] In some embodiments, a linker component comprises a "stretcher unit" (A) that links an antibody to another linker component or to a drug moiety. Nonlimiting exemplary stretcher units are shown below (wherein the wavy line indicates sites of covalent attachment to an antibody, drug, or additional linker components):
[0306] In some embodiments, a linker component comprises an "amino acid unit" (W). In some such embodiments, the amino acid unit allows for cleavage of the linker by a protease, thereby facilitating release of the drug from the immunoconjugate upon exposure to intracellular proteases, such as lysosomal enzymes (Doronina et al. (2003) Nat. Biotechnol. 21 :778-784). Exemplary amino acid units include, but are not limited to, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or phe-lys);
phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val-cit).
Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). An amino acid unit may comprise amino acid residues that occur naturally and/or minor amino acids and/or non-naturally occurring amino acid analogs, such as citrulline. Amino acid units can be designed and optimized for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.
[0307] Typically, peptide-type linkers can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (e.g., E. Schroder and K. Liibke (1965) "The Peptides", volume 1, pp 76-136, Academic Press).
[0308] In some embodiments, a linker component comprises a "spacer unit" (Y) that links the antibody to a drug moiety, either directly or through a stretcher unit and/or an amino acid unit. A spacer unit may be "self-immolative" or a "non-self-immolative." A "non-self- immolative" spacer unit is one in which part or all of the spacer unit remains bound to the drug moiety upon cleavage of the ADC. Examples of non-self-immolative spacer units include, but are not limited to, a glycine spacer unit and a glycine-glycine spacer unit. In some embodiments, enzymatic cleavage of an ADC containing a glycine-glycine spacer unit by a tumor-cell associated protease results in release of a glycine-glycine-drug moiety from the remainder of the ADC. In some such embodiments, the glycine-glycine-drug moiety is subjected to a hydrolysis step in the tumor cell, thus cleaving the glycine-glycine spacer unit from the drug moiety.
[0309] A "self-immolative" spacer unit allows for release of the drug moiety. In certain embodiments, a spacer unit of a linker comprises a p-aminobenzyl unit. In some such
embodiments, a p-aminobenzyl alcohol is attached to an amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is made between the benzyl alcohol and the drug (Hamann et al. (2005) Expert Opin. Ther. Patents (2005) 15: 1087-1103). In some embodiments, the spacer unit comprises p-aminobenzyloxycarbonyl (PAB). In some embodiments, an ADC comprising a self-immolative linker has the structure:
wherein Q is -Ci-Cs alkyl, -0-(Ci-Cs alkyl), -halogen, -nitro, or -cyano; m is an integer ranging from 0 to 4; X may be one or more additional spacer units or may be absent; and p ranges from 1 to about 20. In some embodiments, p ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4. Nonlimiting exemplary X spacer units include: independently selected from H and Ci-Ce alkyl. In some embodiments, Rl and R2 are each -CH3.
[0310] Other examples of self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazol-5- methanol derivatives (U.S. Patent No. 7,375,078; Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho- or para-aminobenzylacetals. In some embodiments, spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4- aminobutyric acid amides ( odrigues et al (1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) J. Amer. Chem. Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) J. Org. Chem. 55:5867). Linkage of a drug to the a-carbon of a glycine residue is another example of a self- immolative spacer that may be useful in ADC (Kingsbury et al (1984) J. Med. Chem. 27: 1447).
[0311 ] In some embodiments, linker L may be a dendritic type linker for covalent attachment of more than one drug moiety to an antibody through a branching, multifunctional linker moiety (Sun et al (2002) Bioorganic & Medicinal Chemistry Letters 12:2213-2215; Sun et al (2003) Bioorganic & Medicinal Chemistry 11 :1761-1768). Dendritic linkers can increase the molar ratio of drug to antibody, i.e. loading, which is related to the potency of the ADC. Thus, where an antibody bears only one reactive cysteine thiol group, a multitude of drug moieties may be attached through a dendritic linker.
[0312] Nonlimiting exemplary linkers are shown below in the context of an ADC of
MC-val-cit
; wherein Ri and
R2 are independently selected from H and Ci-Ce alkyl. In some embodiments, Rl and R2 are each -
wherein n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8.
0313] Further nonlimiting exemplary ADCs include the structures:
each is independently H or Ci-Ce alkyl; and n is 1 to 12.
[0314] In some embodiments, a linker is substituted with groups that modulate solubility and/or reactivity. As a nonlimiting example, a charged substituent such as sulfonate (-S03 ~) or ammonium may increase water solubility of the linker reagent and facilitate the coupling reaction of the linker reagent with the antibody and/or the drug moiety, or facilitate the coupling reaction of Ab-L (antibody-linker intermediate) with D, or D-L (drug-linker intermediate) with Ab, depending on the synthetic route employed to prepare the ADC. In some embodiments, a portion of the linker is coupled to the antibody and a portion of the linker is coupled to the drug, and then the Ab-(linker portion)a is coupled to drug-(linker portion)13 to form the ADC of Formula I.
[0315] The compounds of the invention expressly contemplate, but are not limited to, ADC prepared with the following linker reagents: bis-maieimido-trioxyethylene glycol (BMPEO), N-(P-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS), Ν-(ε- maleimidocaproyloxy) succinimide ester (EMCS), N-fy-maleimidobutyryloxy] succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N- maleimidomethyl)cyclohexane- 1 -carboxy-(6-amidocaproate) (LC-SMCC), m-maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N- maleimidomethyl)cyclohexane-l-carboxylate (SMCC), succinimidyl 4-(p- maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(beta-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB), and including bis-maleimide reagents: dithiobismaleimidoethane (DTME), 1,4-Bismaleimidobutane (BMB), 1,4 Bismaleimidyl-2,3-dihydroxybutane (BMDB), bismaleimidohexane (BMH), bismaleimidoethane (BMOE), BM(PEG)2 (shown below), and BM(PEG)3 (shown below);
bifunctional derivatives of imidoesters (such as dimethyl adipimidate HC1), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene). In some embodiments, bis-maleimide reagents allow the attachment of the thiol group of a cysteine in the antibody to a thiol-containing drug moiety, linker, or linker-drug intermediate. Other functional groups that are reactive with thiol groups include, but are not limited to, iodoacetamide, bromoacetamide, vinyl pyridine, disulfi
BM(PEG)2 BM(PEG)3
[0316] Certain useful linker reagents can be obtained from various commercial sources, such as Pierce Biotechnology, Inc. ( ockford, IL), Molecular Biosciences Inc.(Boulder, CO), or synthesized in accordance with procedures described in the art; for example, in Toki et al (2002) J. Org. Chem. 67:1866-1872; Dubowchik, et al. (1997) Tetrahedron Letters, 38:5257-60; Walker, M.A. (1995) J. Org. Chem. 60:5352-5355; Frisch et al (1996) Bioconjugate Chem. 7:180-186; US 6214345; WO 02/088172; US 2003130189; US2003096743; WO 03/026577; WO 03/043583; and WO 04/032828. [0317] Carbon- 14-labeled l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See, e.g., WO94/11026. b) Exemplary Drug Moieties
(1) Maytansine and maytansinoids
[0318] In some embodiments, an immunoconjugate comprises an antibody conjugated to one or more maytansinoid molecules. Maytansinoids are derivatives of maytansine, and are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Patent No. 3896111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821 ; 4,322,348;
4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.
[0319] Maytansinoid drug moieties are attractive drug moieties in antibody-drug conjugates because they are: (i) relatively accessible to prepare by fermentation or chemical modification or derivatization of fermentation products, (ii) amenable to derivatization with functional groups suitable for conjugation through non-disulfide linkers to antibodies, (iii) stable in plasma, and (iv) effective against a variety of tumor cell lines.
[0320] Certain maytansinoids suitable for use as maytansinoid drug moieties are known in the art and can be isolated from natural sources according to known methods or produced using genetic engineering techniques (see, e.g., Yu et al (2002) PNAS 99:7968-7973). Maytansinoids may also be prepared synthetically according to known methods.
[0321] Exemplary maytansinoid drug moieties include, but are not limited to, those having a modified aromatic ring, such as: C-19-dechloro (US Pat. No. 4256746) (prepared, for example, by lithium aluminum hydride reduction of ansamytocin P2); C-20-hydroxy (or C-20- demethyl) +/-C-19-dechloro (US Pat. Nos. 4361650 and 4307016) (prepared, for example, by demethylation using Streptomyces ox Actinomyces or dechlorination using LAH); and C-20- demethoxy, C-20-acyloxy (-OCOR), +/-dechloro (U.S. Pat. No. 4,294,757) (prepared, for example, by acylation using acyl chlorides), and those having modifications at other positions of the aromatic ring.
[0322] Exemplary maytansinoid drug moieties also include those having modifications such as: C-9-SH (US Pat. No. 4424219) (prepared, for example, by the reaction of maytansinol with H2S or P2S5); C-14-alkoxymethyl(demethoxy/CH2 OR)(US 4331598); C-14-hydroxymethyl or acyloxymethyl (CH2OH or CH2OAc) (US Pat. No. 4450254) (prepared, for example, from Nocardia); C-15-hydroxy/acyloxy (US 4364866) (prepared, for example, by the conversion of maytansinol by Streptomyces); C-15-methoxy (US Pat. Nos. 4313946 and 4315929) (for example, isolated from Trewia nudlflora); C-18-N-demethyl (US Pat. Nos. 4362663 and 4322348) (prepared, for example, by the demethylation of maytansinol by Streptomyces); and 4,5-deoxy (US 4371533) (prepared, for example, by the titanium trichloride/LAH reduction of maytansinol).
[0323] Many positions on maytansinoid compounds are useful as the linkage position. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. In some embodiments, the reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In some embodiments, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.
[0324] Maytansinoid drug moieties include those having the structure:
where the wavy line indicates the covalent attachment of the sulfur atom of the maytansinoid drug moiety to a linker of an ADC. Each R may independently be H or a Ci-Ce alkyl. The alkylene chain attaching the amide group to the sulfur atom may be methanyl, ethanyl, or propyl, i.e., m is 1, 2, or 3 (US 633410; US 5208020; Chari et al (1992) Cancer Res. 52: 127-131 ; Liu et al (1996) Proc. Natl. Acad. Sci USA 93:8618-8623).
[0325] All stereoisomers of the maytansinoid drug moiety are contemplated for the ADC of the invention, i.e. any combination of R and S configurations at the chiral carbons (US 7276497; US 6913748; US 6441163; US 633410 (RE39151); US 5208020; Widdison et al (2006) J. Med. Chem. 49:4392-4408, which are incorporated by reference in their entirety). In some embodiments, the maytansinoid drug moiety has the following stereochemistry:
[0326] Exemplary embodiments of maytansinoid drug moieties include, but are not limited to, DM
wherein the wavy line indicates the covalent attachment of the sulfur atom of the drug to a linker (L) of an antibody-drug conjugate.
[0327] Other exemplary maytansinoid antibody-drug conjugates have the following structures and abbreviations (wherein Ab is antibody and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4):
[0328] Exemplary antibody-drug conjugates where DM1 is linked through a BMPEO linker to a thiol group of the antibody have the structure and abbreviation:
where Ab is antibody; n is 0, 1, or 2; and p is 1 to about 20. In some embodiments, p is 1 to 10, p is 1 to 7, p is 1 to 5, or p is 1 to 4.
[0329] Immunoconjugates containing maytansinoids, methods of making the same, and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020 and 5,416,064; US 2005/0276812 Al ; and European Patent EP 0 425 235 Bl, the disclosures of which are hereby expressly incorporated by reference. See also Liu et al. Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996); and Chari et al. Cancer Research 52:127-131 (1992).
[0330] In some embodiments, antibody-maytansinoid conjugates may be prepared by chemically linking an antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. See, e.g., U.S. Patent No. 5,208,020 (the disclosure of which is hereby expressly incorporated by reference). In some embodiments, ADC with an average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody. In some instances, even one molecule of toxin/antibody is expected to enhance cytotoxicity over the use of naked antibody.
[0331] Exemplary linking groups for making antibody -maytansinoid conjugates include, for example, those described herein and those disclosed in U.S. Patent No. 5208020; EP Patent 0 425 235 Bl ; Chari et al. Cancer Research 52: 127-131 (1992); US 2005/0276812 Al; and US 2005/016993 Al, the disclosures of which are hereby expressly incorporated by reference.
(2) Auristatins and dolastatins
[0332] Drug moieties include dolastatins, auristatins, and analogs and derivatives thereof (US 5635483; US 5780588; US 5767237; US 6124431). Auristatins are derivatives of the marine mollusk compound dolastatin-10. While not intending to be bound by any particular theory, dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al (2001) Antimicrob. Agents and Chemother. 45(12):3580-3584) and have anticancer (US 5663149) and antifungal activity (Pettit et al (1998) Antimicrob. Agents Chemother. 42:2961-2965). The dolastatin/auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172; Doronina et al (2003) Nature Biotechnology
21(7):778-784; Francisco et al (2003) Blood 102(4): 1458-1465).
[0333] Exemplary auristatin embodiments include the N-terminus linked
monomethylauristatin drug moieties DE and DF, disclosed in US 7498298 and US 7659241, the
wherein the wavy line of DE and DF indicates the covalent attachment site to an antibody or antibody-linker component, and independently at each location:
R2 is selected from H and Ci-Cs alkyl;
R3 is selected from H, Ci-Cs alkyl, C3-C8 carbocycle, aryl, Ci-Cs alkyl-aryl, Ci-Cs alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and Ci-Cs alkyl-(C3-Cs heterocycle);
R4 is selected from H, Ci-Cs alkyl, C3-C8 carbocycle, aryl, Ci-Cs alkyl-aryl, Ci-Cs alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and Ci-Cs alkyl-(C3-Cs heterocycle);
R5 is selected from H and methyl;
or R4 and R5 jointly form a carbocyclic ring and have the formula -(CRaRb)n- wherein Ra and Rb are independently selected from H, Ci-Cs alkyl and C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6;
R6 is selected from H and Ci-Cs alkyl;
R7 is selected from H, Ci-Cs alkyl, C3-C8 carbocycle, aryl, Ci-Cs alkyl-aryl, Ci-Cs alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and Ci-Cs alkyl-(C3-Cs heterocycle);
each R8 is independently selected from H, OH, Ci-Cs alkyl, C3-C8 carbocycle and 0-(Ci- C8 alkyl);
R9 is selected from H and Ci-Cs alkyl;
R10 is selected from aryl or C3-C8 heterocycle;
Z is O, S, NH, or NR12, wherein R12 is Ci-Cg alkyl;
R11 is selected from H, Ci-C20 alkyl, aryl, C3-C8 heterocycle, -(R130)m-R14, or -(R130)m- CH(R15)2;
m is an integer ranging from 1-1000;
R13 is C2-Cs alkyl;
R14 is H or Ci-Cg alkyl;
each occurrence of R15 is independently H, COOH, -(CH2)n-N(R16)2, -(CH2)n-S03H, or -(CH2)n-S03-C1-C8 alkyl;
each occurrence of R16 is independently H, Ci-Cg alkyl, or -(CH2)n-COOH;
R18 is selected from -C(R8)2-C(R8)2-aryl, -C(R8)2-C(R8)2-(C3-C8 heterocycle), and -C(R8)2-C(R8)2-(C3-C8 carbocycle); and
n is an integer ranging from 0 to 6.
[0334] In one embodiment, R3, R4 and R7 are independently isopropyl or sec-butyl and R5 is -H or methyl. In an exemplary embodiment, R3 and R4 are each isopropyl, R5 is -H, and R7 is sec-butyl.
[0335] In yet another embodiment, R2 and R6 are each methyl, and R9 is -H.
[0336] In still another embodiment, each occurrence of R8 is -OCH3. [0337] In an exemplary embodiment, R3 and R4 are each isopropyl, R2 and R6 are each methyl, R5 is -H, R7 is sec-butyl, each occurrence of R8 is -OCH3, and R9 is -H.
[0338] In one embodiment, Z is -O- or -NH-.
[0339] In one embodiment, R10 is aryl.
[0340] In an exemplary embodiment, R10 is -phenyl.
[0341] In an exemplary embodiment, when Z is -0-, R11 is -H, methyl or t-butyl.
[0342] In one embodiment, when Z is -NH, R11 is -CH(R15)2, wherein R15 is -(CH2)n- N(R16)2, and R16 is -Ci-Cg alkyl or -(CH2)n-COOH.
[0343] In another embodiment, when Z is -NH, R11 is -CH(R15)2, wherein R15 is -(CH2)n-
S03H.
[0344] An exemplary auristatin embodiment of formula DE is MMAE, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:
[0345] An exemplary auristatin embodiment of formula DF is MMAF, wherein the wavy line indicates the covalent attachment to a linker (L) of an antibody-drug conjugate:
[0346] Other exemplary embodiments include monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008848) and monomethylvaline compounds having phenylalanine sidechain modifications at the C-terminus of the pentapeptide auristatin drug moiety (WO 2007/008603).
[0347] Nonlimiting exemplary embodiments of ADC of Formula I comprising MMAE or MMAF and various linker components have the following structures and abbreviations (wherein "Ab" is an antibody; p is 1 to about 8, "Val-Cit" is a valine-citrulline dipeptide; and "S" is a sulfur atom:
Ab-MC-vc-PAB-MMAF
Ab-MC-vc-PAB-MMAE
Ab-MC-MMAF
[0348] Nonlimiting exemplary embodiments of ADCs of Formula I comprising MMAF and various linker components further include Ab-MC-PAB-MMAF and Ab-PAB-MMAF. Immunoconjugates comprising MMAF attached to an antibody by a linker that is not proteolytically cleavable have been shown to possess activity comparable to immunoconjugates comprising MMAF attached to an antibody by a proteolytically cleavable linker (Doronina et al. (2006) Bioconjugate Chem. 17:114-124). In some such embodiments, drug release is believed to be effected by antibody degradation in the cell.
[0349] Typically, peptide-based drug moieties can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to a liquid phase synthesis method (see, e.g., E. Schroder and K. Liibke, "The Peptides", volume 1, pp 76-136, 1965, Academic Press). Auristatin/dolastatin drug moieties may, in some embodiments, be prepared according to the methods of: US 7498298; US 5635483; US 5780588; Pettit et al (1989) J. Am. Chem. Soc. 111 :5463-5465; Pettit et al (1998) Anti-Cancer Drug Design 13:243-277; Pettit, G. ., et al. Synthesis, 1996, 719-725; Pettit et al (1996) J. Chem. Soc. Perkin Trans. 1 5:859-863; and Doronina (2003) Nat. Biotechnol.
21(7):778-784. [0350] In some embodiments, auristatin/dolastatin drug moieties of formulas DE such as MMAE, and DF, such as MMAF, and drug-linker intermediates and derivatives thereof, such as MC-MMAF, MC-MMAE, MC-vc-PAB-MMAF, and MC-vc-PAB-MMAE, may be prepared using methods described in US 7498298; Doronina et al. (2006) Bioconjugate Chem. 17:114-124; and Doronina et al. (2003) Nat. Biotech. 21 :778-784and then conjugated to an antibody of interest.
(3) Calicheamicin
[0351] In some embodiments, the immunoconjugate comprises an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics, and analogues thereof, are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al., (1993) Cancer Research 53:3336-3342; Lode et al., (1998) Cancer Research 58:2925-2928). Calicheamicin has intracellular sites of action but, in certain instances, does not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody- mediated internalization may, in some embodiments, greatly enhances their cytotoxic effects. Nonlimiting exemplary methods of preparing antibody-drug conjugates with a calicheamicin drug moiety are described, for example, in US 5712374; US 5714586; US 5739116; and US 5767285.
(4) Pyrrolobenzodiazepines
[0352] In some embodiments, an ADC comprises a pyrrolobenzodiazepine (PBD). In some embodiments, PDB dimers recognize and bind to specific DNA sequences. The natural product anthramycin, a PBD, was first reported in 1965 (Leimgruber, et al., (1965) J. Am. Chem. Soc, 87:5793-5795; Leimgruber, et al., (1965) J. Am. Chem. Soc, 87:5791-5793). Since then, a number of PBDs, both naturally-occurring and analogues, have been reported (Thurston, et al., (1994) Chem. Rev. 1994, 433-465 including dimers of the tricyclic PBD scaffold (US 6884799; US 7049311; US 7067511 ; US 7265105; US 7511032; US 7528126; US 7557099). Without intending to be bound by any particular theory, it is believed that the dimer structure imparts the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In Antibiotics III. Springer- Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, (1986) Acc. Chem. Res., 19:230-237). Dimeric PBD compounds bearing C2 aryl substituents have been shown to be useful as cytotoxic agents (Hartley et al (2010) Cancer Res. 70(17):6849-6858; Antonow (2010) J. Med. Chem. 53(7):2927- 2941 ; Howard et al (2009) Bioorganic and Med. Chem. Letters 19(22):6463-6466).
[0353] PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties. Nonlimiting exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (WO 2009/016516; US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO 2011/130598).
[0 A:
and salts and solvates thereof, wherein:
the wavy line indicates the covalent attachment site to the linker;
the dotted lines indicate the optional presence of a double bond between CI and C2 or C2 and C3;
It2 is independently selected from H, OH, =0, =CH2, CN, R, OR, =CH-RD, =C(RD)2, O-SO2-R, CO2R and COR, and optionally further selected from halo or dihalo, wherein RD is independently selected from R, C02R, COR, CHO, C02H, and halo;
R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', N02, Me3Sn and halo;
R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', N02, MesSn and halo;
Q is independently selected from O, S and NH;
R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation;
R and R' are each independently selected from optionally substituted Ci_s alkyl, C 2 alkyl, C3-8 heterocyclyl, C3_2o heterocycle, and C5_2o aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
R12, R16, R19 and R17 are as defined for R2, R6, R9 and R7 respectively;
R" is a C3_i2 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted; and
X and X' are independently selected from O, S and N(H).
[0355] In some embodiments, R and R' are each independently selected from optionally substituted Ci_i2 alkyl, C3_2o heterocycle, and C5_2o aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring.
[0356] In some embodiments, R9 and R19 are H.
[0357] In some embodiments, R6 and R16 are H.
[0358] In some embodiments, R7 are R17 are both OR7A, where R7A is optionally substituted C1-4 alkyl. In some embodiments, R7A is Me. In some embodiments, R7A is is (¾Ρ1ι, where Ph is a phenyl group.
[0359] In some embodiments, X is O.
[0360] In some embodiments, R11 is H.
[0361] In some embodiments, there is a double bond between C2 and C3 in each monomer unit.
[0362] In some embodiments, R2 and R12 are independently selected from H and R. In some embodiments, R and R are independently R. In some embodiments, R and R are independently optionally substituted C5-20 aryl or C5_7 aryl or Cs-io aryl. In some embodiments, R2 and R12 are independently optionally substituted phenyl, thienyl, napthyl, pyridyl, quinolinyl, or isoquinolinyl. In some embodiments, R2 and R12 are independently selected from =0, =CH2, =CH-RD, and =C(RD)2. In some embodiments, R2 and R12 each =CH2. In some embodiments, R2 and R are each H. In some embodiments, R and R are each =0. In some embodiments, R and
R are each =CF2. In some embodiments, R and/or R are independently =C(R )2. In some embodiments, R2 and/or R12 are independently =CH-RD.
[0363] In some embodiments, when R2 and/or R12 is =CH-RD, each group may independently have either confi uration shown below:
(I) (")
In some embodiments, a =CH-RD is in configuration (I).
[0364] In some embodiments, R" is a C3 alkylene group or a C5 alkylene group.
[0365] In some embodiments, an exemplary PBD dimer component of an ADC 1 structure of Formula A(I):
wherein n is 0 or 1.
[0366] In some embodiments, an exemplary PBD dimer component of an ADC has the
A(II); wherein n is 0 or 1.
[0367] In some embodiments, an exemplary PBD dimer component of an ADC has the structure o
A(III); wherein E and RE are each independently selected from H or RD, wherein RD is defined as above; and
wherein n is 0 or 1.
[0368] In some embodiments, n is 0. In some embodiments, n is 1. In some
embodiments, RE and/or RE is H. In some embodiments, RE and RE are H. In some
embodiments, RE and/or RE is RD, wherein RD is optionally substituted C 2 alkyl. In some embodiments, RE and/or RE is RD, wherein RD is methyl.
[0369] In some embodiments, an exemplary PBD dimer component of an ADC has the
A(IV);
wherein Ar1 and Ar2 are each independently optionally substituted C5_2o aryl; wherein Ar1 and Ar2 may be the same or different; and wherein n is 0 or 1.
[0370] In some embodiments, an exemplary PBD dimer component of an ADC has the structure of Formula A(V):
wherein Ar1 and Ar2 are each independently optionally substituted C5_2o aryl; wherein Ar1 and Ar2 may be the same or different; and
wherein n is 0 or 1.
[0371] In some embodiments, Ar1 and Ar2 are each independently selected from optionally substituted phenyl, furanyl, thiophenyl and pyridyl. In some embodiments, Ar1 and Ar2 are each independently optionally substituted phenyl. In some embodiments, Ar1 and Ar2 are each independently optionally substituted thien-2-yl or thien-3-yl. In some embodiments, Ar1 and Ar2 are each independently optionally substituted quinolinyl or isoquinolinyl. The quinolinyl or isoquinolinyl group may be bound to the PBD core through any available ring position. For example, the quinolinyl may be quinolin-2-yl, quinolin-3-yl, quinolin-4yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl. In some embodiments, the quinolinyl is selected from quinolin-3-yl and quinolin-6-yl. The isoquinolinyl may be isoquinolin-l-yl, isoquinolin-3- yl, isoquinolin-4yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. In some embodiments, the isoquinolinyl is selected from isoquinolin-3-yl and isoquinolin-6-yl.
[0372] Further nonlimiting exemplary PBD dimer components of ADCs are of Formula
B:
and salts and solvates thereof, wherein:
the wavy line indicates the covalent attachment site to the linker;
the wavy line connected to the OH indicates the S or configuration;
Rvl and v2 are independently selected from H, methyl, ethyl and phenyl (which phenyl may be optionally substituted with fluoro, particularly in the 4 position) and C5_6 heterocyclyl; wherein Rvl and Rv2 may be the same or different; and
n is 0 or 1. [0373] In some embodiments, and R are independently selected from H, phenyl, and 4-fluorophenyl.
[0374] In some embodiments, a linker may be attached at one of various sites of the PBD dimer drug moiety, including the N10 imine of the B ring, the C-2 endo/exo position of the C ring, or the tether unit linking the A rings (see structures C(I) and C(II) below).
[0375] Nonlimiting exemplary PBD dimer components of ADCs include Formulas C(I) and C(II):
[0376] Formulas C(I) and C(II) are shown in their N10-C11 imine form. Exemplary PBD drug moieties also include the carbinolamine and protected carbinolamine forms as well, as shown in the table below:
wherein:
X is CH2 (n = 1 to 5), N, or O;
Z and Z' are independently selected from OR and NR2, where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;
Ri, R'i, R2 and R'2 are each independently selected from H, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C5-20 aryl (including substituted aryls), C5-20 heteroaryl groups, -NH2, -NHMe, - OH, and -SH, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;
R3 and R'3 are independently selected from H, OR, NHR, and NR2, where R is a primary, secondary or tertiary alkyl chain containing 1 to 5 carbon atoms;
R4 and R'4 are independently selected from H, Me, and OMe; R5 is selected from Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C5-20 aryl (including aryls substituted by halo, nitro, cyano, alkoxy, alkyl, heterocyclyl) and C5_2o heteroaryl groups, where, in some embodiments, alkyl, alkenyl and alkynyl chains comprise up to 5 carbon atoms;
R11 is H, Ci-Cs alkyl, or a protecting group (such as acetyl, trifluoroacetyl, t- butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethylenoxycarbonyl (Fmoc), or a moiety comprising a self-immolating unit such as valine-citrulline-PAB);
R12 is is H, Ci-Cs alkyl, or a protecting group;
wherein a hydrogen of one of Ri, R'i, R2, R'2, R5, or Ri2 or a hydrogen of the - OCH2CH2(X)nCH2CH20- spacer between the A rings is replaced with a bond connected to the linker of the ADC.
[0377] Exemplary PDB dimer portions of ADC include, but are not limited to (the wavy line indicates the site of covalent attachment to the linker):
PBD dimer-Phe-Lys-PAB-Ab, wherein: n is 0 to 12. In some embodiments, n is 2 to 10. In some embodiments, n is 4 to 8. In some embodiments, n is selected from 4, 5, 6, 7, and 8.
[0379] The linkers of PBD dimer-val-cit-PAB-Ab and the PBD dimer-Phe-Lys-PAB-Ab are protease cleavable, while the linker of PBD dimer-maleimide-acetal is acid- labile.
[0380] PBD dimers and ADC comprising PBD dimers may be prepared according to methods known in the art. See, e.g., WO 2009/016516; US 2009/304710; US 2010/047257; US
2009/036431; US 2011/0256157; WO 2011/130598.
(5) Anthracyclines
[0381] In some embodiments, an ADC comprising anthracycline. Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. While not intending to be bound by any particular theory, studies have indicated that anthracyclines may operate to kill cells by a number of different mechanisms, including: 1) intercalation of the drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; 2) production by the drug of free radicals which then react with cellular macromolecules to cause damage to the cells, and/or 3) interactions of the drug molecules with the cell membrane {see, e.g., C. Peterson et al., "Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia" in
Anthracycline Antibiotics In Cancer Therapy; N. . Bachur, "Free Radical Damage" id. at pp.97- 102). Because of their cytotoxic potential anthracyclines have been used in the treatment of numerous cancers such as leukemia, breast carcinoma, lung carcinoma, ovarian adenocarcinoma and sarcomas {see e.g., P.H- Wiernik, in Anthracycline: Current Status And New Developments p 11).
[0382] Nonlimiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, nemorubicin, and derivatives thereof. Immunoconjugates and prodrugs of daunorubicin and doxorubicin have been prepared and studied (Kratz et al (2006) Current Med. Chem. 13:477-523; Jeffrey et al (2006) Bioorganic & Med. Chem. Letters 16:358-362; Torgov et al (2005) Bioconj. Chem. 16:717-721; Nagy et al (2000) Proc. Natl. Acad. Sci. USA 97:829-834; Dubowchik et al (2002) Bioorg. & Med. Chem. Letters 12:1529-1532; King et al
(2002) J. Med. Chem. 45:4336-4343; EP 0328147; US 6630579). The antibody-drug conjugate BR96-doxorubicin reacts specifically with the tumor-associated antigen Lewis-Y and has been evaluated in phase I and II studies (Saleh et al (2000) J. Clin. Oncology 18:2282-2292; Ajani et al (2000) Cancer Jour. 6:78-81 ; Tolcher et al (1999) J. Clin. Oncology 17:478-484).
[0383] PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri, et al. (2005) Clinical Cancer Research 11(4): 1608-1617). Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino of doxorubicin and has been under clinical evaluation (Grandi et al (1990) Cancer Treat. Rev. 17:133; ipamonti et al (1992) Brit. J. Cancer 65:703; ), including phase II/III trials for hepatocellular carcinoma (Sun et al (2003) Proceedings of the American Society for Clinical Oncology 22, Absl448; Quintieri
(2003) Proceedings of the American Association of Cancer Research, 44: 1st Ed, Abs 4649; Pacciarini et al (2006) Jour. Clin. Oncology 24: 14116).
[0384] A nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula la:
wherein Ri is hydrogen atom, hydroxy or methoxy group and R2 is a C1-C5 alkoxy group, or a pharmaceutically acceptable salt thereof;
Li and Z together are a linker (L) as described herein;
T is an antibody (Ab) as described herein; and
m is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.
[0385] In some embodiments, Ri and R2 are both methoxy (-OMe).
[0386] A further nonlimiting exemplary ADC comprising nemorubicin or nemorubicin derivatives is shown in Formula lb:
wherein Ri is hydrogen atom, hydroxy or methoxy group and R2 is a C1-C5 alkoxy group, or a pharmaceutically acceptable salt thereof;
L2 and Z together are a linker (L) as described herein;
T is an antibody (Ab) as described herein; and
m is 1 to about 20. In some embodiments, m is 1 to 10, 1 to 7, 1 to 5, or 1 to 4.
[0387] In some embodiments, Ri and R2 are both methoxy (-OMe).
[0388] In some embodiments, the nemorubicin component of a nemorubicin-containing ADC is PNU- 159682. In some such embodiments, the drug portion of the ADC may have one of the following structures:
.0
; or
.0 wherein the wavy line indicates the attachment to the linker (L).
[0389] Anthracyclines, including PNU-159682, may be conjugated to antibodies through several linkage sites and a variety of linkers (US 2011/0076287; WO2009/099741 ; US
2010/0034837; WO 2010/009124) , including the linkers described herein.
[0390] Exemplary ADCs comprising a nemorubicin and linker include, but are not limited
PNU-159682 maleimide acetal-Ab;
PNU-159682-val-cit-PAB-spacer( 1 2)-Ab, wherein: P i and 2 are independently selected from H and Ci-Ce alkyl; and
PNU- 159682-maleimide-Ab.
[0391] The linker of PNU-159682 maleimide acetal-Ab is acid-labile, while the linkers of PNU-159682-val-cit-PAB-Ab, PNU-159682-val-cit-PAB-spacer-Ab, and PNU-159682-val- cit-PAB-spacer(R1R2)-Ab are protease cleavable.
(6) Other Drug Moieties
[0392] Drug moieties also include geldanamycin (Mandler et al (2000) J. Nat. Cancer Inst. 92(19):1573-1581 ; Mandler et al (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al (2002) Bioconjugate Chem. 13:786-791); and enzymatically active toxins and fragments thereof, including, but not limited to, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, e.g., WO 93/21232.
[0393] Drug moieties also include compounds with nucleolytic activity {e.g., a ribonuclease or a DNA endonuclease).
[0394] In certain embodiments, an immunoconjugate may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated antibodies. Examples include At211, 1131, 1125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu. In some embodiments, when an immunoconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc" or I123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as zirconium-89, iodine-123, iodine-131, indium-I l l, fluorine- 19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Zirconium-89 may be complexed to various metal chelating agents and conjugated to antibodies, e.g., for PET imaging (WO 2011/056983).
[0395] The radio- or other labels may be incorporated in the immunoconjugate in known ways. For example, a peptide may be biosynthesized or chemically synthesized using suitable amino acid precursors comprising, for example, one or more fluorine- 19 atoms in place of one or more hydrogens. In some embodiments, labels such as Tc", I123, Re186, Re188 and In111 can be attached via a cysteine residue in the antibody. In some embodiments, yttrium-90 can be attached via a lysine residue of the antibody. In some embodiments, the IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes certain other methods.
[0396] In certain embodiments, an immunoconjugate may comprise an antibody conjugated to a prodrug-activating enzyme. In some such embodiments, a prodrug-activating enzyme converts a prodrug {e.g., a peptidyl chemotherapeutic agent, see WO 81/01145) to an active drug, such as an anti-cancer drug. Such immunoconjugates are useful, in some embodiments, in antibody-dependent enzyme-mediated prodrug therapy ("ADEPT"). Enzymes that may be conjugated to an antibody include, but are not limited to, alkaline phosphatases, which are useful for converting phosphate-containing prodrugs into free drugs; arylsulfatases, which are useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase, which is useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5- fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), which are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, which are useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β-galactosidase and neuraminidase, which are useful for converting glycosylated prodrugs into free drugs; β- lactamase, which is useful for converting drugs derivatized with β-lactams into free drugs; and penicillin amidases, such as penicillin V amidase and penicillin G amidase, which are useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. In some embodiments, enzymes may be covalently bound to antibodies by recombinant DNA techniques well known in the art. See, e.g., Neuberger et al., Nature 312:604-608 (1984). c) Drug Loading
[0397] Drug loading is represented by p, the average number of drug moieties per antibody in a molecule of Formula I. Drug loading may range from 1 to 20 drug moieties (D) per antibody. ADCs of Formula I include collections of antibodies conjugated with a range of drug moieties, from 1 to 20. The average number of drug moieties per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as mass spectroscopy, ELISA assay, and HPLC. The quantitative distribution of ADC in terms of p may also be determined. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
[0398] For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, where the attachment is a cysteine thiol, as in certain exemplary embodiments above, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached. In certain embodiments, higher drug loading, e.g. p >5, may cause aggregation, insolubility, toxicity, or loss of cellular permeability of certain antibody-drug conjugates. In certain embodiments, the average drug loading for an ADC ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. Indeed, it has been shown that for certain ADCs, the optimal ratio of drug moieties per antibody may be less than 8, and may be about 2 to about 5 (US 7498298).
[0399] In certain embodiments, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, lysine residues that do not react with the drug-linker intermediate or linker reagent, as discussed below. Generally, antibodies do not contain many free and reactive cysteine thiol groups which may be linked to a drug moiety; indeed most cysteine thiol residues in antibodies exist as disulfide bridges. In certain embodiments, an antibody may be reduced with a reducing agent such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP), under partial or total reducing conditions, to generate reactive cysteine thiol groups. In certain embodiments, an antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine.
[0400] The loading (drug/antibody ratio) of an ADC may be controlled in different ways, and for example, by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.
[0401] It is to be understood that where more than one nucleophilic group reacts with a drug-linker intermediate or linker reagent, then the resulting product is a mixture of ADC compounds with a distribution of one or more drug moieties attached to an antibody. The average number of drugs per antibody may be calculated from the mixture by a dual ELISA antibody assay, which is specific for antibody and specific for the drug. Individual ADC molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography (see, e.g., McDonagh et al (2006) Prot. Engr. Design & Selection 19(7):299-307; Hamblett et al (2004) Clin. Cancer Res. 10:7063-7070; Hamblett, K.J., et al. "Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate," Abstract No. 624, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004; Alley, S.C., et al. "Controlling the location of drug attachment in antibody-drug conjugates," Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004). In certain embodiments, a homogeneous ADC with a single loading value may be isolated from the conjugation mixture by electrophoresis or chromatography. d) Certain Methods of Preparing Immunoconiugates
[0402] An ADC of Formula I may be prepared by several routes employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reaction of a nucleophilic group of an antibody with a bivalent linker reagent to form Ab-L via a covalent bond, followed by reaction with a drug moiety D; and (2) reaction of a nucleophilic group of a drug moiety with a bivalent linker reagent, to form D-L, via a covalent bond, followed by reaction with a nucleophilic group of an antibody. Exemplary methods for preparing an ADC of Formula I via the latter route are described in US 7498298, which is expressly incorporated herein by reference.
[0403] Nucleophilic groups on antibodies include, but are not limited to: (i) N- terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; and (iii) aldehydes, ketones, carboxyl, and maleimide groups. Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP), such that the antibody is fully or partially reduced. Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through modification of lysine residues, e.g., by reacting lysine residues with 2-iminothiolane (Traut's reagent), resulting in conversion of an amine into a thiol. Reactive thiol groups may also be introduced into an antibody by introducing one, two, three, four, or more cysteine residues (e.g., by preparing variant antibodies comprising one or more non-native cysteine amino acid residues).
[0404] Antibody-drug conjugates of the invention may also be produced by reaction between an electrophilic group on an antibody, such as an aldehyde or ketone carbonyl group, with a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on a linker reagent include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. In one embodiment, an antibody is modified to introduce electrophilic moieties that are capable of reacting with nucleophilic substituents on the linker reagent or drug. In another embodiment, the sugars of glycosylated antibodies may be oxidized, e.g. with periodate oxidizing reagents, to form aldehyde or ketone groups which may react with the amine group of linker reagents or drug moieties. The resulting imine Schiff base groups may form a stable linkage, or may be reduced, e.g. by borohydride reagents to form stable amine linkages. In one embodiment, reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the antibody that can react with appropriate groups on the drug
(Hermanson, Bioconjugate Techniques). In another embodiment, antibodies containing N- terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate Chem. 3:138-146; US 5362852). Such an aldehyde can be reacted with a drug moiety or linker nucleophile.
[0405] Exemplary nucleophilic groups on a drug moiety include, but are not limited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups.
[0406] Nonlimiting exemplary cross-linker reagents that may be used to prepare ADC are described herein in the section titled "Exemplary Linkers." Methods of using such cross- linker reagents to link two moieties, including a proteinaceous moiety and a chemical moiety, are known in the art. In some embodiments, a fusion protein comprising an antibody and a cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. A recombinant DNA molecule may comprise regions encoding the antibody and cytotoxic portions of the conjugate either adjacent to one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.
[0407] In yet another embodiment, an antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a drug or radionucleotide).
E. Methods and Compositions for Diagnostics and Detection
[0408] In certain embodiments, any of the anti-Lg 5 antibodies provided herein is useful for detecting the presence of LgR5 in a biological sample. The term "detecting" as used herein encompasses quantitative or qualitative detection. A "biological sample" comprises, e.g., a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic, or ovarian tissue).
[0409] In one embodiment, an anti-LgR5 antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of LgR5 in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-LgR5 antibody as described herein under conditions permissive for binding of the anti-LgR5 antibody to LgR5, and detecting whether a complex is formed between the anti-LgR5 antibody and LgR5 in the biological sample. Such method may be an in vitro or in vivo method. In one embodiment, an anti-LgR5 antibody is used to select subjects eligible for therapy with an anti-LgR5 antibody, e.g. where LgR5 is a biomarker for selection of patients. In a further embodiment, the biological sample is a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic, or ovarian tissue).
[0410] In a further embodiment, an anti-LgR5 antibody is used in vivo to detect, e.g., by in vivo imaging, an LgR5 -positive cancer in a subject, e.g., for the purposes of diagnosing, prognosing, or staging cancer, determining the appropriate course of therapy, or monitoring response of a cancer to therapy. One method known in the art for in vivo detection is immuno- positron emission tomography (immuno-PET), as described, e.g., in van Dongen et al., The Oncologist 12:1379-1389 (2007) and Verel et al., J. Nucl. Med. 44:1271-1281 (2003). In such embodiments, a method is provided for detecting an LgR5-positive cancer in a subject, the method comprising administering a labeled anti-LgR5 antibody to a subject having or suspected of having an LgR5-positive cancer, and detecting the labeled anti-LgR5 antibody in the subject, wherein detection of the labeled anti-LgR5 antibody indicates an LgR5 -positive cancer in the subject. In certain of such embodiments, the labeled anti-LgR5 antibody comprises an anti-LgR5 antibody conjugated to a positron emitter, such as 68Ga, 18F, ^Cu, 86Y, 76Br, 89Zr, and 124I. In a particular embodiment, the positron emitter is 89Zr.
[0411] In further embodiments, a method of diagnosis or detection comprises contacting a first anti-LgR5 antibody immobilized to a substrate with a biological sample to be tested for the presence of LgR5, exposing the substrate to a second anti-LgR5 antibody, and detecting whether the second anti-LgR5 is bound to a complex between the first anti-LgR5 antibody and LgR5 in the biological sample. A substrate may be any supportive medium, e.g., glass, metal, ceramic, polymeric beads, slides, chips, and other substrates. In certain embodiments, a biological sample comprises a cell or tissue (e.g., biopsy material, including cancerous or potentially cancerous colon, colorectal, small intestine, endometrial, pancreatic or ovarian tissue). In certain embodiments, the first or second anti-LgR5 antibody is any of the antibodies described herein. In some such embodiments, the second anti-LgR5 antibody may be 8E11 or antibodies derived from 8E11, e.g., as described herein. In some such embodiments, the second anti-LgR5 antibody may be YW353 or antibodies derived from YW353, e.g., as described herein. In some embodiments, the first or second anti-LgR5 antibody is selected from 3G12 and 2H6 and antibodies derived from 3G12 and/or 2H6, e.g., as described herein.
[0412] Exemplary disorders that may be diagnosed or detected according to any of the above embodiments include LgR5-positive cancers, such as LgR5-positive colorectal cancer (including adenocarcinoma), LgR5 -positive small intestine cancer (including adenocarcinoma, sarcoma (e.g., leiomyosarcoma), carcinoid tumors, gastrointestnal stromal tumor, and lymphoma) LgPv5-positive ovarian cancer (including ovarian serous adenocarcinoma), LgR5-positive pancreatic cancer (including pancreatic ductal adenocarcinoma), and LgR5 -positive endometrial cancer. In some embodiments, an LgR5 -positive cancer is a cancer that receives an anti-LgR5 immunohistochemistry (IHC) or in situ hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example B. In another embodiment, an LgR5-positive cancer expresses LgR5 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example B. In some embodiments, an LgR5 -positive cancer is a cancer that expresses LgR5 according to a reverse- transcriptase PCR (RT-PCR) assay that detects LgR5 mRNA. In some embodiments, the RT- PCR is quantitative RT-PCR.
[0413] In certain embodiments, labeled anti-LgR5 antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes 32P, 14C, 1251, 3H, and 131I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP,
lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like. In another embodiment, a label is a positron emitter. Positron emitters include but are not limited to 68Ga, 18F, ^Cu, 86Y, 76Br, 89Zr, and 124I. In a particular embodiment, a positron emitter is 89Zr.
F. Pharmaceutical Formulations
[0414] Pharmaceutical formulations of an anti-LgR5 antibody or immunoconjugate as described herein are prepared by mixing such antibody or immunoconjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3- pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides;
proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include insterstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
[0415] Exemplary lyophilized antibody or immunoconjugate formulations are described in US Patent No. 6,267,958. Aqueous antibody or immunoconjugate formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
[0416] The formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, in some instances, it may be desirable to further provide Avastin® (bevacizumab), e.g., for the treatment of Lg 5-positive cancer such as LgR5 -positive colon cancer or LgR5 -positive colorectal cancer.
[0417] Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano- particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0418] Sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody or immunoconjugate, which matrices are in the form of shaped articles, e.g. films, or microcapsules. [0419] The formulations to be used for in vivo administration are generally sterile.
Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
G. Therapeutic Methods and Compositions
[0420] Any of the anti-Lg 5 antibodies or immunoconjugates provided herein may be used in methods, e.g., therapeutic methods.
[0421] In one aspect, an anti-LgR5 antibody or immunoconjugate provided herein is used in a method of inhibiting proliferation of an LgR5-positive cell, the method comprising exposing the cell to the anti-LgR5 antibody or immunoconjugate under conditions permissive for binding of the anti-LgR5 antibody or immunoconjugate to LgR5 on the surface of the cell, thereby inhibiting the proliferation of the cell. In certain embodiments, the method is an in vitro or an in vivo method. In further embodiments, the cell is a colon, colorectal, small intestine, ovarian, pancreatic, or endometrial cell.
[0422] In some embodiments, an anti-LgR5 antibody or immunoconjugate provided herein is used in a method of treating cancer that comprises a mutation in a Kras gene and/or a mutation in an adenomatous polyposis coli (APC) gene in at least a portion of the cells of the cancer. In various embodiments, the cancer is selected from colon, colorectal, small intestine, ovarian, pancreatic, and endometrial cancer. In some embodiments, an anti-LgR5 antibody or immunoconjugate provided herein is used in a method of treating a colon or colorectal cancer that comprises a mutation in a Kras gene and/or a mutation in an APC gene in at least a portion of the cells of the cancer. Nonlimiting exemplary Kras mutations found in cancers (including colon and colorectal cancers) include mutations at Kras codon 12 (e.g., G12D, G12V, G12R, G12C, G12S, and G12A), codon 13 (e.g., G13D and G13C), codon 61 (e.g., G61H, G61L, G61E, and G61K), and codon 146. See, e.g., Yokota, Anticancer Agents Med. Chem., 12: 163-171 (2012); Wicki et al., Swiss Med. Wkly, 140: wl3112 (2010). Nonlimiting exemplary APC mutations found in cancers include mutations in the mutation cluster region (MCR), such as stop codons and frameshift mutations that result in a truncated APC gene product. See, e.g., Chandra et al., PLoS One, 7: e34479 (2012); and Kohler et al., Hum. Mol. Genet., 17: 1978-1987 (2008).
[0423] In some embodiments, a method of treating cancer comprises administering an anti-LgR5 antibody or immunoconjugate to a subject, wherein the subject has a cancer comprising a Kras mutation and/or an APC mutation in at least a portion of the cancer cells. In some embodiments, the cancer is selected from colon, colorectal, small intestine, ovarian, pancreatic, and endometrial cancer. In some embodiments, the cancer is colon and/or colorectal cancer. In some embodiments, the subject has previously been determined to have a cancer comprising a Kras mutation and/or an APC mutation in at least a portion of the cancer cells. In some embodiments, the cancer is LgR5 -positive.
[0424] Presence of various biomarkers in a sample can be analyzed by a number of methodologies, many of which are known in the art and understood by the skilled artisan, including, but not limited to, immunohistochemistry ("IHC"), Western blot analysis,
immunoprecipitation, molecular binding assays, ELISA, ELIFA, fluorescence activated cell sorting ("FACS"), MassARRAY, proteomics, quantitative blood based assays (as for example Serum ELISA), biochemical enzymatic activity assays, in situ hybridization, Southern analysis, Northern analysis, whole genome sequencing, polymerase chain reaction ("PCR") including quantitative real time PCR ("qRT-PCR") and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like, RNA-Seq, FISH, microarray analysis, gene expression profiling, and/or serial analysis of gene expression ("SAGE"), as well as any one of the wide variety of assays that can be performed by protein, gene, and/or tissue array analysis. Typical protocols for evaluating the status of genes and gene products are found, for example in Ausubel et al, eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunob lotting) and 18 (PCR Analysis). Multiplexed immunoassays such as those available from Rules Based Medicine or Meso Scale Discovery ("MSD") may also be used.
[0425] Inhibition of cell proliferation in vitro may be assayed using the CellTiter-Glo™ Luminescent Cell Viability Assay, which is commercially available from Promega (Madison, WI). That assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells. See Crouch et al. (1993) J. Immunol. Meth. 160:81-88, US Pat. No. 6602677. The assay may be conducted in 96- or 384-well format, making it amenable to automated high-throughput screening (HTS). See Cree et al. (1995) Anticancer Drugs 6:398-404. The assay procedure involves adding a single reagent (CellTiter- Glo® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction. The luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device. The luminescence output is expressed as relative light units (RLU).
[0426] In another aspect, an anti-LgR5 antibody or immunoconjugate for use as a medicament is provided. In further aspects, an anti-LgR5 antibody or immunoconjugate for use in a method of treatment is provided. In certain embodiments, an anti-LgR5 antibody or immunoconjugate for use in treating LgR5-positive cancer is provided. In certain embodiments, the invention provides an anti-LgR5 antibody or immunoconjugate for use in a method of treating an individual having an LgR5-positive cancer, the method comprising administering to the individual an effective amount of the anti-LgR5 antibody or immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
[0427] In a further aspect, the invention provides for the use of an anti-LgR5 antibody or immunoconjugate in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment of LgR5 -positive cancer. In a further embodiment, the medicament is for use in a method of treating LgR5-positive cancer, the method comprising administering to an individual having LgR5-positive cancer an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
[0428] In a further aspect, the invention provides a method for treating LgR5-positive cancer. In one embodiment, the method comprises administering to an individual having such LgR5-positive cancer an effective amount of an anti-LgR5 antibody or immunoconjugate. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below.
[0429] An LgR5 -positive cancer according to any of the above embodiments may be, e.g., LgR5-positive colon or colorectal cancer (including adenocarcinoma), LgR5-positive small intestine cancer (including adenocarcinoma, sarcoma (e.g., leiomyosarcoma), carcinoid tumors, gastrointestnal stromal tumor, and lymphoma)., LgR5-positive ovarian cancer (including ovarian serous adenocarcinoma), LgR5 -positive pancreatic cancer (including pancreatic ductal adenocarcinoma), and LgR5-positive endometrial cancer. In some embodiments, an LgR5- positive cancer is a cancer that receives an anti-LgR5 immunohistochemistry (IHC) or in situ hybridization (ISH) score greater than "0," which corresponds to very weak or no staining in >90% of tumor cells, under the conditions described herein in Example B. In another embodiment, an LgR5-positive cancer expresses LgR5 at a 1+, 2+ or 3+ level, as defined under the conditions described herein in Example B. In some embodiments, an LgR5-positive cancer is a cancer that expresses LgR5 according to a reverse-transcriptase PCR (RT-PCR) assay that detects LgR5 mRNA. In some embodiments, the RT-PCR is quantitative RT-PCR.
[0430] An "individual" according to any of the above embodiments may be a human.
[0431 ] In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-LgR5 antibodies or immunoconjugate provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-LgR5 antibodies or immunoconjugates provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical formulation comprises any of the anti-LgR5 antibodies or immunoconjugates provided herein and at least one additional therapeutic agent, e.g., as described below.
[0432] Antibodies or immunoconjugates of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody or immunoconjugate of the invention may be co-administered with at least one additional therapeutic agent. In certain embodiments, an additional therapeutic agent is Avastin® (bevacizumab), e.g., for the treatment of LgR5-positive cancer such as LgR5-positive colon cancer or LgR5-positive colorectal cancer.
[0433] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody or immunoconjugate of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant. Antibodies or immunoconjugates of the invention can also be used in combination with radiation therapy.
[0434] An antibody or immunoconjugate of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
[0435] Antibodies or immunoconjugates of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody or immunoconjugate need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody or
immunoconjugate present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
[0436] For the prevention or treatment of disease, the appropriate dosage of an antibody or immunoconjugate of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody or immunoconjugate, the severity and course of the disease, whether the antibody or immunoconjugate is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody or immunoconjugate, and the discretion of the attending physician. The antibody or immunoconjugate is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. O.lmg/kg-lOmg/kg) of antibody or immunoconjugate can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody or immunoconjugate would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
[0437] It is understood that any of the above formulations or therapeutic methods may be carried out using both an immunoconjugate of the invention and an anti-Lg 5 antibody.
H. Articles of Manufacture
[0438] In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the disorder and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody or immunoconjugate of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody or immunoconjugate of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
III. EXAMPLES
[0439] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.
A. Human LgR5 Gene Expression
[0440] Human LgR5 gene expression was analyzed using a proprietary database containing gene expression information (GeneExpress®, Gene Logic Inc., Gaithersburg, MD). Graphical analysis of the GeneExpress® database was conducted using a microarray profile viewer. Figure 1 is a graphic representation of human LgR5 gene expression in various tissues. The scale on the y-axis indicates gene expression levels based on hybridization signal intensity. Dots appear both to the left and to the right of the line extending from the name of each listed tissue. The dots appearing to the left of the line represent gene expression in normal tissue, and the dots appearing to the right of the line represent gene expression in tumor and diseased tissue. Figure 1 shows increased LgR5 gene expression in certain tumor or diseased tissues relative to their normal counterparts. In particular, LgR5 is substantially overexpressed in colorectal, endometrial, and ovarian tumors. Figure 1, inset, shows that LgR5 is overexpressed in at least the following colon tumors: adenocarcinoma, benign tumors, and metastatic colon tumors, and also in tissue with a colon tumor content of less than 50% ("low tumor" in Figure 1 inset); but is not overexpressed in normal colon, Crohn's disease, or ulcerative colitis. Human LgR5 expression is much lower in normal tissues, with low levels of expression in normal brain, muscle, ovarian, and placental tissues.
B. Prevalence of Human LgR5 in Colon Tumors
[0441] To evaluate the expression of LgR5 in colorectal cancer, 57 primary colorectal adenocarcinomas were acquired from multiple sources (Asterand, Detroit, MI; Bio-Options, Fullerton, CA; University of Michigan, Ann Arbor, MI; Cytomyx, ockville, MD; Cooperative Human Tissue Network, Nashville, TN; Indivumed, Hamburg, Germany; ProteoGenex, Culver City, CA). Forty-four percent of samples were from men, and the average age of the patients was 66 years (range 31 to 93 years). Tissue microarrays (TMAs) were assembled using duplicate cores as described in Bubendorf L, et al., J Pathol. 2001 Sep;195(l):72-9, and included five normal colorectal mucosa samples from matched cases.
[0442] LgR5 expression was determined by in situ hybridization using the
oligonucleotide probes shown in Table 2. See, e.g., Jubb AM, et al., Methods Mol Biol 2006; 326:255-64. ISH for β-actin was used to confirm mRNA integrity in colorectal cancer tissues prior to analysis.
[0443] LgR5 hybridization intensity was scored by a trained pathologist according to the scheme below, taking into account the intensity (silver grains) as well as breadth of staining.
0 (negative): very weak or no hybridization in >90% of tumor cells
1+ (mild): predominant hybridization pattern is weak
2+ (moderate): predominant hybridization pattern is moderately strong in the majority (> 50%) of neoplastic cells
3+ (strong): predominant hybridization pattern is strong in the majority (>50%) of neoplastic cells
Sense probes were used to control for the specificity of hybridization.
[0444] Figure 2 shows exemplary colon tumor sections with 1+, 2+, and 3+ levels of staining. The top panels show dark field images and the bottom panels show bright field images. The deposition of silver grains in the dark field images indicates hybridization of the probe and expression of LgR5 mRNA. -77% (41/53) of colon tumor sections analyzed were LgR5 positive, showing staining at the 1+, 2+, or 3+ levels, with 34% (18/53) showing 2+ or 3+ staining. Four of the 57 samples analyzed were noninformative for LgR5 expression. [0445] To evaluate the significance of Lgr5 expression in colon tumors, a population- based series of patients who had undergone surgical resections for colorectal adenocarcinoma was compiled retrospectively from the pathology archives at St James' University Hospital (Leeds, UK) from 1988 to 2003. Tissue microarrays (TMAs) were constructed with one core of normal mucosa and three cores of adenocarcinoma per patient as described in Bubendorf L, et al., J Pathol. 2001 Sep;195(l):72-9. ISH was performed and scored as described above. The heterogeneity of expression across three cores from the same tumor was also determined, and is expressed as the proportion of tumors that showed a particular level of discordance in one of the three cores. For example, if three cores had scores of +1, +3, and +3, one of the three cores from that tumor is discordant by 2.
[0446] Figure 3 A shows the prevalence of 0, 1+, 2+, and 3+ levels of LgR5 staining in the colon tumor tissue microarray, measured by in situ hybridization. 75% of the colon tumor tissues showed staining at the 1+, 2+, or 3+ levels, with 37% showing 2+ or 3+ staining. Figure 3B shows the heterogeneity of LgR5 expression. 67% of tumors showed no heterogeneity across the three cores. 32% shows a discordance of 1 in one of the three cores, and only 1% showed a discordance greater than 1.
C. Mouse Monoclonal Antibody Generation
[0447] Monoclonal antibodies against human LgR5 were generated using the following procedures. Human LgR5 extracellular domain (ECD; amino acids 22-557) with a C-terminal His-tagged Fc was expressed from a baculovirus expression system, and purified on a Ni-NTA column (Qiagen), followed by gel filtration on a Superdex 200 column in 20mM MES pH 6.0, 6M guanidine HC1 as previously described (Kirchhofer et al., 2003) and dialysis into PBS for storage at -80°C.
[0448] Fifteen Balb/c mice (Charles River Laboratories International, Inc., Hollister, CA, USA) were injected with either huLgR5 plasmid DNA in lactated Ringer's solution (via tail vein) or with recombinant human LgR5 ECD as described above (via rear footpads) in adjuvant containing metabolizable squalene (4% v/v), Tween 80 (0.2 % v/v), trehalose 6,6-dimycolate (0.05% w/v) and monophosphoryl lipid A (0.05% w/v; Sigma Aldrich, USA). Serum titers were evaluated by standard enzyme linked immunosorbant assay (ELISA) and FACS following 6-9 injections. Splenic B cells harvested from a total of 5 mice were fused with mouse myeloma cells (X63.Ag8.653; American Type Culture Collection, Manassas, VA, USA) by electrofusion (Hybrimune; Harvard Apparatus, Inc., Holliston, MA, USA). After 10-14 days, hybridoma supernatants were screened for antibody secretion by ELISA. All positive clones were then expanded and re-screened for binding to huLgR5 and muLgR5 by ELISA and FACS (i.e., for binding to 293-huLGR5 and 293-muLGR5 cells). Hybridoma clones 8E11.1.1 (identified from the DNA immunized mice), and 2H6.3.5 and 3G12.2.1 (both from the protein immunized mice) showed high immunobinding after two rounds of subcloning (by limiting dilution) and were scaled up for purification in INTEGRA CELLine 1000 bioreactors (INTEGRA Biosciences AG, Zizers, Switzerland). Supematants were then purified by affinity chromatography, sterile-filtered, and stored at 4°C in PBS. The isotypes of the mAbs were determined to be IgGl (kappa light chain) using the Isostrip Mouse mAb Isotyping Kit (Roche Applied Biosciences, Indianapolis, IN, USA).
[0449] Figure 4 shows certain monoclonal antibodies generated, along with certain properties, some of which will be described in further detail below.
D. Cloning and Chimerization of Mouse Monoclonal Antibodies
[0450] Monoclonal antibodies 8E11, 3G12, and 2H6 were cloned and chimerized as follows.
[0451] Total RNA was extracted from hybridoma cells producing murine 8E11, murine 3G12, or murine 2H6 using standard methods. The variable light (VL) and variable heavy (VH) domains were amplified using RT-PCR with degenerate primers to the heavy and light chains. The forward primers were specific for the N-terminal amino acid sequence of the VL and VH regions. Respectively, the LC and HC reverse primers were designed to anneal to a region in the constant light (CL) and constant heavy domain 1 (CHI), which are highly conserved across species. The polynucleotide sequence of the inserts was determined using routine sequencing methods. The 8E11 VL and VH amino acid sequences are shown in Figures 5 and 6, respectively (SEQ ID NOs: 3 and 4, respectively). The 3G12 and 2H6 VL and VH amino acid sequences are shown in Figures 7 and 8, respectively. The VL and VH sequences of antibody 3G12 are shown in SEQ ID NOs: 21 and 22, respectively, and the VL and VH sequences of antibody 2H6 are shown in SEQ ID NOs: 23 and 24, respectively.
[0452] Each antibody was chimerized by cloning the mouse heavy chain variable region onto a human IgGl heavy chain constant region and cloning the light chain variable region onto a human kappa light chain constant region.
E. Humanization of 8E11
[0453] Monoclonal antibody 8E11 was humanized as described below. Residue numbers are according to Kabat et al., Sequences of proteins of immunological interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Direct hypervariable region gra fts onto the acceptor human consensus framework
[0454] Variants constructed during the humanization of 8E11 were assessed in the form of an IgG. The VL and VH domains from murine 8E11 were aligned with the human VL kappa IV (VLKIV) and human VH subgroup I (V¾) consensus sequences. Hypervariable regions from the murine 8E11 (mu8El 1) antibody were engineered into VLKrv and V¾ acceptor frameworks to generate 8El l .vl. Specifically, from the mu8El l VL domain, positions 24-34 (LI), 50-56 (L2) and 89-97 (L3) were grafted into VLKrv- From the mu8El 1 VH domain, positions 26-35 (HI), 49-65 (H2) and 95-102 (H3) were grafted into V¾. In addition, positions 71 and 78 in framework III of VH were retained from the mouse sequence in 8E11.vl . Those residues were found to be part of the framework residues acting as "Vernier" zone, which may adjust CDR structure and fine-tune the antigen fit. See, e.g., Foote and Winter, J. Mol. Biol. 224: 487-499 (1992) (Figures 5 and 6). These CDR definitions include positions defined by their sequence hypervariability (Wu, T. T. & Kabat, E. A. (1970)), their structural location (Chothia, C. & Lesk, A. M. (1987)) and their involvement in antigen-antibody contacts (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)).
[0455] Additional 8E11 variants were generated to evaluate the contributions of other Vernier positions, such as position 68 in the light chain, and positions 67 and 69 in the heavy chain. Humanized 8E11.v2 was generated by retaining two addition mouse residues, at positions 67 and 69 of the heavy chain variable region. The light chain variable region sequence and heavy chain variable region sequence for 8E11.v2, and other variants, are shown in Figures 5 and 6, respectively.
[0456] The humanized variants of 8E11 were generated by Kunkel mutagenesis using a separate oligonucleotide for each hypervariable region. Correct clones were identified by DNA sequencing.
Assessment of variants
[0457] For screening purposes, IgG variants were initially produced in 293 cells. Vectors coding for VL and VH were transfected into 293 cells. IgG was purified from cell culture media by protein A affinity chromatography.
[0458] The affinity of each 8E11 IgG variant for human LgR5 was determined by surface plasmon resonance using a BIAcore™-3000. BIAcore™ research grade CM5 chips were activated with l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N- hydroxysuccinimide (NHS) reagents according to the supplier's instructions. Goat anti-human Fc IgGs were coupled to the chips to achieve approximately 10,000 response units (RU) in each flow cell. Unreacted coupling groups were blocked with 1M ethanolamine. For kinetics measurements, anti-LGR5 antibodies were captured to achieve approximately 300 RU. Two-fold serial dilutions of human LgR5 ECD (amino acids 22-557 fused to His-Fc expressed in a baculovirus system, or amino acids 22-558 fused to Fc expressed from CHO cells; 125 nM to 0.49 nM) were injected in HBS-P buffer (0.01M HEPES pH7.4, 0.15M NaCl, 0.005% surfactant P20) at 25°C with a flow rate of 30 μΐ/min. Association rates (kon) and dissociation rates (koff) were calculated using a 1 : 1 Langmuir binding model (BIAcore™ Evaluation Software version 3.2). The equilibrium dissociation constant (Kd) was calculated as the ratio k0ff/kon.
Results
[0459] The human acceptor framework used for humanization of 8E11 is based on the human VL kappa IV consensus (VLKiv) and the acceptor VH framework V¾. Eight humanized variants of mu8El 1 were produced and tested for LgR5 affinity by BIAcore™. The light chain variable regions and heavy chain variable regions of each of the variants is shown in Figures 5 and 6, respectively. The results of the affinity measurements are shown in Figure 9.
[0460] To improve the binding affinity of 8E11.vl, position 68 in the light chain and positions of 67 and 69 in the heavy chain were changed to residues found at these positions in mu8El 1. Positions 71 and 78 in the heavy chain were changed to residues found at these positions in the human framework V¾. Combinations of these altered light and heavy chains were expressed as IgG and purified as described above, and assessed for binding to human LgR5 by Biacore (Figure 9).
[0461 ] Variant hu8El 1.v2 was generated by changing positions 67 and 69 of the hu8El 1.vl heavy chain to the residues found at those positions in mu8El 1. The affinity (KD) of hu8El 1.v2 was found to be about the same as the parental ch8El 1 antibody.
Summary of changes for humanized 8Ell.v2
[0462] The 6 murine 8E11 CDRs (defined as positions 24-34 (LI), 50-56 (L2) and 89-97 (L3), 26-35 (HI), 49-65 (H2) and 93-102 (H3)) were grafted into the human consensus VLKiv and VHi acceptor domains. Positions 67, 69, 71, and 78 were changed back to murine residues from mu8E 11. Humanized 8E 11.v2 has comparable affinity for LgR5 to chimeric 8E 11.
[0463] Throughout this application, mouse monoclonal antibodies 8E11, 2H6, and 3G12 are referred to in the alternative as 8E11, m8El 1, or mu8El 1; and 2H6, m2H6 or mu2H6; and 3G12, m3G12, or mu3G12; respectively. Chimeric monoclonal antibodies 8E11, 2H6, and 3G12 are referred to as chimeric 8E11 or ch8El 1; chimeric 2H6 or ch2H6; and chimeric 3G12 or ch3G12; respectively. Humanized monoclonal antibody 8E11.v2 may also be referred to as 8E1 lv2, h8El lv.2, or hu8El lv.2. F. Generation of a Human Monoclonal Antibody by Phage Display
[0464] Human LgR5 ECD (amino acids 22-555) with an N-terminal FLAG was expressed in CHO cells and purified on an anti-FLAG resin overnight, and then eluted with 0.1M acetic acid, pH 2.7. The protein was then purified by gel filtration on a Superdex 200 column in PBS and then dialyzed into PBS for storage at -80°C.
[0465] Human phage antibody libraries with synthetic diversities in the selected complementary determining regions (HI, H2, H3), mimicking the natural diversity of human IgG repertoire were used for panning. The Fab fragments were displayed bivalently on the surface of M13 bacteriophage particals (Lee et al. (2004) JMol Biol 340, 1073-93). Human LgR5 ECD (amino acids 22-555) produced as described above was used as an antigen. Nunc 96-well MaxiSorp immnoplates (Nunc) were coated overnight at 4°C with LgR5 ECD protein (10 μg/ml) and blocked for 1 hour with PBST buffer (PBS, 0.05% Tween 20) supplemented with 1% BSA. The antibody phage libraries were added and incubated overnight at room temperature. The plates were washed with PBST buffer and bound phage were eluted with 50 mM HCL/500 mM NaCl for 30 minutes and neutralized with an equal volume of 1M Tris base. Recovered phages were amplified in E.coli XL-1 blue cells. During subsequent selection rounds, the incubation time of the phage antibodies was decreased to 2 hours and the stringency of plate washing was gradually increased (Liang et al. (2007) JMol Biol 366, 815-829). Unique and specific phage antibodies that bind to human LgR5 ECD were identified by phage ELISA and DNA sequencing. Certain clones, including YW353, were reformatted to full length IgGs by cloning the VL and VH regions into LPG3 and LPG4 vectors, respectively. Antibodies were transiently expressed in mammalian cells and and purified on protein A columns (Carter et al. (1992) Proc Natl Acad Sci USA 89, 4285-9).
[0466] The light chain and heavy chain variable regions sequence for human antibody YW353 are shown in Figures 10 and 11, respectively (SEQ ID NOs: 26 and 25). IgGl heavy chain and kappa light chain sequences for human antibody YW353 are shown in SEQ ID NOs: 66 and 65, respectively. Since YW353 was generated from a human antibody phage library, the terms "YW353" and "huYW353" are used interchangeably herein.
G. Species Cross-Reactivity
[0467] Monoclonal antibodies were tested to determine if they cross-react with LgR5 from species other than human. Figures 12A to C shows an alignment between human (SEQ ID NO: 67), cynomolgus monkey (SEQ ID NO: 69), rat (SEQ ID NO: 70) and mouse (SEQ ID NO: 72) LgR5. Residues that are identical among all four species are indicated by asterisks (*). Figure 4 shows the results of FACS analysis of 293 cells stably transfected with gD epitope-tagged LgR5 (human, cynomolgus monkey, rat, or mouse LgR5); stained with 10 μg/ml YW353, ch8El 1, hu8El l.v2, 2H6, or 3G12 antibody; and detected with R-Phycoerythrin conjugated goat anti-human antibody. Untransfected 293 cells do not normally express LgR5. YW353 antibody binds human and cynomolgus monkey LgR5, but not rat or mouse LgR5. Ch8El 1 and hu8El 1.v2 antibodies bind all four species of LgR5, although binding to rat LgR5 is not as strong as binding to human, cynomolgus monkey, or mouse LgR5. 2H6 antibody binds to human and mouse LgR5, and was not tested for binding to cynomolgus monkey or rat LgR5. 3G12 antibody shows strong binding to human LgR5, less strong binding to mouse LgR5, and was not tested for binding to cynomolgus monkey or rat LgR5.
H. Antibody Affinities
[0468] The affinity of each antibody for human LgR5 was determined by surface plasmon resonance using a BIAcore™-3000, substantially as described above in Example E.
[0469] As shown in Figure 4, YW353 antibody bound to human LgR5 with an affinity of 1.6 nM. Ch8El 1 and hu8El l.v2 antibodies bound to human LgR5 with affinities of 2.4 nm and 3.1 nm, respectively. 2H6 and 3G12 antibodies bound to human LgR5 with affinities of 208 nM and 72 nM, respectively.
[0470] Scatchard analysis was performed following standard procedures (Holmes et al., Science 256:1205-1210 (1992)) to determine the relative binding affinities of YW353, ch8El 1 and hu8El lv2 antibodies.
[0471] Anti-Lgr5 antibodies were [I125] labeled using the indirect Iodogen method. The [I125] labeled anti-Lgr5 antibodies were purified from free 125I-Na by gel filtration using a NAP-5 column (GE Healthcare); the purified iodinated anti-Lgr5 antibodies had a range of specific activities of 13.92 to 19.01 Competition assay mixtures of 50 volume containing a fixed concentration of [I125] labeled antibody and decreasing concentrations of serially diluted, unlabeled antibody were placed into 96-well plates. 293 cells stably expression human, rat, or mouse Lgr5 were cultured in growth media at 37°C in 5% CO2. Cells were detached from the flask using Sigma Cell Dissociation Solution and were washed with binding buffer, which consisted of Dulbecco's Modified Eagle Medium (DMEM) with 2% fetal bovine serum (FBS), 50 mM HEPES (pH 7.2) and 0.1% sodium azide. The washed cells were added to the 96 well plates at a density of 250,000 cells in 0.2 mL of binding buffer. The final concentration of the [I125] labeled antibody in each well was 200 pM. The final concentration of the unlabeled antibody in the competition assay ranged from 500 nM through ten 2-fold diluation steps to a 0 nM buffer-only assay. Competition assays were carried out in triplicate. Competition assays were incubated for 2 hours at room temperature. After the 2-hour incubation, the competition assays were transferred to a Millipore Multiscreen filter plate (Billerica, MA) and washed 4 times with binding buffer to separate the free from bound [I125] labeled antibody. The filters were counted on a Wallac Wizard 1470 gamma counter (PerkinElmer Life and Analytical Sciences Inc.;
Wellesley, MA). The binding data was evaluated using NewLigand software (Genentech), which uses the fitting algorithm of Munson and Robard to determine the binding affinity of the antibody (Munson and Robard 1980)
[0472] As shown in Figure 4, YW353 bound to gD-tagged human LgR5 expressed on stably transfected 293 cells with an affinity of 0.2 nM. Ch8El 1 bound to gD-tagged human LgR5 and gD-tagged mouse LgR5 expressed on stably transfected 293 cells with affinities of 0.4 nM and 0.2 nM, respectively. Hu8El lv2 bound to gD-tagged human LgR5, gD-tagged mouse LgR5, and gD-tagged rat LgR5 expressed on stably transfected 293 cells with affinities 0.3-0.7 nM, 0.5- 0.6 nM, and 2.4-2.8 nM, respectively. These Kd values were generally lower than those determined by BIAcore®.
I. Epitope Mapping
[0473] To determine the region of LgR5 bound by each antibody, 293 cells transiently transfected with gD epitope-tagged LgR5 with various N- and/or C-terminal deletions were stained with 10 μg/ml YW353, ch8El 1, hu8El lv2, 2H6, or 3G12 antibody; and binding was detected with R-Phycoerythrin conjugated goat anti-human antibody. Antibodies YW353, 8E11, 2H6, and 3G12 all bound to gD epitope-tagged full-length LgR5. Antibodies 2H6 and 3G12 bound to gD epitope-tagged LgR5324-s>07 (amino acids 324-907 of SEQ ID NO: 67). Antibodies YW353 and 8E11 did not bind to gD epitope-tagged LgR5324-s>07. Only antibody YW353 bound to gD epitope-tagged LgR522-i23 (amino acids 22-123 of SEQ ID NO: 67) with a C-terminal GPI anchor. Antibodies YW353 and 8E11 both bound to to gD epitope-tagged LgR522-323 (amino acids 22-323 of SEQ ID NO: 67) with a C-terminal GPI anchor, but antibodies 2H6 and 3G12 did not. Finally, none of the antibodies bound to gD epitope-tagged LgR5424-907 (amino acids 424-907 of SEQ ID NO: 67).
[0474] Figure 4 summarizes those results in the column titled "epitope region." As shown in that figure, antibody YW353 binds to an epitope in the region of amino acids 22 to 123 of SEQ ID NO: 67; antibody 8E11 and its humanized variants bind to an epitope in the region of amino acids 22 to 323 of SEQ ID NO: 67; and antibodies 2H6 and 3G12 bind to an epitope in the region of amino acids 324 to 423 of SEQ ID NO: 67. J. Production of Anti-LgR5 Antibody Drug Conjugates
[0475] For larger scale antibody production, antibodies were produced in CHO cells. Vectors coding for VL and VH were transfected into CHO cells and IgG was purified from cell culture media by protein A affinity chromatography.
Anti-Lg 5 Antibody MMAE Conjugates
[0476] Anti-LgR5 antibody-drug conjugates (ADCs) were produced by conjugating YW353 (IgGl heavy chain and kappa light chain sequences shown in SEQ ID NOs: 66 and 65, respectively), hu8El lv2 (IgGl heavy chain and kappa light chain sequences shown in SEQ ID NOs: 64 and 63, respectively), mu8El 1, ch8El 1, 2H6, ch2H6, 3G12, and ch3G12 to the drug- linker moiety MC-vc-PAB-MMAE, which is depicted herein. For convenience, the drug-linker moiety MC-vc-PAB-MMAE is sometimes referred to in these Examples and in the Figures as "vcMMAE" or "VCE." Prior to conjugation, the antibodies were partially reduced with TCEP using standard methods in accordance with the methodology described in WO 2004/010957 A2. The partially reduced antibodies were conjugated to the drug-linker moiety using standard methods in accordance with the methodology described, e.g., in Doronina et al. (2003) Nat. Biotechnol. 21 :778-784 and US 2005/0238649 Al . Briefly, the partially reduced antibodies were combined with the drug- linker moiety to allow conjugation of the drug-linker moiety to reduced cysteine residues of the antibody. The conjugation reactions were quenched, and the ADCs were purified. The drug load (average number of drug moieties per antibody) for each ADC was determined and was between 3.3 and 4.0 for the anti-LgR5 antibodies. The structure of an antibody-vcMMAE immunoconjugate is shown in Figure 35A (p = drug load).
Anti-LgR5 Antibody PNU Conjugates
[0477] Anti-LgR5 antibody-PNU drug conjugates (ADCs) were produced by conjugating YW353 Al 18C thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 78 and 65, respectively) or hu8El lv2 thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 75 and 63, respectively) to PNU drug-linker moieties. Prior to conjugation, the antibody was reduced with dithiothreitol (DTT) to remove blocking groups (e.g. cysteine) from the engineered cysteines of the thio-antibody. This process also reduces the interchain disulfide bonds of the antibody. The reduced antibody was purified to remove the released blocking groups and the interchain disulfides were reoxidized using dehydro- ascorbic acid (dhAA).
[0478] For antibody-drug conjugates comprising a val-cit linker and PNU, the intact antibody was combined with the drug-linker moiety MC-val-cit-PAB-spacer-PNU- 159682 ("val- cit" may also be referred to herein as "vc") to allow conjugation of the drug-linker moiety to the engineered cysteine residues of the antibody. The conjugation reaction was quenched by adding excess N-acetyl-cysteine to react with any free linker-drug moiety, and the ADC was purified. The drug load (average number of drug moieties per antibody) for the ADC was in the range of about 1.8 to 2. The structure of an antibody -vcPNU immunoconjugate is shown in Figure 35B (p = drug load).
[0479] For antibody drug conjugates comprising an acetal linker and PNU, the intact antibody was combined with the drug- linker moiety MC-acetal-PNU- 159682 to allow conjugation of the drug-linker moiety to the engineered cysteine residues of the antibody. The conjugation reaction was quenched by adding excess N-acetyl-cysteine to react with any free linker-drug moiety, and the ADC was purified. The drug load (average number of drug moieties per antibody) for the ADC was about 1.8 to 2. The structure of an antibody-acetal-PNU immunoconjugate is shown in Figure 35C (p = drug load).
[0480] For antibody drug conjugates comprising a noncleavable linker and PNU, the intact antibody was combined with the drug-linker moiety MC-PNU-159682 to allow conjugation of the drug-linker moiety to the engineered cysteine residues of the antibody. The conjugation reaction was quenched by adding excess N-acetyl-cysteine to react with any free linker-drug moiety, and the ADC was purified. The drug load (average number of drug moieties per antibody) for the ADC was about 1.8 to 2. The structure of an antibody-PNU immunoconjugate is shown in Figure 35D (p = drug load).
Anti-LgR5 Antibody PBD Conjugate
[0481] Anti-LgR5 antibody-PBD drug conjugates (ADCs) were produced by conjugating YW353 Al 18C thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 78 and 65, respectively) or hu8El lv2 thioMab (IgGl Al 18C heavy chain and kappa light chain sequences shown in SEQ ID NOs: 75 and 63, respectively) to PBD drug-linker moieties. Prior to conjugation, the antibody was reduced with dithiothreitol (DTT) to remove blocking groups (e.g. cysteine) from the engineered cysteines of the thio-antibody. This process also reduces the interchain disulfide bonds of the antibody. The reduced antibody was purified to remove the released blocking groups and the interchain disulfides were reoxidized using dehydro-ascorbic acid (dhAA).
[0482] For antibody-drug conjugates comprising a val-cit linker and PBD, the intact antibody was combined with the drug-linker moiety MC-val-cit-PAB-PBD ("val-cit" may also be referred to herein as "vc") to allow conjugation of the drug-linker moiety to the engineered cysteine residues of the antibody. The conjugation reaction was quenched by adding excess N-acetyl-cysteine to react with any free linker-drug moiety, and the ADC was purified. The drug load (average number of drug moieties per antibody) for the ADC was in the range of about 1.8 to 2. The structure of an antibody- vcPBD is shown in Figure 35E (p = drug load).
K. Toxicity of Anti-LgR5 Antibody Drug Conjugate in Rats
[0483] In order to evaluate potential toxicity of anti-LgR5 antibody 8E11.v2-vcMMAE, six male Sprague-Dawley rats were administered 12 mg/kg 8E11.v2-vcMMAE once per week for four weeks, and six male Sprague-Dawley rats were administered 20 mg/kg 8E11.v2-vcMMAE once per week for two weeks. Four male Sprague-Dawley control rats were administered vehicle alone once per week for two weeks, and four male Sprague-Dawley control rats were administered vehicle alone once per week for four weeks. The rats in the two-week groups were necropsied on day 12 and the rats in the four-week groups were necropsied on day 26.
[0484] Briefly, all rats administered 8E11.v2-vcMMAE showed reduced red cell mass (red blood cells, hematocrit, hemoglobin, and reticulocytes), neutrophils, and platelets compared to control rats. Rats administered 20 mg/kg 8E1 l.v2-vcMMAE also showed reduced white blood cell count and lymphocytes compared to control rats. In addition, all rats administered 8E11.v2- vcMMAE showed increases in liver enzymes ALT, AST, ALP, and GGT, and increased total billirubin compared to control rats.
[0485] Histopathologic analysis of tissues collected from the study showed cellular depletion of lymphoid and hemopoietic tissues in rats administered 8E1 l.v2-vcMMAE, as well as increased mitotic figures in rapidly dividing tissues. Rats administered 20 mg/kg 8El l .v2- vcMMAE also showed minimal liver necrosis, minimal increased mitotic figures and single cell cryptal necrosis/apoptosis, and minimal mild alveolar histiocytosis and type II cell hyperplasia.
[0486] The pathology changes observed were similar to pathology observed in rats administered other vcMMAE antibody-drug conjugates. There did not appear to be any evidence of LgR5 antigen-dependent toxicity in the GI tract.
L. Efficacy of anti-LgR5 Antibody Drug Conjugates in LoVo Colon Cancer Cell Line Xenograft
[0487] The efficacy of the anti-LgR5 ADCs was investigated using a LoVo colon cancer xenograft model. LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229). LgR5 is highly expressed in LoVo cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Five million LoVo cells (LgR5 -positive by FACS using YW353) in HBSS-matrigel were injected
subcutaneously into the dorsal flank of NCR nude mice and six days post- inoculation mice were given a single intravenous injection of 5 mg/kg murine anti-gpl20-vcMMAE control antibody- drug conjugate, human anti-gD 5B6-vcMMAE control antibody-drug conjugate, huYW353- vcMMAE antibody-drug conjugate, mu8El 1-vcMMAE antibody-drug conjugate, mu2H6- vcMMAE antibody-drug conjugate, or mu3G12-vcMMAE antibody-drug conjugate; or with vehicle (PBS) alone. The presence of the antibodies was confirmed by PK bleeds one day post injection.
[0488] As shown in Figure 13, substantial tumor growth inhibition was achieved with all four anti-LgPv5 antibody-drug conjugates tested.
M. Efficacy of anti-LgR5 Antibody Drug Conjugates in D5124 Pancreatic Cancer Xenograft
[0489] The efficacy of the anti-LgR5 ADCs was investigated using a D5124 pancreatic cancer xenograft model, which has a β-catenin mutation. LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Twenty to 30 mm3 D5124 tumor fragments (LgR5-positive by FACS using YW353 and 8E11) were implanted subcutaneously into the dorsal flank area of NCR nude mice and 18 days post-transplantation the mice were given a single intravenous injection of 6 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate, 3 mg/kg or 6 mg/kg huYW353-vcMMAE antibody-drug conjugate, 3 mg/kg or 6 mg/kg ch8El 1-vcMMAE antibody- drug conjugate, 3 mg/kg or 6 mg/kg ch2H6-vcMMAE antibody-drug conjugate, or 3 mg/kg or 6 mg/kg ch3G12-vcMMAE antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5; "HB#8" in Figure 14) alone. The presence of the antibodies was confirmed by PK bleeds one and eight days post injection.
[0490] As shown in Figure 14, substantial tumor growth inhibition was achieved at both doses ofhuYW353-vcMMAE, ch8El 1-vcMMAE, and ch3G12-vcMMAE. Substantial tumor growth inhibition was also achieved at 6 mg/kg ch2H6-vcMMAE.
[0491] The efficacy of various doses of YW353-vcMMAE was then tested in the D5124 pancreatic cancer xenograft model described above. Twenty to 30 mm3 D5124 tumor fragments (LgR5-positive by FACS using YW353 and 8E11) were implanted subcutaneously into the dorsal flank area of NCR nude mice and 23 days post-transplantation mice were given a single intravenous injection of 0.5 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, or 12 mg/kg huYW353- vcMMAE antibody-drug conjugate; or 12 mg/kg huYW353; or 7.2 mg/kg or 14.4 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate; or vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5; "HB#8" in Figure 15) alone. The presence of the antibodies was confirmed by PK bleeds one, four, and 14 days post injection. [0492] As shown in Figure 15, substantial tumor growth inhibition was achieved at 3 mg/kg huYW353-vcMMAE, and almost complete tumor growth inhibition was achieved at 6 mg/kg and 12 mg/kg huYW353-vcMMAE.
N. Efficacy of mu8Ell and mu8Ell-vcMMAE in Murine Intestinal
Tumorigenesis Model
[0493] The efficacy of mu8El 1 and mu8El 1-vcMMAE was investigated in a murine intestinal tumorigenesis model, APCmin/+; LSL-KrasG12D; VillinCre ("AKV mice"). AKV mice are the result of crossing APCmin/+; VillinCre ("AV mice") with LSL-KrasG12D mice. While AV mice develop 0-4 adenomas in the colon and 100 adenomas in the small intestine, AKV mice develop an average of 140 adenomas in the colon and 100 adenomas in the small intestine (data not shown). LgR5 mRNA expression was measured in normal tissue and polyps of AV and AKV mice, and LgR5 was found to be significantly overexpressed in polyps from both the small intestine and colon in AKV mice (Figure 16). To visualize expression of LgR5 in the small intestine and colon of AKV mice, AKV mice were crossed with mice having a cassette containing an enhanced green fluorescent protein (EGFP) linked in frame to human diphtheria toxin receptor cDNA located in the Lgr5 gene. See Tian et al., Nature, 478: 255-260 (2011). The area of EGFP expression in small intestine polyps and large intestine polyps were visualized in the AKV Lgr5mRJ+ mice. The results of that experiment are shown in Figure 20. It was found that LgR5 expression did not significantly differ between small intestine polyps and colon polyps, and further, there was no correlation between tumor size and LgR5+ area. The mean LgR5+ area of the tumors was 8%, but varied widely between tumors. Preliminary results show that the LgR5+ area in colorectal tumors of humans may be significantly higher than in mice, suggesting that the therapeutic index of anti-LgR5 ADC therapy in humans may be even better than in mice.
[0494] To assess Lgr5 expression differences between intestinal crypts and tumors within these animals, intestinal tracts from AKV Lgr5mRJ+ mice were obtained and direct visualization of GFP was performed on tissue sections. Tumors and normal crypts were thereafter quantitated for the intensity of each GFP postive pixel. To determine relative GFP intensity, the intensity score is divided by the GFP+ area. As shown in Figure 23, LgR5 expression is higher in tumors than in intestinal crypts in of AKV Lgr5mRJ+ mice.
[0495] An overall survival study was carried out with AKV mice to determine whether anti-LgR5 antibody can increase survival. Ten AKV mice were administered 15 mg/kg mu8El 1- MC-vc-PAB-MMAE; six AKV mice were administered 15 mg/kg mu8El 1, and 9 mice were administered 15 mg/kg control antibody anti-gpl20-MC-vc-MMAE. The antibodies and ADCs were administered weekly beginning at 6 weeks of age until the mice either died or were deemed moribund (as determined by standard criteria related to signs of severe lethargy, weight loss and anemia), in which case the mice were sacrificed.
[0496] The results of the overall survival study are shown in Figure 17. The untreated control data represents historical survival rates for 22 AKV mice. In that experiment, AKV mice administered either mu8El 1 or mu8El 1-MC-vc-PAB-MMAE had significantly longer survival times than untreated AKV mice or AKV mice administered a control ADC. Based on these results, additional animals were evaluated as described above. The results of that experiment are shown in Figure 19. In the larger experiment, AKV mice administered mu8El 1-MC-vc-PAB- MMAE had significantly longer survival times than untreated AKV mice or AKV mice administered a control ADC, and also had a longer survival time than mice administered mu8El 1. At the time of death, the AKV mice administered control ADC and anti-LgR5-ADC had similar numbers and sizes of polyps, suggesting that anti-LgR5-ADC may slow the disease and thereby extend survival.
[0497] In order to determine whether anti-LgR5 antibody and/or anti-LgR5 ADC caused apoptosis in the gastrointestinal tumors of AKV mice, the presence of cleaved caspase 3 was measured as a function of tumor area. Formalin fixed paraffin embedded (FFPE) small intestine and colon tissue collected at time of death were subjected to immunohistochemical staining for cleaved caspase 3 (Cell Signaling Technologies; Danvers, MA, cat# 9661L). Images of the stained slides were acquired by the Olympus Nanozoomer automated slide scanning platform and manually identified tumor-specific areas were analyzed in the Matlab software package
(Mathworks, Natick, MA). Postively stained area and total tumor area were quantified. Although rare, cleaved caspase 3 was visible in the crypts following treatment with anti-LgR5 ADC, but was not observed in control ADC treated animals, suggesting that LgR5- expressing cells are being specifically targeted.
[0498] The results of that experiment are shown in Figure 18. Both anti-LgR5 antibody and anti-LgR5 ADC administration caused a statistically significant increase in the percentage of tumor area in AKV mice that was positive for the presence of cleaved caspase 3, compared to control ADC-treated AKV mice.
[0499] In order to demonstrate that the apoptosis is occurring in LgR5+ cells, AKV Lgr5mRJ+ mice were administered 15 mg/kg mu8El 1-MC-vc-PAB-MMAE or 15 mg/kg control antibody anti-gpl20-MC-vc-MMAE (day 1). On day 4, the mice were sacrificed and tumors from the gastrointestinal tract (small and large intestine) were visualized for expression of EGFP and cleaved caspase 3. The amount of CC3+GFP+ area per total cellular area was then determined. As shown in Figure 21 A, anti-LgR5-ADC treated mice tended to have a greater proportion of CC3+GFP+ area than control treated mice, although not stastically significant in that experiment. Figure 21 B shows exemplary immunohistochemical staining from control ADC treated mice (left panels) and anti-LgR5-ADC treated mice (right panels). These results demonstrate a trend towards increased apoptosis in LgR5 -expressing cells upon anti-LgR5-ADC treatment.
[0500] To determine whether cell proliferation of LgR5 expressing cells is affected by anti-LgR5 treatment, the Ki67+ area per cellular area was measured in the EGFP+ cell population and EGFP- cell population from the gastrointestinal tract of control-ADC treated and anti-LgR5- ADC treated AKV Lgr5mRJ+ mice. Ki67 is a nuclear protein associated with cellular
proliferation. Ki67 antibodies for immunohistochemical staining were obtained from Neomarker. The results of that experiment are shown in Figure 22. There was significantly less proliferating cell area, as measured by Ki67 staining, in tumors from AKV Lgr5mRJ+ mice treated with anti- LgR5-ADC than control ADC, in both the GFP+ and GFP- cell populations. These results suggest that anti-LgR5-ADC reduces proliferation and/or inhibits formation of proliferative progeny.
O. Efficacy of anti-LgR5 Antibody Drug Conjugates in D5124 Pancreatic Cancer Xenograft
[0501] The efficacy of the anti-LgR5 ADCs was investigated using a D5124 pancreatic cancer xenograft model, which has a β-catenin mutation. LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Twenty to 30 mm3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 22 days post-transplantation the mice were given a single intravenous injection of 2.62 mg/kg or 5.23 mg/kg huYW353-vcMMAE antibody-drug conjugate, 3 mg/kg or 6 mg/kg ch8El 1-vcMMAE antibody-drug conjugate, or 3 mg/kg or 6 mg/kg hu8El 1V2-VCMMAE antibody-drug conjugate; or 6 mg/kg humanized anti-gD 5B6-vcMMAE control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5) alone (n = 8 mice per group). The presence of the antibodies was confirmed by PK bleeds one and eight days post injection.
[0502] As shown in Figure 24, substantial tumor growth inhibition was achieved at both doses of huYW353-vcMMAE, both doses of hu8El 1V2-VCMMAE, and 6 mg/kg ch8El lv2- vcMMAE.
[0503] The efficacy of various doses of hu8El 1V2-VCMMAE antibody-drug conjugate was then tested in the D5124 pancreatic cancer xenograft model described above. Twenty to 30 mm3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 26 days post-transplantation mice were given a single intravenous injection of 0.5 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, or 12 mg/kg hu8El 1V2-VCMMAE antibody-drug conjugate; or 15 mg/kg hu8El lv2; or 6.37 mg/kg or 12.73 mg/kg human anti-gD 5B6-vcMMAE control antibody-drug conjugate; or 15 mg/kg humanized anti-gD control antibody; or vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5) alone (n = 8 mice per group).
[0504] As shown in Figure 25, substantial tumor growth inhibition was achieved at 3 mg/kg and 6 mg/kg hu8El 1V2-VCMMAE, and tumor regression was achieved at 12 mg/kg hu8El lv2-vcMMAE.
P. Efficacy of anti-LgR5 Antibody Drug Conjugates in LoVoXl.l Colon Cancer Cell Line Xenograft
[0505] The efficacy of the anti-Lg 5 ADCs was investigated using a LoVo colon cancer xenograft model. LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229), and subline LoVoXl.l was derived for optimal growth in mice. Briefly, mice were inoculated with LoVo cells. Once tumors were growing, a tumor with a desirable growth rate was harvested. The tumor was minced and grown in culture to establish cell line LoVoXl .l . LgR5 is expressed in LoVoXl.l cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Five million LoVoXl. l cells in HBSS-matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCIDmice and 13 days post-inoculation mice were given a single intravenous injection of 3 mg/kg or 6 mg/kg huYW353-vcMMAE antibody-drug conjugate, 3 mg/kg or 6 mg/kg hu8El 1V2-VCMMAE antibody-drug conjugate; 15 mg/kg hu8El lv2 antibody; 15 mg/kg humanized anti-gD 5B6 control antibody; or 6 mg/kg humanized anti-gD 5B6-vcMMAE control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5) alone (n = 10 mice per group).
[0506] As shown in Figure 26, substantial tumor growth inhibition was achieved at 6 mg/kg hu8El 1V2-VCMMAE and 6 mg/kg huYW353-vcMMAE.
[0507] The efficacy of various doses of hu8El 1V2-VCMMAE antibody-drug conjugate was then tested in the LoVoXl. l colorectal adenocarcinoma xenograft model described above. Five million LoVoXl .l cells in HBSS-matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCID mice and 10 days post- inoculation mice were given a single intravenous injection of 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, or 15 mg/kg hu8El 1V2-VCMMAE antibody- drug conjugate; or 15 mg/kg hu8El lv2; or 6 mg/kg or 15 mg/kg humanized anti-gD 5B6- vcMMAE control antibody-drug conjugate; or vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5) alone (n = 9 mice per group). The presence of the antibodies was confirmed by PK bleeds one, seven, and 14 days post injection. [0508] As shown in Figure 27, substantial tumor growth inhibition was achieved at 6 mg/kg, 10 mg/kg, and 15 mg/kg hu8El 1V2-VCMMAE.
Q. Efficacy of anti-LgR5 Antibody Drug Conjugates in D5124 Pancreatic Cancer Xenograft
[0509] The efficacy of the anti-LgR5 ADCs was investigated using a D5124 pancreatic cancer xenograft model, which has a β-catenin mutation. LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Twenty to 30 mm3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 26 days post-transplantation the mice were given a single intravenous injection of 1 mg/kg huYW353-vcMMAE antibody-drug conjugate, 1 mg/kg huYW353-vcPNU antibody-drug conjugate, 1 mg/kg huYW353 -PNU antibody-drug conjugate, 1 mg/kg huYW353-acetal-PNU antibody-drug conjugate; or 1 mg/kg humanized anti-gD 5B6-vcPNU control antibody-drug conjugate, 1 mg/kg humanized anti-gD 5B6-PNU control antibody-drug conjugate, or 1 mg/kg humanized anti-gD 5B6-acetal-PNU control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 niM sucrose, 0.02% Tween 20, pH5.5) alone (n = 9 mice per group). The presence of the antibodies was confirmed by PK bleeds three, seven, and 14 days post injection.
[0510] As shown in Figure 28, substantial tumor growth inhibition was achieved with 1 mg/kg huYW353-vcMMAE and 1 mg/kg huYW353-acetal-PNU, and almost complete tumor growth inhibition was achieved with 1 mg/kg huYW353-vcPNU. One of the mice treated with 1 mg/kg huYW353-acetal-PNU showed a complete response (i.e., the mouse had no detectable tumor at the end of the study). In addition, two of the mice treated with 1 mg/kg huYW353- vcPNU showed a partial response (i.e., >50% reduction of the initial tumor volume at day 0).
R. Efficacy of anti-LgR5 Antibody Drug Conjugates in D5124 Pancreatic Cancer Xenograft
[0511] The efficacy of various doses of hu8El lv2 antibody-drug conjugate was tested in the D5124 pancreatic cancer xenograft model. Twenty to 30 mm3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 22 days posttransplantation mice were given a single intravenous injection of 2 mg/kg hu8El 1V2-VCMMAE antibody-drug conjugate; or 2 mg/kg hu8El 1V2-VCPNU; or 2 mg/kg or 10 mg/kg hu8El lv2- acetal-PNU; or 2 mg/kg or 10 mg/kg hu8El Iv2-PNU; 2 mg/kg humanized anti-gD 5B6-vcPNU control antibody-drug conjugate, 10 mg/kg humanized anti-gD 5B6-acetal-PNU control antibody drug conjugate, or 10 mg/kg humanized anti-gD 5B6-PNU control antibody drug conjugate; or vehicle (histidine buffer: 20mM histidine acetate, 240 niM sucrose, 0.02% Tween 20, pH5.5) alone (n = 8 mice per group).
[0512] As shown in Figure 29, substantial tumor growth inhibition was achieved at 2 mg/kg hu8El lv2-acetal-PNU, and almost complete tumor growth inhibition was achieved at 10 mg/kg hu8El lv2-acetal-PNU, 2 mg/kg hu8El 1V2-VCPNU, and 2 mg/kg and 10 mg/kg hu8El lv2-PNU.
S. Efficacy of anti-LgR5 Antibody Drug Conjugates in LoVo Colon Cancer Cell Line Xenograft
[0513] The efficacy of the anti-LgR5 ADCs was investigated using a LoVo colon cancer xenograft model. LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229), and subline LoVoXl.l was derived for optimal growth in mice. Briefly, mice were inoculated with LoVo cells. Once tumors were growing, a tumor with a desirable growth rate was harvested. The tumor was minced and grown in culture to establish cell line LoVoXl .l . LgR5 is expressed in LoVoXl.l cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Five million LoVoXl. l cells in HBSS-matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCID mice and 11 days post-inoculation mice were given a single intravenous injection of 2 mg/kg hu8El lv2-vcMMAE antibody-drug conjugate, 2 mg/kg hu8El 1V2-VCPNU, 2 mg/kg hu8El lv2- acetal-PNU, or 2 mg/kg hu8El Iv2-PNU; or 2 mg/kg humanized anti-gD 5B6-vcPNU control antibody-drug conjugate, 2 mg/kg humanized anti-gD 5B6-acetal-PNU control antibody drug conjugate, or 2 mg/kg humanized anti-gD 5B6-PNU control antibody drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 niM sucrose, 0.02% Tween 20, pH5.5) alone (n = 10 mice per group). The presence of the antibodies was confirmed by PK bleeds one, seven, and 14 days post injection.
[0514] As shown in Figure 30, in this experiment, certain control antibodies appeared to show substantial tumor growth inhibition {see 2 mg/kg humanized anti-gD 5B6-vcPNU and 2 mg/kg humanized anti-gD 5B6-acetal-PNU control antibody drug conjugate).
[0515] Because of the apparent non-specific effects of the control antibody in the prior experiment, the LoVoXl .l colorectal adenocarcinoma model was tested with a different control antibody-drug conjugate (that binds to a different antigen not expressed on the surface of LoVo cells), and with administration of an excess of anti-gD control antibody to block possible nonspecific antibody binding sites on the tumor cells. Five million LoVoXl.l cells in HBSS- matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCID mice and seven days post-inoculation mice were given a single intravenous injection of 10 mg/kg hu8El lv2-acetal- PNU antibody-drug conjugate; or 10 mg/kg thioAb-acetal-PNU control antibody-drug conjugate; or vehicle (50 mM sodium phosphate, 240 mM sucrose, 0.02% Tween20, pH 7) alone (n = 5 mice per group). In addition, the mice were administered 30 mg/kg humanized anti-gD control antibody i.p. once per week until the end of the study, beginning on the same day as, but 4 hours prior to, administration of the test antibodies.
[0516] As shown in Figure 31, substantial tumor growth inhibition was achieved with 10 mg/kg hu8El lv2-acetal-PNU and the control antibody did not inhibit tumor growth.
T. Efficacy of anti-LgR5 Antibody Drug Conjugates in D5124 Pancreatic Cancer Xenograft
[0517] The efficacy of the YW353 anti-LgR5 ADCs was investigated using the D5124 pancreatic cancer xenograft model, which has a β-catenin mutation. LgR5 is highly expressed in D5124 tumors, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Twenty to 30 mm3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 26 days posttransplantation the mice were given a single intravenous injection of 1 mg/kg huYW353- vcMMAE antibody-drug conjugate, 1 mg/kg huYW353-vcPBD antibody-drug conjugate; or 1 mg/kg humanized anti-gD 5B6-vcPBD control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5) alone (n = 9 mice per group). The presence of the antibodies was confirmed by PK bleeds one, seven, and fourteen days post injection.
[0518] As shown in Figure 32, substantial tumor growth inhibition was achieved with 1 mg/kg huYW353-vcMMAE and 1 mg/kg huYW353-vcPBD. One of the mice treated with 1 mg/kg huYW353-vcPBD showed a complete response (i.e., the mouse had no detectable tumor at the end of the study).
[0519] In a separate experiment, efficacy of the hu8El lv2 anti-LgR5 ADCs was investigated using the D5124 pancreatic cancer xenograft model. Twenty to 30 mm3 D5124 tumor fragments were implanted subcutaneously into the dorsal flank area of NCR nude mice and 22 days post-transplantation the mice were given a single intravenous injection of 2 mg/kg hu8El lv2-vcMMAE antibody-drug conjugate, 2 mg/kg hu8El lv2-vcPBD antibody-drug conjugate; or 2 mg/kg humanized anti-gD 5B6-vcPBD control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 mM sucrose, 0.02% Tween 20, pH5.5) alone (n= 8 mice per group). [0520] As shown in Figure 33, substantial tumor growth inhibition was achieved with 2 mg/kg hu8El 1V2-VCMMAE, and tumor regression was achieved with 2 mg/kg hu8El lv2- vcPBD.
U. Efficacy of anti-LgR5 Antibody Drug Conjugates in LoVoXl.l Colon Cancer Cell Line Xenograft
[0521] The efficacy of the anti-Lg 5 ADCs was investigated using a LoVoXl .l colon cancer xenograft model. LoVo cells are a colorectal adenocarcinoma cell line with an APC mutation (ATCC #CCL 229), and subline LoVoXl .l was derived for optimal growth in mice. Briefly, mice were inoculated with LoVo cells. Once tumors were growing, a tumor with a desirable growth rate was harvested. The tumor was minced and grown in culture to establish cell line LoVoXl .l . LgR5 is expressed in LoVoXl. l cells, and was confirmed by microarray, TaqMan® quantitative RT-PCR, in situ hybridization, FACS, and Western blot. Five million LoVoXl .l cells in HBSS-matrigel were injected subcutaneously into the dorsal flank of C.B-17 SCID mice and 11 days post-inoculation mice were given a single intravenous injection of 2 mg/kg hu8El 1V2-VCMMAE antibody-drug conjugate, 2 mg/kg hu8El 1V2-VCPBD antibody-drug conjugate; or 2 mg/kg humanized anti-gD 5B6-vcPBD control antibody-drug conjugate; or with vehicle (histidine buffer: 20mM histidine acetate, 240 niM sucrose, 0.02% Tween 20, pH5.5) alone (n = 10 mice per group). The presence of the antibodies was confirmed by PK bleeds one, seven, and 14 days post injection.
[0522] As shown in Figure 34, complete tumor growth inhibition was achieved with 2 mg/kg hu8El 1V2-VCPBD.
[0523] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.
Table of Sequences
F 3
Hu8Ell.v4 LC
FR3
Hu8Ell.v7 LC
FR3
Hu8Ell.v8 LC
FR3
Hu8Ell LC FR4 FGQGTKVEIK R
Hu8El 1 heavy EVQLVQSGAE VKKPGASVKV SCKAS
chain (HC)
frameworkl (FR1)
Hu8Ell HC FR2 WVRQAPGQGL EWIG
Hu8Ell.vl HC RVTITSDTST STVYLELSSL RSEDTAVYYC AR
FR3
Hu8Ell.v3 HC
FR3
Hu8Ell.v2HC RATFTSDTST STVYLELSSL RSEDTAVYYC AR
FR3
Hu8Ell.v4HC
FR3
Hu8Ell.v5 HC RVTITRDTST STAYLELSSL RSEDTAVYYC AR
FR3
Hu8Ell.v7 HC
FR3
Hu8Ell.v6 HC RV I AD ST STAYLELSSL RSEDTAVYYC AR
FR3
Hu8Ell.v8 HC
FR3
Hu8Ell HC FR4 WGQGTLVTVS S
mu3G12HVRLl RSSQSLVHSN GNTYLQ
mu3G12HVRL2 KVSNRFS
mu3G12HVRL3 SQSTHFPYT
mu3G12HVRHl VD F SYWMH
mu3G12HVRH2 EINPSNGRTN YIEKFKN
mu3G12HVRH3 GWYFDV
mu2H6HVRLl KSSQSLLNSG NQKNYLT
mu2H6 HVR L2 WAS RES
mu2H6 HVR L3 QNDYSFPFT
mu2H6HVRHl GYSFTGYTMN
mu2H6 HVR H2 LINCYNGGTN YNQKFKG
mu2H6 HVR H3 GGSTMITPRF AY
YW353 HVR LI RASQDVSTAV A
YW353 HVR L2 SASFLYS
YW353 HVR L3 QQSYTTPPT
YW353 HVR HI GFTFTSYSIS
YW353 HVR H2 EIYPPGGYTD YADSVKG
YW353 HVR H3 ARLFFDY
hu8Ell.v2 light DIVMTQSPDS LAVSLGERAT INCRASESVD NYGNSFMHWY chain QQKPGQPPKL LIYLASNLES GVPDRFSGSG SGTDFTLTIS
SLQAEDVAVY YCQQNYEDPF TFGQGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASWCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
I hu8El l .v2 heavy EVQLVQSGAE VKKPGASVKV SCKASGYTFS AYWIEWVRQA chain PGQGLEWIGE ILPGSDSTDY NEKFKVRATF TSDTSTSTVY
LELSSLRSED TAVYYCARGG HYGSLDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSWTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVWDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRWSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
YW353 light DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP chain GKAPKLLIYS ASFLYSGVPS RFSGSGSGTD FTLTISSLQP
EDFATYYCQQ SYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SWCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
YW353 heavy EVQLVESGGG LVQPGGSLRL SCAASGFTFT SYSISWVRQA chain PGKGLEWVAE IYPPGGYTDY ADSVKGRFTI SADTSKNTAY
LQMNSLRAED TAVYYCAKAR LFFDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSWTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VWDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR WSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK
I Human Lg 5 MDTSRLGVLL SLPVLLQLAT GGSSPRSGVL LRGCPTHCHC precursor; EPDGRMLLRV DCSDLGLSEL PSNLSVFTSY LDLSMNNISQ LGR5_human LLPNPLPSLR FLEELRLAGN ALTYIPKGAF TGLYSLKVLM NP_003658; LQNNQLRHVP TEALQNLRSL QSLRLDANHI SYVPPSCFSG signal sequence LHSLRHLWLD DNALTEIPVQ AFRSLSALQA MTLALNKIHH amino acids 1-21 IPDYAFGNLS SLWLHLHNN RIHSLGKKCF DGLHSLETLD
LNYNNLDEFP TAIRTLSNLK ELGFHSNNIR SIPEKAFVGN PSLITIHFYD NPIQFVGRSA FQHLPELRTL TLNGASQITE FPDLTGTANL ESLTLTGAQI SSLPQTVCNQ LPNLQVLDLS YNLLEDLPSF SVCQKLQKID LRHNEIYEIK VDTFQQLLSL RSLNLAWNKI AIIHPNAFST LPSLIKLDLS SNLLSSFPIT GLHGLTHLKL TGNHALQSLI SSENFPELKV IEMPYAYQCC AFGVCENAYK ISNQWNKGDN SSMDDLHKKD AGMFQAQDER DLEDFLLDFE EDLKALHSVQ CSPSPGPFKP CEHLLDGWLI RIGVWTIAVL ALTCNALVTS TVFRSPLYIS PIKLLIGVIA AVNMLTGVSS AVLAGVDAFT FGSFARHGAW WENGVGCHVI GFLSIFASES SVFLLTLAAL ERGFSVKYSA KFETKAPFSS LKVI ILLCAL LALTMAAVPL LGGSKYGASP LCLPLPFGEP STMGYMVALI LLNSLCFLMM TIAYTKLYCN LDKGDLENIW DCSMVKHIAL LLFTNCILNC PVAFLSFSSL INLTFISPEV IKFILLVWP LPACLNPLLY ILFNPHFKED LVSLRKQTYV WTRSKHPSLM SINSDDVEKQ SCDSTQALVT FTSSSITYDL PPSSVPSPAY PVTESCHLSS VAFVPCL
I Human Lg 5 GSSPRSGVL LRGCPTHCHC EPDGRMLLRV DCSDLGLSEL mature, without PSNLSVFTSY LDLSMNNISQ LLPNPLPSLR FLEELRLAGN signal sequence; ALTYIPKGAF TGLYSLKVLM LQNNQLRHVP TEALQNLRSL amino acids 22 to QSLRLDANHI SYVPPSCFSG LHSLRHLWLD DNALTEIPVQ 907 AFRSLSALQA MTLALNKIHH IPDYAFGNLS SLWLHLHNN
RIHSLGKKCF DGLHSLETLD LNYNNLDEFP TAIRTLSNLK ELGFHSNNIR SIPEKAFVGN PSLITIHFYD NPIQFVGRSA FQHLPELRTL TLNGASQITE FPDLTGTANL ESLTLTGAQI SSLPQTVCNQ LPNLQVLDLS YNLLEDLPSF SVCQKLQKID LRHNEIYEIK VDTFQQLLSL RSLNLAWNKI AIIHPNAFST LPSLIKLDLS SNLLSSFPIT GLHGLTHLKL TGNHALQSLI SSENFPELKV IEMPYAYQCC AFGVCENAYK ISNQWNKGDN SSMDDLHKKD AGMFQAQDER DLEDFLLDFE EDLKALHSVQ CSPSPGPFKP CEHLLDGWLI RIGVWTIAVL ALTCNALVTS TVFRSPLYIS PIKLLIGVIA AVNMLTGVSS AVLAGVDAFT FGSFARHGAW WENGVGCHVI GFLSIFASES SVFLLTLAAL ERGFSVKYSA KFETKAPFSS LKVI ILLCAL LALTMAAVPL LGGSKYGASP LCLPLPFGEP STMGYMVALI LLNSLCFLMM TIAYTKLYCN LDKGDLENIW DCSMVKHIAL LLFTNCILNC PVAFLSFSSL INLTFISPEV IKFILLVWP LPACLNPLLY ILFNPHFKED LVSLRKQTYV WTRSKHPSLM SINSDDVEKQ SCDSTQALVT FTSSSITYDL PPSSVPSPAY PVTESCHLSS VAFVPCL I Cynomolgus GCPTHCHCEP DGRMLLRVDC SDLGLSELPS NLSVFTSYLD monkey LgR5 LSMNNISQLL PNPLPSLRFL EELRLAGNAL TYIPKGAFTG partial sequence, LYSLKVLMLQ NNQLRQVPTE ALQNLRSLQS LRLDANHISY predicted; VPPSCFSGLH SLRHLWLDDN ALTEIPVQAF RSLSALQAMT predicted to LALNKIHHIP DYAFGNLSSL WLHLHNNRI HSLGKKCFDG correspond to LHSLETLDLN YNNLDEFPTA IRTLSNLKEL GFHSNNIRSI amino acids 33 to PEKAFVGNPS LITIHFYDNP IQFVGRSAFQ HLPELRTLTL 907 of full-length NGASQITEFP DLTGTANLES LTLTGAQISS LPQTVCNQLP precursor NLQVLDLSYN LLEDLPSFSV CQKLQKIDLR HNEIYEIKVD
TFQQLLSLRS LNLAWNKIAI IHPNAFSTLP SLIKLDLSSN LLSSFPVTGL HGLTHLKLTG NHALQSLISS ENFPELKI IE MPYAYQCCAF GVCENAYKIS NQWNKGDNSS MDDLHKKDAG MFQVQDERDL EDFLLDFEED LKALHSVQCS PSPGPFKPCE HLLDGWLIRI GVWTIAVLAL TCNALVTSTV FRSPLYISPI KLLIGVIAW NMLTGVSSAV LAGVDAFTFG SFARHGAWWE NGVGCQVIGF LSIFASESSV FLLTLAALER GFSVKCSAKF ETKAPFSSLK VI ILLCALLA LTMAAVPLLG GSEYGASPLC LPLPFGEPST TGYMVALILL NSLCFLMMTI AYTKLYCNLD KGDLENIWDC SMVKHIALLL FTNCILYCPV AFLSFSSLLN LTFISPEVIK FILLVIVPLP ACLNPLLYIL FNPHFKEDLV SLGKQTYFWT RSKHPSLMSI NSDDVEKQSC DSTQALVTFT SSSIAYDLPP SSVPSPAYPV TESCHLSSVA FVPCL
I Rat LgR5 MDTSRVRMLL SLLALLQLVA AGSPPRPDTM PRGCPSYCHC precursor; ELDGRMLLRV DCSDLGLSEL PSNLSVFTSY LDLSMNNISQ LGR5_rat LPASLLHRLR FLEELRLAGN ALTHIPKGAF AGLHSLKVLM NP_001100254; LQNNQLRQVP EEALQNLRSL QSLRLDANHI SYVPPSCFSG signal sequence LHSLRHLWLD DNALTDVPVQ AFRSLSALQA MTLALNKIHH amino acids 1-21 IADHAFGNLS SLWLHLHNN RIHSLGKKCF DGLHSLETLD LNYNNLDEFP TAIKTLSNLK ELGFHSNNIR SIPERAFVGN PSLITIHFYD NPIQFVGISA FQHLPELRTL TLNGASQITE FPDLTGTATL ESLTLTGAKI SSLPQTVCDQ LPNLQVLDLS YNLLEDLPSL SGCQKLQKID LRHNEIYEIK GGTFQQLFNL RSLNLARNKI AIIHPNAFST LPSLIKLDLS SNLLSSFPVT GLHGLTHLKL TGNRALQSLI PSANFPELKI IEMPYAYQCC AFGGCENVYK IPNQWNKDDS SSVDDLRKKD AGLFQVQDER DLEDFLLDFE EDLKVLHSVQ CSPPPGPFKP CEHLFGSWLI RIGVWTTAVL ALSCNALVAF TVFRTPLYIS SIKLLIGVIA WDILMGVSS AILAWDTFT FGSFAQHGAW WEGGIGCQIV GFLSIFASES SVFLLTLAAL ERGFSVKCSS KFEMKAPLSS LKAI ILLCVL LAL IATVPL LGGSEYNASP LCLPLPFGEP S GYMVALV LLNSLCFLIM TIAYTRLYCS LEKGELENLW DCSMVKHTAL LLFTNCILYC PVAFLSFSSL LNLTFISPEV IKFILLVIVP LPACLNPLLY IVFNPHFKED MGSLGKQTRF WTRAKHPSLL SINSDDVEKR SCDSTQALVS FTHASIAYDL PSDSGSSPAY PMTESCHLSS VAFVPCL
I Rat LgR5 mature, GSPPRPDTM PRGCPSYCHC ELDGRMLLRV DCSDLGLSEL without signal PSNLSVFTSY LDLSMNNISQ LPASLLHRLR FLEELRLAGN sequence; amino ALTHIPKGAF AGLHSLKVLM LQNNQLRQVP EEALQNLRSL acids 22 to 907 QSLRLDANHI SYVPPSCFSG LHSLRHLWLD DNALTDVPVQ
AFRSLSALQA MTLALNKIHH IADHAFGNLS SLWLHLHNN RIHSLGKKCF DGLHSLETLD LNYNNLDEFP TAIKTLSNLK ELGFHSNNIR SIPERAFVGN PSLITIHFYD NPIQFVGISA FQHLPELRTL TLNGASQITE FPDLTGTATL ESLTLTGAKI SSLPQTVCDQ LPNLQVLDLS YNLLEDLPSL SGCQKLQKID LRHNEIYEIK GGTFQQLFNL RSLNLARNKI AIIHPNAFST LPSLIKLDLS SNLLSSFPVT GLHGLTHLKL TGNRALQSLI PSANFPELKI IEMPYAYQCC AFGGCENVYK IPNQWNKDDS SSVDDLRKKD AGLFQVQDER DLEDFLLDFE EDLKVLHSVQ CSPPPGPFKP CEHLFGSWLI RIGVWTTAVL ALSCNALVAF TVFRTPLYIS SIKLLIGVIA WDILMGVSS AILAWDTFT FGSFAQHGAW WEGGIGCQIV GFLSIFASES SVFLLTLAAL ERGFSVKCSS KFEMKAPLSS LKAI ILLCVL LALTIATVPL LGGSEYNASP LCLPLPFGEP STTGYMVALV LLNSLCFLIM TIAYTRLYCS LEKGELENLW DCSMVKHTAL LLFTNCILYC PVAFLSFSSL LNLTFISPEV IKFILLVIVP LPACLNPLLY IVFNPHFKED MGSLGKQTRF WTRAKHPSLL SINSDDVEKR SCDSTQALVS FTHASIAYDL PSDSGSSPAY PMTESCHLSS VAFVPCL
I Mouse LgR5 MDTSCVHMLL SLLALLQLVA AGSSPGPDAI PRGCPSHCHC precursor; ELDGRMLLRV DCSDLGLSEL PSNLSVFTSY LDLSMNNISQ LGR5_mouse LPASLLHRLC FLEELRLAGN ALTHIPKGAF TGLHSLKVLM NP_034325; LQNNQLRQVP EEALQNLRSL QSLRLDANHI SYVPPSCFSG signal sequence LHSLRHLWLD DNALTDVPVQ AFRSLSALQA MTLALNKIHH amino acids 1-21 IADYAFGNLS SLWLHLHNN RIHSLGKKCF DGLHSLETLD
LNYNNLDEFP TAIKTLSNLK ELGFHSNNIR SIPERAFVGN PSLITIHFYD NPIQFVGVSA FQHLPELRTL TLNGASHITE FPHLTGTATL ESLTLTGAKI SSLPQAVCDQ LPNLQVLDLS YNLLEDLPSL SGCQKLQKID LRHNEIYEIK GSTFQQLFNL RSLNLAWNKI AIIHPNAFST LPSLIKLDLS SNLLSSFPVT GLHGLTHLKL TGNRALQSLI PSANFPELKI IEMPSAYQCC AFGGCENVYK ISNQWNKDDG NSVDDLHKKD AGLFQVQDER DLEDFLLDFE EDLKALHSVQ CSPSPGPFKP CEHLFGSWLI RIGVWTTAVL ALSCNALVAL TVFRTPLYIS SIKLLIGVIA WDILMGVSS AVLAAVDAFT FGRFAQHGAW WEDGIGCQIV GFLSIFASES SIFLLTLAAL ERGFSVKCSS KFEVKAPLFS LRAIVLLCVL LALTIATIPL LGGSKYNASP LCLPLPFGEP S GYMVALV LLNSLCFLIM TIAYTKLYCS LEKGELENLW DCSMVKHIAL LLFANCILYC PVAFLSFSSL LNLTFISPDV IKFILLVIVP LPSCLNPLLY IVFNPHFKED MGSLGKHTRF WMRSKHASLL SINSDDVEKR SCESTQALVS FTHASIAYDL PS SGASPAY PMTESCHLSS VAFVPCL
I Mouse Lg 5 GSSPGPDAI PRGCPSHCHC ELDGRMLLRV DCSDLGLSEL mature, without PSNLSVFTSY LDLSMNNISQ LPASLLHRLC FLEELRLAGN signal sequence; ALTHIPKGAF TGLHSLKVLM LQNNQLRQVP EEALQNLRSL amino acids 22 to QSLRLDANHI SYVPPSCFSG LHSLRHLWLD DNALTDVPVQ 907 AFRSLSALQA MTLALNKIHH IADYAFGNLS SLWLHLHNN
RIHSLGKKCF DGLHSLETLD LNYNNLDEFP TAIKTLSNLK ELGFHSNNIR SIPERAFVGN PSLITIHFYD NPIQFVGVSA FQHLPELRTL TLNGASHITE FPHLTGTATL ESLTLTGAKI SSLPQAVCDQ LPNLQVLDLS YNLLEDLPSL SGCQKLQKID LRHNEIYEIK GSTFQQLFNL RSLNLAWNKI AIIHPNAFST LPSLIKLDLS SNLLSSFPVT GLHGLTHLKL TGNRALQSLI PSANFPELKI IEMPSAYQCC AFGGCENVYK ISNQWNKDDG NSVDDLHKKD AGLFQVQDER DLEDFLLDFE EDLKALHSVQ CSPSPGPFKP CEHLFGSWLI RIGVWTTAVL ALSCNALVAL TVFRTPLYIS SIKLLIGVIA WDILMGVSS AVLAAVDAFT FGRFAQHGAW WEDGIGCQIV GFLSIFASES SIFLLTLAAL ERGFSVKCSS KFEVKAPLFS LRAIVLLCVL LALTIATIPL LGGSKYNASP LCLPLPFGEP STTGYMVALV LLNSLCFLIM TIAYTKLYCS LEKGELENLW DCSMVKHIAL LLFANCILYC PVAFLSFSSL LNLTFISPDV IKFILLVIVP LPSCLNPLLY IVFNPHFKED MGSLGKHTRF WMRSKHASLL SINSDDVEKR SCESTQALVS FTHASIAYDL PSTSGASPAY PMTESCHLSS VAFVPCL
I hu8El l .v2 V205C DIVMTQSPDS LAVSLGERAT INCRASESVD NYGNSFMHWY cysteine QQKPGQPPKL LIYLASNLES GVPDRFSGSG SGTDFTLTIS engineered light SLQAEDVAVY YCQQNYEDPF TFGQGTKVEI KRTVAAPSVF chain (IgK) IFPPSDEQLK SGTASWCLL NNFYPREAKV QWKVDNALQS
GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPCT KSFNRGEC
I hu8El l .v2 A118C EVQLVQSGAE VKKPGASVKV SCKASGYTFS AYWIEWVRQA cysteine PGQGLEWIGE ILPGSDSTDY NEKFKVRATF TSDTSTSTVY engineered heavy LELSSLRSED TAVYYCARGG HYGSLDYWGQ GTLVTVSSCS chain (IgGl) TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN
SGALTSGVHT FPAVLQSSGL YSLSSWTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVWDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRWSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
I hu8El l .v2 S400C EVQLVQSGAE VKKPGASVKV SCKASGYTFS AYWIEWVRQA cysteine PGQGLEWIGE ILPGSDSTDY NEKFKVRATF TSDTSTSTVY
13£ engineered heavy LELSSLRSED TAVYYCARGG HYGSLDYWGQ GTLVTVSSAS chain (IgGl) TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN
SGALTSGVHT FPAVLQSSGL YSLSSWTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVWDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRWSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD CDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
I YW353 V205C DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP cysteine GKAPKLLIYS ASFLYSGVPS RFSGSGSGTD FTLTISSLQP engineered light EDFATYYCQQ SYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP chain (IgK) SDEQLKSGTA SWCLLNNFY PREAKVQWKV DNALQSGNSQ
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPCTKSFN RGEC
I YW353 A118C EVQLVESGGG LVQPGGSLRL SCAASGFTFT SYSISWVRQA cysteine PGKGLEWVAE IYPPGGYTDY ADSVKGRFTI SADTSKNTAY engineered heavy LQMNSLRAED TAVYYCAKAR LFFDYWGQGT LVTVSSCSTK chain (IgGl) GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG
ALTSGVHTFP AVLQSSGLYS LSSWTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VWDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR WSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK
I YW353 S400C EVQLVESGGG LVQPGGSLRL SCAASGFTFT SYSISWVRQA cysteine PGKGLEWVAE IYPPGGYTDY ADSVKGRFTI SADTSKNTAY engineered heavy LQMNSLRAED TAVYYCAKAR LFFDYWGQGT LVTVSSASTK chain (IgGl) GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG
ALTSGVHTFP AVLQSSGLYS LSSWTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VWDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR WSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDCD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK
I V205C cysteine TVAAPSVFIF PPSDEQLKSG TASWCLLNN FYPREAKVQW engineered light KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK chain constant HKVYACEVTH QGLSSPCTKS FNRGEC
region (IgK)
I A118C cysteine CSTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS engineered heavy WNSGALTSGV HTFPAVLQSS GLYSLSSWT VPSSSLGTQT chain constant YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG region (IgGl) PSVFLFPPKP KDTLMISRTP EVTCVWDVS HEDPEVKFNW
YVDGVEVHNA KTKPREEQYN STYRWSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK S400C cysteine ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS engineered heavy WNSGALTSGV HTFPAVLQSS GLYSLSSWT VPSSSLGTQT chain constant YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG region (IgGl) PSVFLFPPKP KDTLMISRTP EVTCVWDVS HEDPEVKFNW
YVDGVEVHNA KTKPREEQYN STYRWSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDCDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK

Claims

WHAT IS CLAIMED IS:
1. An isolated antibody that binds to LgR5, wherein the antibody binds an epitope within amino acids 22-323 of SEQ ID NO: 67 or within amino acids 22-123 of SEQ ID NO: 67 and binds to LgR5 with an affinity of < 5 nM.
2. The antibody of claim 1 , which is a monoclonal antibody.
3. The antibody of claim 1, which is a human, humanized, or chimeric antibody.
4. The antibody of claim 1, which is an antibody fragment that binds LgR5.
5. The antibody of claim 1, wherein LgR5 is human LgR5 of SEQ ID NO: 67.
6. The antibody of claim 1, wherein the antibody comprises:
a) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31; or
b) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59, and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61.
7. The antibody of claim 1, wherein the antibody comprises:
a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32; or
b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 60, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62.
8. The antibody of claim 7, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, and:
a) heavy chain framework FR3 sequence of SEQ ID NO: 40;
b) heavy chain framework FR3 sequence of SEQ ID NO: 41 ;
c) heavy chain framework FR3 sequence of SEQ ID NO: 42; or
d) heavy chain framework FR3 sequence of SEQ ID NO: 43.
9. The antibody of claim 7 or claim 8, wherein the antibody comprises:
a) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29; or b) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 62, HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 61, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
10. The antibody of claim 1, wherein the antibody comprises:
a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29; or
b) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 58, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59.
11. The antibody of claim 9 or claim 10, wherein the antibody comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 27, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29, and further comprises a light chain framework FR3 sequence of SEQ ID NO: 35.
12. The antibody of any one of the preceding claims, wherein the antibody comprises: a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6;
b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 5;
c) a VH sequence as in (a) and a VL sequence as in (b);
d) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8;
e) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7;
f) a VH sequence as in (d) and a VL sequence as in (e);
g) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10;
h) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9;
i) a VH sequence as in (g) and a VL sequence as in (h);
j) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12; k) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11 ;
1) a VH sequence as in (J) and a VL sequence as in (k);
m) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14;
n) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 13;
o) a VH sequence as in (m) and a VL sequence as in (n);
p) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16;
q) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15;
r) a VH sequence as in (p) and a VL sequence as in (q);
s) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18;
t) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17;
u) a VH sequence as in (s) and a VL sequence as in (t);
v) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20;
w) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19;
x) a VH sequence as in (v) and a VL sequence as in (w);
y) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26;
z) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25; or
aa) a VH sequence as in (y) and a VL sequence as in (z).
13. The antibody of claim 12, comprising a VH sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, and 26.
14. The antibody of claim 12 or claim 13, comprising a VL sequence selected from SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, 19, and 25.
15. An antibody comprising:
a) a VH sequence of SEQ ID NO: 6 and a VL sequence of SEQ ID NO: 5;
b) a VH sequence of SEQ ID NO: 8 and a VL sequence of SEQ ID NO: 7; c) a VH sequence of SEQ ID NO: 10 and a VL sequence of SEQ ID NO: 9;
d) a VH sequence of SEQ ID NO: 12 and a VL sequence of SEQ ID NO: 11;
e) a VH sequence of SEQ ID NO: 14 and a VL sequence of SEQ ID NO: 13;
f) a VH sequence of SEQ ID NO: 16 and a VL sequence of SEQ ID NO: 15;
g) a VH sequence of SEQ ID NO: 18 and a VL sequence of SEQ ID NO: 17;
h) a VH sequence of SEQ ID NO: 20 and a VL sequence of SEQ ID NO: 19; or i) a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25.
16. The antibody of any one of claims 1 to 15, which is an IgGl, IgG2a or IgG2b antibody.
17. Isolated nucleic acid encoding the antibody of any one of claims 1 to 16.
18. A host cell comprising the nucleic acid of claim 17.
19. A method of producing an antibody comprising culturing the host cell of claim 18 so that the antibody is produced.
20. An immunoconjugate comprising the antibody of any one of claims 1 to 16 and a cytotoxic agent.
21. The immunoconjugate of claim 20 having the formula Ab-(L-D)p, wherein:
(a) Ab is the antibody of any one of claim 1 to 15;
(b) L is a linker;
(c) D is a drug selected from a maytansinoid, an auristatin, a calicheamicin, a pyrrolobenzodiazepine, and a nemorubicin derivative; and
(d) p ranges from 1-8.
The immunoconjugate of claim 21, wherein D is an auristatin.
and wherein R2 and R6 are each methyl, R3 and R4 are each isopropyl, R5 is H, R7 is sec-butyl, each R8 is independently selected from CH3, 0-CH3, OH, and H; R9 is H; and R18 is -C(R8)2-C(R8)2-aryl.
The immunoconjugate of claim 21, wherein the drug is MMAE.
The immunoconjugate of claim 21, wherein D is a pyrrolobenzodiazepine of
wherein the dotted lines indicate the optional presence of a double bond between CI and C2 or C2 and C3;
R2 is independently selected from H, OH, =0, =CH2, CN, R, OR, =CH-RD, =C(RD)2, O-SO2-R, CO2R and COR, and optionally further selected from halo or dihalo, wherein RD is independently selected from R, C02R, COR, CHO, C02H, and halo;
R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', N02, Me3Sn and halo;
R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', N02, MesSn and halo;
Q is independently selected from O, S and NH;
R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation;
R and R' are each independently selected from optionally substituted Ci_s alkyl,
C3-8 heterocyclyl and C5_2o aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
R12, R16, R19 and R17 are as defined for R2, R6, R9 and R7 respectively;
R" is a C3- alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings that are optionally substituted; and
X and X' are independently selected from O, S and N(H).
:
A(II); wherein n is 0 or 1.
The immunoconjugate of claim 25, wherein D has a structure selected from: wherein E and RE are each independently selected from H or RD, wherein RD is independently selected from R, C02R, COR, CHO, C02H, and halo;
wherein Ar1 and Ar2 are each independently optionally substituted C5-20 aryl; and wherein n is 0 or 1.
28. The immunoconjugate of claim 21, wherein D is a pyrrolobenzodiazepine of Formul
wherein the horizontal wavy line indicates the covalent attachement site to the linker; Rvl and Rv2 are independently selected from H, methyl, ethyl, phenyl, fluoro-substiruted phenyl, and C5_6 heterocyclyl; and
n is 0 or 1.
29. The immunoconjugate of claim 21, wherein D is a nemorubicin derivative.
30. The immunoconjugate of claim 29, wherein D has a structure selected from:
31. The immunoconjugate of any one of claims 21 to 30, wherein the linker is cleavable by a protease.
32. The immunoconjugate of claim 31, wherein the linker comprises a val-cit dipeptide or a Phe-Lys dipeptide.
33. The immunoconjugate of any one of claims 21 to 30, wherein the linker is acid- labile.
34. The immunoconjugate of claim 33, wherein the linker comprises hydrazone.
35. The immunoconjugate of claim 23 having the formula: wherein S is a sulfur atom.
36. The immunoconjugate of claim 26 having the formula:
148
149
38. The immunoconjugate of any one of claims 21 to 37, wherein p ranges from 2-5.
39. The immunoconjugate of any one of claims 21 to 38, comprising the antibody of claim 9.
40. The immunoconjugate of any one of claims 21 to 38, comprising the antibody of claim 15.
41. A pharmaceutical formulation comprising the immunoconjugate of any one of claims 21 to 40 and a pharmaceutically acceptable carrier.
42. The pharmaceutical formulation of claim 41, further comprising an additional therapeutic agent.
43. The pharmaceutical formulation of claim 42, wherein the additional therapeutic agent is Avastin® (bevacizumab).
44. A method of treating an individual having an LgR5-positive cancer, the method comprising administering to the individual an effective amount of the immunoconjugate of any one of claims 21 to 40.
45. The method of claim 44, wherein the LgR5 -positive cancer is selected from colorectal cancer, pancreatic cancer, ovarian cancer, and endometrial cancer.
46. The method of claim 45, further comprising administering an additional therapeutic agent to the individual.
47. The method of claim 46, wherein the additional therapeutic agent is Avastin® (bevacizumab).
48. A method of inhibiting proliferation of an LgR5 -positive cell, the method comprising exposing the cell to the immunoconjugate of any one of claims 21 to 40 under conditions permissive for binding of the immunoconjugate to LgR5 on the surface of the cell, thereby inhibiting proliferation of the cell.
49. The method of claim 48, wherein the cell is a colorectal, pancreatic, ovarian, or endometrial cancer cell.
50. The antibody of any one of claims 1 to 16 conjugated to a label.
51. The antibody of claim 50, wherein the label is a positron emitter.
52. The antibody of claim 51, wherein the positron emitter is 89Zr.
53. A method of detecting human LgR5 in a biological sample comprising contacting the biological sample with the anti-LgR5 antibody of any one of claims 1 to 16 under conditions permissive for binding of the anti-LgR5 antibody to a naturally occurring human LgR5, and detecting whether a complex is formed between the anti-LgR5 antibody and a naturally occurring human LgR5 in the biological sample.
54. The method of claim 53, wherein the anti-LgR5 antibody is an antibody as in claim 9 or claim 15.
55. The method of claim 53, wherein the biological sample is a colorectal cancer sample, pancreatic cancer sample, ovarian cancer sample, or endometrial cancer sample.
56. A method for detecting an LgR5-positive cancer comprising (i) administering a labeled anti-LgR5 antibody to a subject having or suspected of having a LgR5 -positive cancer, wherein the labeled anti-LgR5 antibody comprises the anti-LgR5 antibody of any one of claims 1 to 16, and (ii) detecting the labeled anti-LgR5 antibody in the subject, wherein detection of the labeled anti-LgR5 antibody indicates a LgR5-positive cancer in the subject.
57. The method of claim 56, wherein the labeled anti-LgR5 antibody is an antibody as in claim 8 or claim 14 that is labeled.
58. The method of claim 56 or claim 57, wherein the labeled anti-LgR5 antibody comprises an anti-LgR5 antibody conjugated to a positron emitter.
59. The method of claim 58, wherein the positron emitter is 89Zr.
EP13716131.1A 2012-03-30 2013-03-29 Anti-lgr5 antibodies and immunoconjugates Withdrawn EP2831118A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261618232P 2012-03-30 2012-03-30
US201261683048P 2012-08-14 2012-08-14
US201361778710P 2013-03-13 2013-03-13
PCT/US2013/034629 WO2013149159A1 (en) 2012-03-30 2013-03-29 Anti-lgr5 antibodies and immunoconjugates

Publications (1)

Publication Number Publication Date
EP2831118A1 true EP2831118A1 (en) 2015-02-04

Family

ID=48093115

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13716131.1A Withdrawn EP2831118A1 (en) 2012-03-30 2013-03-29 Anti-lgr5 antibodies and immunoconjugates

Country Status (19)

Country Link
US (2) US9175089B2 (en)
EP (1) EP2831118A1 (en)
JP (2) JP6404811B2 (en)
KR (1) KR20150003162A (en)
CN (1) CN104411721A (en)
AR (1) AR090549A1 (en)
AU (1) AU2013237892A1 (en)
CA (1) CA2864311A1 (en)
CL (1) CL2014002549A1 (en)
CO (1) CO7071096A2 (en)
CR (1) CR20140441A (en)
EA (1) EA201491811A1 (en)
HK (1) HK1208038A1 (en)
MX (1) MX2014011006A (en)
PE (1) PE20142167A1 (en)
PH (1) PH12014502132A1 (en)
SG (1) SG11201405881TA (en)
TW (1) TW201343674A (en)
WO (1) WO2013149159A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP3401329A1 (en) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
BR112014027166A2 (en) 2012-05-01 2017-06-27 Genentech Inc antibody, nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, treatment method, proliferation inhibiting method and detection methods.
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
JP6436965B2 (en) 2013-03-14 2018-12-12 ジェネンテック， インコーポレイテッド Anti-B7-H4 antibody and immunoconjugate
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2016003248A (en) * 2013-09-17 2016-06-07 Genentech Inc Methods of using anti-lgr5 antibodies.
CN106104273A (en) * 2013-12-12 2016-11-09 施特姆森特克斯股份有限公司 Novel anti-DPEP3 antibody and using method
BR112016012410A2 (en) * 2013-12-16 2017-09-26 Genentech Inc drug-antibody conjugate, drug-antibody conjugate, non-peptide compound, method of treating human disease and pharmaceutical composition
EP3110846B1 (en) 2014-02-28 2020-08-19 Merus N.V. Antibodies that bind egfr and erbb3
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
JP2015209384A (en) * 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Pharmaceutical formulation
CA2949982A1 (en) * 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
SG11201701627PA (en) * 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
CN113698485A (en) 2014-09-12 2021-11-26 基因泰克公司 anti-B7-H4 antibodies and immunoconjugates
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
RU2727663C2 (en) * 2014-09-17 2020-07-22 Дженентек, Инк. Immunoconjugates, containing antibodies against her2 and pyrrolbenzodiazepines
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CN106188293A (en) * 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof
SI3365373T1 (en) 2015-10-23 2021-08-31 Merus N.V. Binding molecules that inhibit cancer growth
CN105274061A (en) * 2015-10-26 2016-01-27 无锡傲锐东源生物科技有限公司 Hybridoma cell capable of producing anti-LGR5 (leucine-rich repeat-containing G-protein coupled receptor 5) monoclonal antibody, anti-LGR5 monoclonal antibody produced by hybridoma cell and application of hybridoma cell and anti-LGR5 monoclonal antibody
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017161414A1 (en) * 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
JP2019529418A (en) * 2016-09-16 2019-10-17 バイオノミックス リミテッド Combination therapy with antibodies and checkpoint inhibitors
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
WO2018103739A1 (en) * 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 Antibody-drug conjugate, preparation method, intermediate, pharmaceutical composition and use
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
IL310223A (en) 2017-03-31 2024-03-01 Merus Nv Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
JP7296891B2 (en) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ Combining ErbB-2/ErbB-3 bispecific antibodies with endocrine therapy for breast cancer
US20200114017A1 (en) * 2017-06-16 2020-04-16 Bionomics Limited Antibody drug conjugates that bind lgr5
JP7304846B2 (en) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ANTI-CD8 ANTIBODY AND USES THEREOF
MX2020001432A (en) 2017-08-09 2020-03-20 Merus Nv Antibodies that bind egfr and cmet.
CN108273070B (en) * 2018-02-11 2020-10-16 上海交通大学 Cell and drug targeting transfer structure and its preparation and application
TW202003047A (en) * 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
US20210380605A1 (en) * 2018-10-19 2021-12-09 Medimmune Limited Pyrrolobenzodiazepine conjugates
JP2023520392A (en) * 2020-04-01 2023-05-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Immunotheranostic agents targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell-related diseases (IMMUNOTHERANOSTIC AGENT)
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
KR20240153604A (en) * 2022-03-03 2024-10-23 캠브리지 엔터프라이즈 리미티드 therapeutic antibodies
CN115368435A (en) * 2022-09-06 2022-11-22 联宁（苏州）生物制药有限公司 A kind of synthesis method of antibody-conjugated drug linker SET0568
WO2024092016A1 (en) * 2022-10-26 2024-05-02 Research Development Foundation Cell targeting constructs and uses thereof
WO2024235120A1 (en) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 Fused ring compound, and preparation method therefor and use thereof

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU688743B2 (en) 1992-11-13 1998-03-19 Biogen Idec Inc. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
DE69434136T2 (en) 1993-10-01 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. Dolastatin DERIVATIVES
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (en) 1997-06-24 2005-06-15 Genentech Inc COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
PT1034298E (en) 1997-12-05 2012-02-03 Scripps Research Inst Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
ES2340112T3 (en) 1998-04-20 2010-05-28 Glycart Biotechnology Ag ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES.
ES2260570T3 (en) 1998-08-27 2006-11-01 Spirogen Limited PIRROLOBENZIODIAZEPINAS DIMERICAS.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2274823T3 (en) 1999-12-29 2007-06-01 Immunogen, Inc. COTOTOXIC AGENTS THAT INCLUDE DOXORRUBICINAS AND DAUNORRUBICINAS AND ITS THERAPEUTIC USE.
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU9419801A (en) 2000-10-06 2002-04-22 Kyowa Hakko Kogyo Kk Cells producing antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (en) 2000-11-30 2008-04-16 Medarex, Inc. TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES.
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
PL217751B1 (en) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM
JPWO2003084569A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Antibody composition-containing medicine
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
KR20050000380A (en) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 Cells with modified genome
JP4753578B2 (en) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド Synthetic antibody phage library
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
WO2004016801A2 (en) 2002-08-16 2004-02-26 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (en) 2002-12-16 2010-07-22 Genentech Inc IMMUNOGLOBULIN VARIANTS AND ITS USES
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004087717A1 (en) 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
DE10339820A1 (en) * 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Use of G-protein coupled receptor, GPR49, peptides, protein and nucleic acid, for diagnosis and prognosis of tumors, also in screening for therapeutic and diagnostic agents
JPWO2005035586A1 (en) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Fusion protein composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
CA2543318C (en) 2003-10-22 2013-01-08 B. Rao Vishnuvajjala Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
RS54450B1 (en) 2003-11-05 2016-06-30 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
EP1723152B1 (en) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
RU2386638C2 (en) 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
CA2559870A1 (en) 2004-04-07 2005-10-27 Genetech,Inc. Mass spectrometry of antibody conjugates
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP4993645B2 (en) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド Antibody drug conjugates and methods
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
EP1942944A2 (en) 2005-10-31 2008-07-16 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
PT1813614E (en) 2006-01-25 2012-01-09 Sanofi Sa Cytotoxic agents comprising new tomaymycin derivatives
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
EP3424529A1 (en) * 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
PL2019104T3 (en) 2007-07-19 2014-03-31 Sanofi Sa Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
JP5676107B2 (en) * 2007-11-14 2015-02-25 中外製薬株式会社 Diagnosis and treatment of cancer using anti-GPR49 antibody
GB0723317D0 (en) 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8742076B2 (en) 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
CA2727915C (en) 2008-07-15 2016-04-26 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
ES2547712T3 (en) 2009-02-27 2015-10-08 Genentech, Inc. Methods and compositions for protein labeling
WO2011014457A1 (en) * 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
RU2613886C2 (en) 2010-06-03 2017-03-21 Дженентек, Инк. Antibodies and immunoconjugates rendered by immuno-positron emission tomography, methods of application
RU2626537C2 (en) 2010-06-08 2017-07-28 Дженентек, Инк. Antibodies with cysteine substituitions and their conjugates produced by gene engineering
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
EP2670776B1 (en) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 Utilize framework signature peptide to detect the multiple reaction monitoring LC-MS/MS method of the therapeutic antibodies in animal sample
DK2750713T3 (en) 2011-10-14 2015-12-21 Medimmune Ltd PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LISA BERGLUND ET AL: "The epitope space of the human proteome", PROTEIN SCIENCE, vol. 17, no. 4, 1 April 2008 (2008-04-01), pages 606 - 613, XP055176015, ISSN: 0961-8368, DOI: 10.1110/ps.073347208 *

Also Published As

Publication number Publication date
MX2014011006A (en) 2014-10-13
JP6404811B2 (en) 2018-10-17
PH12014502132A1 (en) 2014-12-10
CN104411721A (en) 2015-03-11
CO7071096A2 (en) 2014-09-30
JP2019030303A (en) 2019-02-28
SG11201405881TA (en) 2014-10-30
CA2864311A1 (en) 2013-10-03
AU2013237892A1 (en) 2014-08-28
PE20142167A1 (en) 2014-12-13
HK1208038A1 (en) 2016-02-19
US20130336885A1 (en) 2013-12-19
EA201491811A1 (en) 2015-01-30
WO2013149159A1 (en) 2013-10-03
US9175089B2 (en) 2015-11-03
TW201343674A (en) 2013-11-01
AR090549A1 (en) 2014-11-19
US20160102146A1 (en) 2016-04-14
CR20140441A (en) 2014-11-17
JP2015521027A (en) 2015-07-27
KR20150003162A (en) 2015-01-08
CL2014002549A1 (en) 2015-01-16
WO2013149159A9 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US11230600B2 (en) Anti-B7-H4 antibodies and immunoconjugates
US9175089B2 (en) Anti-LGR5 antibodies and immunoconjugates
US10653792B2 (en) Anti-Ly6E antibodies and immunoconjugates and methods of use
EP3461845B1 (en) Anti-cd33 antibodies and immunoconjugates
US9056910B2 (en) Anti-PMEL17 antibodies and immunoconjugates
WO2015179658A2 (en) Anti-gpc3 antibodies and immunoconjugates
US10246515B2 (en) Methods of treating hedgehog-related diseases with an anti-LGR5 antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160623

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20190502BHEP

Ipc: C07K 16/28 20060101AFI20190502BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20190627

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191108